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Abstract 
 
Current pharmaceutical engineering for the manufacture of binary and combined dry 
powder inhaler (DPI) dosage forms relies on destructive strategies such as 
micronisation to generate respirable drug particles. Such processes are inefficient and 
difficult to control to produce particles of defined quality and functionality for inhaled 
drug delivery, which can affect drug product performance throughout the shelf-life of 
the product. Furthermore, owing to current pharmaceutical manufacturing practises of 
combined inhalation products, these products are subject to greater variability in dose 
delivery of each active, which may be perpetuated as a function of product storage 
conditions and limit clinical efficacy of the drug product. Hence, there is a requirement 
of processes that may enable production of binary and combination DPI products that 
will allow actives to be delivered more efficiently and independently of dose variations. 
The aim, therefore, of this study was to develop the solution atomisation and 
crystallisation by sonication (SAX) process for engineering of single and combination 
drug particles with suitable physicochemical properties for delivery to the lungs. 
 
The SAX process consists of key stages, which include, solution atomisation to 
produce aerosol droplets, generation of highly supersaturated droplets by evaporation 
of carrier solvent from aerosol droplet, collection of droplets in a crystallisation vessel 
containing appropriate non-solvent and the application of ultrasonic waves to the 
crystallisation vessel. Atomisation of a 1.5% w/v solution of budesonide in 
dichloromethane resulted in particles with defined surface geometry, which were 
formulated in binary dry powder inhaler (DPI) formulations and assessed using the next 
generation impactor. The percentage fine particle fraction (%FPF) of the SAX 
budesonide particles was significantly (p<0.05) greater than micronised budesonide, 
which was related to smaller contact area of the SAX particles that result in lower 
adhesion and therefore, greater fine drug particle aerosolisation. In contrast, 
atomisation of a 3% w/v solution of budesonide resulted in hollow/porous particles of 
budesonide that possessed a volume median diameter of 10 µm, which owing to their 
lower density behaved aerodynamically as micronised budesonide particles. 
 
Crystalline particles containing both fluticasone propionate (FP) and salmeterol 
xinafoate (SX) were prepared upon atomisation of a solution consisting of FP and SX. 
FP and SX were dissolved in an appropriate solvent with a 10:1 ratio. Particle size 
analysis of SAX FP/SX suggested a monomodal particle size distribution presenting a 
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median equivalent volume diameter of 4.68 ± 0.01 µm. Chemical analysis of the SAX 
processed FP/SX showed that both materials were present in the correct ratio. 
The %FPF of micronised FP/SX formulation was 7.88 ± 0.46 % for FP and 6.70 ± 
0.53 % for SX. In comparison, the formulation of SAX processed FP/SX particles 
showed significantly (p<0.05) greater %FPF of FP (10.68 ± 0.32 %) and SX (11.96 ± 
1.09 %). Stage-by-stage analysis suggested that the SAX-processed FP/SX 
formulations were deposited on stages 2–5 consistently in the correct ratio, whereas 
the micronised FP/SX formulation resulted in greater FP deposition than SX into the 
lower stages of the NGI on aerosolisation. Following storage at 25˚C/75% RH and 
40˚C/75 % RH  for four weeks, the %FPF of FP and SX from combination formulations 
of micronised FP/SX had significantly (p<0.05) decreased, whereas the %FPF of either 
active from SAX FP/SX formulations showed no significant change.  
 
In addition, crystalline particles containing both budesonide (Bud) and formoterol 
fumarate dihydrate (FFD) were prepared upon atomisation of a solution consisting of 
Bud and FFD.  Both drugs were dissolved in an appropriate solvent in the ratio 36:1 of 
Bud:FFD. The %FPF of Bud and FFD from SAX-produced Bud/FFD formulation was 
significantly (p<0.05) greater than micronised Bud/FFD formulation. The combination 
particles of Bud/FFD engineered from SAX process were successfully deposited 
consistently on to the lower stages of NGI in comparison with combined micronised 
particles. However, following storage of the formulations at 25˚C/75% RH and 
40˚C/75% RH for four weeks, the %FPF of Bud from combination formulations of 
micronised and SAX Bud/FFD had significantly (p<0.05) decreased, whereas 
the %FPF of FFD from micronised Bud/FFD formulations showed no significant change. 
In contrast, the %FPF of FFD following aerosolisation of the SAX Bud/FFD formulation 
after storage decreased significantly (p<0.05). This may be related to the fact that 
performance of both actives in the SAX preparation are affected by one another, 
therefore, changes in one active may affect the delivery of the other after storage. 
 
In conclusion, these data demonstrate that the SAX process has been successfully 
deployed for the fabrication of particles with desired physicochemical properties for 
pulmonary drug delivery. Furthermore, the SAX process may be utilised to produce 
individual particulates of two active ingredients, which will allow the delivery of 
combination medicaments effectively and independently of dose variation. This 
approach presents itself as novel means to produce inhaled combination dosage forms.  
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Chapter 1: Introduction 
 
1.1 Respiratory Medicine 
 
1.1.1 Structure of the Human Respiratory Tract 
 
The human respiratory tract starts from the nose and ends in the peripheral regions of 
the lung at the respiratory bronchioles and alveoli (Gurney, 1991). The respiratory tract 
comprises a series of bifurcating airways (Figure 1.1). The trachea, which is connected 
to the oral and nasal cavities by the oropharynx, divides into right and left main bronchi, 
which in turn bifurcate into narrower and shorter bronchi and bronchioles. The 
dichotomous branching of the airways from the bronchi to the bronchioles undergoes 
over 32 bifurcations (Gurney, 1991). The trachea, bronchi and bronchioles are all 
together known as the conducting airways, and their major function is to lead inspired 
air to the gas exchanging regions of the lung. The respiratory bronchioles and alveoli 
are the site of gas exchange, where the whole of the cardiac output supplies capillaries 
in the peripheral regions of the lungs via the pulmonary artery. The entire respiratory 
tract is lined with a continuous sheet of epithelial cells, which vary in type and function 
throughout the tracheobronchial tree (Jeffery, 1997). The main role of the epithelial 
cells is to separate the external environment from the internal environment of the sub-
epithelial airway structures. This is achieved by mucus secretion and by the specialised 
tight junctions between the epithelial cells that limit the penetration of inhaled 
substances through intercellular channels into the sub-epithelial areas (Knowles and 
Boucher, 2002).  
 
In addition to being a portal for the exchange of oxygen and carbon dioxide between 
inhaled and exhaled air, the lungs have evolved to protect the peripheral regions from 
deposition of airbone particles through a number of different mechanisms (Lippmann, 
Yeates et al., 1980). With the movement of large volumes of air via the lungs, the 
respiratory tract is unavoidably exposed to a large amount of airborne particles. The 
human lung effectively filters over a billion particles each and every day (Lippmann, 
Yeates et al., 1980). These airborne particles include and are not limited to pollen 
grains, fungal spores, viruses, bacteria, diesel particulates and pet dander (Bascom, 
Bromberg et al., 1996). The efficient protection against particulate material is as a 
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result of the physical structure of the lung, and the internal surface coating of the 
bronchi and bronchioles with mucus as well as beating cilia hairs, which constantly 
expel entrapped particles from the respiratory tract (Gurney, 1991; Boucher, 1994). 
 
 
 
 
 
   
 
 
 
 
 
 
 
 
 
 
Figure 1.1: Structure of the human respiratory tract adapted 
from http://www.oup.co.uk/oxed/children/oise/pictures/humans/lungs/ 
 
1.1.2 Asthma and Chronic Obstructive Pulmonary Disease (COPD) 
 
Asthma and chronic obstructive pulmonary disease (COPD) are both common 
diseases, and their incidence is increasing globally, placing an increasing burden on 
health services in industrialised and developing countries (Mannino and Buist, 2007; 
Barnes, 2007; Pearce, it-Khaled et al., 2007). Such diseases are characterised by 
airway obstruction, which is variable and reversible in asthma but is progressive and 
largely irreversible in COPD (Barnes, Chung et al., 1998; Barnes, Shapiro et al., 2003). 
Furthermore, both diseases are characterised by chronic inflammation of the 
respiratory tract, which is mediated by increasing expression of multiple inflammatory 
proteins, enzymes and receptors (Barnes, 2008). As the intensity of the inflammation 
increases in both diseases, there are exacerbations (Barnes, 2008).  
 
Trachea 
Bronchioles 
Alveoli 
Diaphragm 
Bronchi 
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1.1.2.1 Asthma 
 
A series of factors combines to produce increasing airway inflammation and airway 
hyper-responsiveness and, when these features reach a sufficient level, 
bronchoconstriction and asthma symptoms are triggered (Holgate, Davies et al., 2007). 
Typically, the inhalation of an allergen in an asthmatic can result in an episode of 
asthma. Asthmatics have high levels of the antibody immunoglobulin E (IgE), which 
binds to receptors on inflammatory cells, most notably mast cells (Holgate, 2008). The 
interaction of the inhaled allergen and IgE results in the activation of mast cells, 
releasing pre-formed mediators such as histamine, prostaglandins and leukotrienes, 
which cause the smooth muscle of the airways to contract, thereby producing 
bronchoconstriction (Holgate, 2007). 
 
The inflammatory response in asthma is highly complex involving inflammatory cells 
such as mast cells, eosinophils, B-lymphocytes, and T-lymphocytes (Holgate, 2008). 
These inflammatory mediators regulate the response of other mediators and have a 
number of effects resulting in contraction of airway smooth muscle, increase of 
vascular permeability and stimulation of airway mucus secretion (Holgate, 2008). 
Hence, the wall of the airway in asthma is thickened by edema, and cellular infiltration, 
thereby increasing smooth muscle mass and glands. With increasing severity of the 
disease, remodelling of the airways leads to fibrosis of the airway wall, fixed narrowing 
of the airway and reduced response to therapy (Holgate and Polosao, 2008). 
  
1.1.2.2 Chronic Obstructive Pulmonary Disease (COPD) 
 
The global initiative on obstructive lung disease (GOLD) defines COPD as a disease 
state characterised by airflow limitation that is not fully reversible. The airflow limitation 
is usually progressive and this limitation is associated with an abnormal inflammatory 
response of the lungs to noxious particles and gases (Pauwels, Buist et al., 2001). This 
definition encompasses the idea that COPD is a chronic inflammatory disease, which is 
characterised by acceleration in the normal decline of lung function seen with age 
(Pauwels and Rabe, 2004). Amongst other inflammatory mediators, the key 
inflammatory cells that play a pivotal role in COPD include neutrophils, macrophages, 
B-lymphocytes and T-lymphocytes.  
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In developed countries, cigarette smoking is by far the commonest cause of COPD 
accounting for >95% of cases, but there are several other risk factors, including air 
pollution, poor diet and occupational exposure (Barnes, Shapiro et al., 2003). Cigarette 
smoke extract can activate macrophages, which secrete many inflammatory proteins 
that orchestrate the inflammatory response in COPD (Barnes, Shapiro et al., 2003). 
Inflammatory mediators attract inflammatory cells such as neutrophils, which secrete 
proteases that contribute to alveolar destruction and mucus hyper-secretion (Barnes, 
Shapiro et al., 2003). Furthermore, macrophages generate reactive oxygen species 
and nitric oxide, which together with peroxynitrate may contribute to steroid therapy 
resistance in COPD (Barnes, 2004). 
 
COPD includes chronic obstructive bronchiolitis with fibrosis, obstruction of the small 
airways, emphysema with enlargement of airspaces, destruction of lung parenchyma, 
loss of elasticity, and closure of small airways (Barnes, Shapiro et al., 2003). All of 
these features are induced by smoking. The slowly progressive airflow limitations in 
COPD eventually lead to disability and premature death. 
 
1.1.2.3 Differences between Asthma and COPD 
 
Although there are some overlaps in the features of asthma and COPD, they are 
separate disorders with different aetiologies, pathologies, natural history and responses 
to treatment (Barnes, 2008). In asthma, airway inflammation and hyper-reactivity are 
the key factors giving rise to bronchial muscle contraction and airway obstruction. In 
COPD, structural changes arising from alveolar destruction by emphysema result in a 
loss of elastic recoil and collapse of small airways on expiration contributing to airway 
obstruction.  
 
There are marked differences in the pattern of inflammation that occurs in asthma and 
COPD (Barnes, Shapiro et al., 2003). The inflammatory cells recruited and mediators 
released in both disease conditions are different, which poses distinct consequences of 
inflammation and differing response to therapy (Barnes, 2008). The inflammation 
observed in asthma is mainly located in the larger conducting airways, and small 
airways can also be affected in more severe forms of the disease. In contrast, 
inflammation in COPD is located in the peripheral regions of the lung and small airways 
(Tiddens, 2004). These differences in disease may partly reflect the distribution of 
inhaled agents such as allergens in asthma and tobacco smoke in COPD. 
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1.1.3 Treatment of Asthma and COPD 
 
Asthma and COPD are both characterised by airflow limitation and chronic 
inflammation. Hence, the most effective treatment for reducing airway constriction and 
inflammation is to deploy medicaments that target these aspects of the disease 
pathophysiology. The first-line treatments in both asthma and COPD are 
bronchodilators (short and long acting β2-agonists) and anti-inflammatory therapy 
(inhaled corticosteroids), which are employed to aid bronchodilation and reduce 
inflammation, respectively  (Greening, Ind et al., 1994; Matz, Emmett et al., 2001). 
 
1.1.3.1 Bronchodilators 
 
Bronchodilator drugs (relievers) are used to relieve symptoms of bronchoconstriction 
(Barnes, 2002). These drug agents are typically β2-agonists, which stimulate β-
adrenoceptors in the smooth muscle of the airway, producing smooth-muscle 
relaxation and bronchodilatation (Holgate and Polosao, 2008). The short-acting β2-
agonists (SABA) include salbutamol and terbutaline, which have a duration of action of 
3-4 hours with an onset of action of 15 minutes (Biddiscombe, Melchor et al., 1987). In 
contrast, the long-acting β2-agonists, including salmeterol xinafoate (SX) and formoterol 
fumarate dihydrate (FFD), have a duration of action of more than 12 hours and are 
helpful in controlling chronic asthma (Cazzola, Testi et al., 2002).  
 
Other agents that are able to induce bronchodilation in asthma and COPD include anti-
cholinergic agents, which produce bronchodilation by blocking the bronchoconstrictor 
effect of vagal nerve stimulation on bronchial smooth muscle (Barnes, Shapiro et al., 
2003). The short-acting anti-cholinergic agents such as ipratropium bromide take about 
1 hour to reach their maximum effect and have a duration of action of about 4-6 hours 
(Pauwels, Buist et al., 2001). However, longer acting anti-cholinergic agents are in 
development. Tiotropium is a long-acting anti-cholinergic drug which has greater affinity 
and a slower rate of dissolution from muscarinic receptors than iprotropium with a once 
daily dosage regimen (Cazzola, Ando et al., 2007).  
 
Theophylline is also capable of bronchodilation. Theophyllines increase cyclic 
adenosine monophosphate (cAMP) stimulation of β2-adrenoceptors by inhibiting the 
metabolism of cAMP by the enzyme phosphodiesterase (Cazzola, Ando et al., 2007). 
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However, the high incidence of side-effects has been prohibitive to its use in 
mainstream therapy. 
 
1.1.3.2 Anti-Inflammatory Drugs 
 
Inhaled corticosteroids (ICS), such as budesonide (Bud), fluticasone propionate (FP) 
and mometasone furoate, are the mainstay of asthma and COPD treatment. They 
reduce airway inflammation which is the underlying pathophysiological process in both 
diseases (Barnes, 2002). ICS therapy responsiveness is usually high in asthma. 
Corticosteroids suppress inflammation by inducing the recruitment of nuclear enzyme 
histone deacetylase 2 (HDAC2), which suppresses the expression of genes of various 
inflammatory mediators (Barnes, 2004). By contrast, patients with COPD respond 
poorly to ICS therapy, which fails to suppress inflammation (Barnes, 2008). This has 
been reported to be related to the decrease of activity and expression of HDAC2 in the 
inflammatory cells and peripheral lungs of COPD patients (Barnes, 2008). However, 
low concentrations of theophylline have been able to restore HDAC2 activity in vitro 
and reverse corticosteroid resistance in COPD (Barnes, 2008). 
 
1.1.3.3 Combination Inhalation Therapy 
 
It has been demonstrated that addition of a long-acting β2-agonist (LABA) to an ICS is 
superior to ICS alone in achieving asthma control (Matz, Emmett et al., 2001). Data 
have shown that when FP and SX are combined, there is an increased clinical benefit if 
compared to the individual drug components used separately (Nelson, Chapman et al., 
2003). For patients with more severe COPD, the study has suggested that using a 
combination of Bud and FFD improves the overall exacerbation rate when compared 
with β2-agonist alone (Campbell and Szafranski, 2002). In addition, a 3-year 
retrospective study of COPD patients managed in primary care concluded that regular 
use of FP in combination with SX is associated with significantly greater survival of 
COPD patients (Calverley, Pauwels et al., 2003).  
 
The explanation for the superior clinical effect of combination inhalation therapy over 
that of treatment with the individual medicaments has been related to complementary 
efficacy of both LABA and ICS when co-administered (Zetterstrom, Buhl et al., 2001). 
However, the superior clinical efficacy of combined inhalation therapy may also be due 
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to synergistic interactions of ICS (FP) and LABA (SX) at the receptor, molecular and 
cellular level (Nelson, Chapman et al., 2003).  
 
Inhalers combining a LABA and an ICS are now available. One such combination is a 
combination of FP with SX in Advair®/Seretide® inhaler (GlaxoSmithKline, UK) and the 
other is Bud with FFD in Symbicort® (AstraZeneca, UK). 
 
1.2 Pulmonary Drug Delivery 
 
The use of the inhalant route allows easy accessibility to the respiratory tract as anti-
asthma drugs and other medication can be administered directly to their site of action 
in the lungs (Byron and Patton, 1994). Therefore, this route of drug delivery has 
become the primary route of administration in the therapy of a number of respiratory 
disorders. Advantages of inhalation drug therapy include these facts: small amounts of 
drug are sufficient to prevent or treat symptoms; adverse reactions are usually much 
less than those produced by systemic administration; and there is rapid and predictable 
onset of action (Byron and Patton, 1994). The pulmonary epithelium provides an 
excellent absorptive surface for aerosolised compounds and may be more suitable for 
selected compounds than the gastrointestinal tract. In addition, the exceedingly large 
surface area (143 m2) of the lungs and slow mucociliary clearance from the lung 
periphery render this a viable route of administration for systemically acting agents 
(Lalor and Hickey, 1996). 
 
The target site of drug delivery systems for inhalation depends on the condition being 
treated. The respiratory bronchioles and alveoli would potentially be a target site of 
drug absorption for systemic circulation and can be targeted by formulations designed 
for the treatment of non-respiratory disease (Patton, 1996). Local respiratory diseases 
treated by inhalation therapy such as asthma and COPD are diseases that affect the 
conducting airways (Bryon and Patton, 1994), so therapeutic drugs for these conditions 
are targeted directly to the site of action within the lungs (Virchow, Crompton et al., 
2008). 
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1.2.1 Particle Deposition in the Lungs 
 
An inhaled drug particle must deposit at the site of action to have a pharmacological 
effect (Byron and Patton, 1994). How and where particles deposit in the lung is highly 
dependant on the aerodynamic particle size and three main deposition mechanisms: 
Inertial impaction, sedimentation and diffusion. Other deposition mechanisms include 
interception and electrostatic precipitation (Heyder, Gebhart et al., 1986; Lalor and 
Hickey, 1996). Deposition may occur by a number of these mechanisms, which are 
dependant upon a variety of variables (Martonen and Katz, 1993). These mechanisms 
are described below. 
 
1.2.1.1 Inertial Impaction 
 
The predominant mechanism of particle deposition in the lungs is inertial impaction and 
this mechanism occurs mainly in the upper and conducting airways (Asgharian and 
Anjilvel, 1994). As an inhaled airstream changes direction on passing through the 
repeated bifurcations and bends of the respiratory tract, a particle suspended in the 
airflow may not lose its inertia and relax into the new direction of the airflow, thereby 
impacting on the respiration surface (Martonen, Katz et al., 1992). Deposition by inertial 
impaction is highly dependant on the material density and size of the suspended 
particles. The probability of impaction for a particle travelling in an airway is related to 
its Stokes’ number ( Stk ), a dimensionless parameter that can be calculated using 
Equation 1.1.  
R
Vd
Stk pη
ρ
18
2
=      Equation 1.1 
 
where pρ  is the particle density, d  is the particle diameter,  V  is the air velocity, η  is 
the air viscosity and R  is the airway radius. From this equation, the higher the value of 
Stokes’ number, the more readily particles will deposit by inertial impaction  (Morrison, 
1974; Martonen and Katz, 1993; Crowder, Rosati et al., 2002). 
 
1.2.1.2 Sedimentation   
 
Sedimentation occurs as particles suspended in the respiratory tract settle under the 
influence of gravity (Clark and Egan, 1994). According to the particle size range 
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between 1 and 40 µm diameter in a laminar airstream, the terminal velocity ( tV ) at 
which this settling occurs is described by the Stokes’ law (Stokes, 1908). 
 
η
ρρ
18
)( 2 gd
V apt
−=     Equation 1.2 
 
where pρ  is the particle density, aρ  is the density of air, d  is the particle diameter, g  
is acceleration due to gravity and η  is the air viscosity. Particles <1 µm tend to settle 
with a faster terminal velocity than that predicted by Equation 1.2, whilst particles >40 
µm diameter tend to settle at a slower terminal velocity (Nowak, Kakade et al., 2003). 
 
Sedimentation is a time dependant process as particles must have a sufficient 
residence time in the airway to settle from their initial position to deposit on the 
respiratory surface (Taulbee and Yu, 1975). It is, therefore, the dominant mechanism of 
deposition in the bronchioles due to the small airway dimensions and low air flow 
velocities found in these regions  (Heyder, Gebhart et al., 1986; Tsuda, Butler et al., 
1994b; Lalor and Hickey, 1996). 
 
1.2.1.3 Brownian Motion 
 
As the diameter of a suspended particle drops below 1 µm, the influence of gravity on 
its motion decreases, whereas the influence of Brownian motion caused by the random 
bombardment of the particle by gas molecules becomes ever greater (Mcmurry and 
Rader, 1985). Brownian motion results in particles following a random and variable 
path. For particles which are less than 0.5 µm, Brownian motion will cause greater 
deposition than sedimentation and may be the primary mechanism of deposition in the 
peripheral regions of the lung (Mcmurry and Rader, 1985; Tsuda, Butler et al., 1994a). 
Nevertheless, due to the relative magnitudes of displacement caused by sedimentation 
and Brownian motion, particles >2 µm diameter are more likely to deposit in the 
airways than those <0.5 µm diameter (Tsuda, Butler et al., 1994b). 
 
1.2.1.4 Interception 
 
Interception occurs when a particle moving within the airstream makes contact with the 
respiratory surface (Taulbee and Yu, 1975). Elongated particles are most likely to 
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deposit in this manner. However, as the typical size of drug particles used in respiratory 
drug delivery is much smaller than that of the airways, this mechanism of deposition is 
relatively unimportant in most cases (Martonen and Katz, 1993). 
 
1.2.1.5 Electrostatic Precipitation 
 
During aerosolisation, drug particles may become electrostatically charged (Yeomans, 
Rogers et al., 1949). In theory, charged particles may influence the deposition 
mechanism either through the induction of an image charge on the respiratory surface 
and subsequent electrostatic attraction or via the repulsion between like charged 
aerosol particles directing them towards the airway walls (Balashazy and Hofmann, 
1993).  
 
1.2.2 The Effect of Particle Size on Deposition in the Respiratory Tract 
 
From Equations 1.1 and 1.2, it is clear that particle size is one of the major variables 
controlling particle deposition in the lung (Taulbee and Yu, 1975; Park and Lee, 2000). 
Inhalation formulations need to produce an aerosol cloud of appropriately sized drug 
particles to circumvent deposition prior to reaching their target site (Timsina, Martin et 
al., 1994; Virchow, Crompton et al., 2008). Even before a particle enters the trachea, it 
must negotiate a 90° bend between the oral cavity and pharynx without impacting on 
the back of the throat (Taulbee and Yu, 1975). At each bifurcation, the cross-sectional 
area of an individual airway decreases, providing an ever more convoluted path for a 
particle to negotiate without succumbing to deposition (Balashazy and Hofmann, 1993). 
Drug particles with aerodynamic diameters larger than 10 µm will tend to impact on the 
throat and upper airways (Taulbee and Yu, 1975), whereas particles with an 
aerodynamic diameter less than 0.5 µm will tend to be exhaled (Hofmann, Sturm et al., 
2003). The majority of particles with aerodynamic diameters between 2.5 µm and 6 µm 
will deposit in the conducting airways, whilst particles with an aerodynamic diameter 
less than 2.5 µm will tend to deposit in the alveoli (Tsuda, Butler et al., 1994a; Tsuda, 
Butler et al., 1994b). It is accepted that the target drug aerosol aerodynamic particle 
diameter for an inhalation formulation is between 1 and 5 µm, depending on the 
desired target site (Heyder, Gebhart et al., 1986). 
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1.2.3 Respiratory Drug Delivery Systems 
 
In essence, there are three main drug delivery systems employed to deliver 
therapeutics to the lungs: pressurised metered dose inhalers (pMDIs), dry powder 
inhalers (DPIs) and nebulisers (Hickey and Dunbar, 1997). All three systems are used 
to treat local conditions within the lung, for example, in asthma and COPD (Lalor and 
Hickey, 1996). 
 
1.2.3.1 Nebulisers 
 
Nebulisers are devices used to convert aqueous solutions or aqueous suspensions of 
drug into an aerosol (Clarke, 1995). Nebulisers apply either compressed gas or 
ultrasonic energy for the aerosolisation of the aqueous based solution, which is then 
inhaled by the patient (Dalby and Suman, 2003). Unlike other devices, they do not 
require the use of a complicated breathing movement, and, by extending the time of 
operation, they can be used to deliver large doses (de Boer, Hagedoorn et al., 2003). 
However, due to the prolonged amount of time required to deliver an adequate dose 
(typically 10 to 15 minutes) and the high running cost, nebulisers are typically limited to 
hospital and non-ambulatory patients (Garcia-Contreras and Hickey, 2003). Recent 
developments in nebuliser technology are beginning to overcome some of these 
problems, allowing accurate metering of doses and increasing their portability (Dalby, 
Spallek et al., 2004). 
 
1.2.3.2 Pressurised Metered Dose Inhalers (pMDIs) 
 
Since 1956, pressurised metered dose inhalers (pMDIs) have been the drug delivery 
system of choice for respiratory diseases because of a result of their cheap, robust and 
convenient characteristics (Hickey and Dunbar, 1997). Traditionally, these devices 
consist of a solution or suspension of fine drug particles in a chlorofluorocarbon (CFC) 
propellant sealed in a canister at high pressure (Biddiscombe, Melchor et al., 1987). 
The formulation may also contain formulation additives including surfactants and co-
solvents (McDonald and Martin, 2000). The propellant is the main component of pMDI 
formulations and performs the role of solvent and dispersion medium for drug 
substance and other excipients (Young, Price et al., 2003a). Actuation of the inhaler 
results in the release of a metered volume of this solution or suspension, which is 
driven by the high vapour pressure within the canister, which in turn emerges at a high 
 Chapter 1: Introduction  12 
 
 
velocity through a narrow orifice (Smyth, Hickey et al., 2006). This process, combined 
with evaporation of the propellant, results in an aerosol of drug particles in the 
respirable size range that are able to enter and deposit in the respiratory tract (Berry, 
Kline et al., 2003). Despite pMDIs being the most frequently prescribed inhalation 
dosage form, the fact remains that most patients cannot use them correctly (Virchow, 
Crompton et al., 2008). This is because the high speed aerosol plume generated by a 
pMDI requires the patient to use accurate co-ordination of inspiration and inhaler 
activation to ensure correct inhalation and deposition of the drug in the lung (Virchow, 
Crompton et al., 2008). Even with the correct inhalation technique, pMDIs are 
inefficient, often delivering less than 1/3 of the emitted dose to the lungs (Virchow, 
Crompton et al., 2008). In addition to these problems, the introduction of the Montreal 
Protocol results in the phase out of chlorofluorocarbon (CFC) propellant gas in all 
aerosol-based products, including pMDIs. As a result, all pharmaceutical CFC-based 
pMDI products were re-formulated using hydrofluoroalkanes (HFAs) propellant and 
replaced (Richards, Hirst et al., 2001). The difficulties and expense, incurred in re-
formulating pMDI products and long term issues regarding the future of HFA-based 
propellants, have prevented companies to launch new drugs as pMDI formulations 
(McDonald and Martin, 2000).  
 
1.2.3.3 Dry Powder Inhalers (DPIs) 
 
Dry powder inhalers (DPIs) permit a metered dose of drug to be delivered to the 
airways as a dry powder aerosol (Timsina, Martin et al., 1994). A patent from 1950, by 
Mack R. Fields, described the first metered dose DPI for the delivery of medicaments 
to lungs (Fields, 1950). Later, DPIs had their application in inhalation therapy as a 
CFC-free alternative for the older pMDIs (McDonald and Martin, 2000). Currently, the 
spectrum of application of DPIs has become much broader, due to the high lung 
deposition that can be attained and their suitability for pulmonary delivery of therapeutic 
peptides and proteins both for local and systemic conditions (Byron and Patton, 1994). 
 
DPIs are breath-actuated drug delivery systems, which enable a respirable cloud to be 
produced in response to the patient’s inspiratory effort (Timsina, Martin et al., 1994). 
DPIs may therefore have many advantages over pMDIs (Hannemann, 1999; Newman 
and Busse, 2002; Virchow, Crompton et al., 2008). Firstly, DPIs do not need a 
propellant, which has been the driving force behind the introduction of a large number 
of novel DPI devices in recent years (Timsina, Martin et al., 1994). The second benefit 
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is that DPIs eliminate the need for patient co-ordination of actuation and inhalation 
(Newman and Busse, 2002). Finally, in DPIs, the particles are travelling at a slower 
rate, therefore, an excessive drug loss due to impaction in the throat is avoided 
(Pauwels, Newman et al., 1997). 
 
Successful deposition of drug particles into the lung requires the delivery of particles 
with a mass median aerodynamic diameter (MMAD) less than 5 µm  (Heyder, Gebhart 
et al., 1986; Timsina, Martin et al., 1994; Prime, Atkins et al., 1997). A control of 
particle size of medicaments to be delivered by DPIs is typically achieved through high-
energy micronisation techniques (Thibert and Tawashi, 1999), although numerous 
other technologies, for example, spray drying (Li, Seville et al., 2005) and supercritical 
fluid technologies (Shekunov, Feeley et al., 2003) have been evaluated. However, 
respirable sized particles exhibit high surface energies, which lead to particle 
aggregation, poor flow and entrainment properties, and thereby make re-dispersion of 
the drug a difficult process (Feeley, York et al., 1998). 
 
The most common method employed to solve the problems associated with cohesive 
respirable powder materials is to formulate the drug with an excipient, traditionally 
lactose monohydrate (Bell, Hartley et al., 1971). The micronised drug is blended with 
carrier particles of a much larger size range (usually 20-100 µm), whereby the drug 
particles form an interactive mixture with the surfaces of the coarse lactose particles 
(Ganderton, 1992). The turbulent airflow generated within the device upon forced 
inspiration should be sufficient to fluidise the formulation from the device and to de-
aggregate the drug particles from the carrier particles (Telko and Hickey, 2005; Shur, 
Harris et al., 2008). The drug particles are then entrained into the airstream, which 
enables the drug particle to enter the lungs (Shur, Harris et al., 2008). The carrier 
particles are subsequently deposited in the oropharynx of the patient. Although high 
levels of turbulence are required to be engineered into the device for efficient 
deaggregation (Louey, Van Oort et al., 2006), there is a need to balance the resistance 
of the inhaler to airflow and in inhaling through the device at a flow rate which produces 
optimum drug delivery (Crowder and Hickey, 2006). One way to provide high levels of 
turbulence without imposing large increase in airflow resistance is the use and 
placement of grids of varying mesh sizes (Helgesson, Jennings et al., 2005; Telko and 
Hickey, 2005).  
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There are currently three types of DPIs available on the market. These include a 
single-dose, multidose and reservoir-based device (Prime, Atkins et al., 1997; 
Malcolmson and Embleton, 1998; Smith and Parry-Billings, 2003). Early DPI devices 
were all unit-dose systems and were dependent on loading and triggering procedures. 
The Spinhaler® and Rotahaler® are two early examples of DPI technologies. Both 
utilise pre-metered doses packed into hard gelatin capsules although different 
mechanisms of powder delivery and power technology are employed (Vidgren, 
Karkkainen et al., 1987). 
 
Multidose pre-metered DPIs include the successful Diskhaler® and Diskus® devices 
from GlaxoSmithkline. The Diskhaler® employs individual doses contained within 
blisters (4 or 8 blisters) on a disk. On actuation, a needle pierces the upper and lower 
surfaces of a blister. As the patient inhales, the contents of the blister are dispersed 
into the airstream. The drug particles are dissociated from the carrier and a fraction 
delivered to the lung. On re-priming the device, the disk rotates to expose the next 
blister to the piercing needle (Prime, Atkins et al., 1997). The Accuhaler® DPI device  
produced by GSK retains the blister pack and unit-dose approach of the Diskhaler®, but 
has the advantage of holding additional doses. The pack consists of a coiled, double-
foil strip of 60 blisters, each containing one dose of drug powder formulated with a 
lactose carrier (Malcolmson and Embleton, 1998). 
 
Reservoir DPIs contain all the doses in a bulk reservoir, and each dose is dispensed 
from this reservoir by manipulation of the device prior to inhalation (Smith and Parry-
Billings, 2003). The first device employing a multi-dose reservoir was the Turbuhaler 
(Newman, Moren et al., 1991). The dose is metered into conical cavities by rotating the 
base of the inhaler. The inhaled airstream dislodges the drug from the cavities and 
dispersion continues in the inhalation channels, which are helical to induce turbulent 
flow (Helgesson, Jennings et al., 2005). A desiccant is employed to ensure that the 
powder reservoir remains dry during the shelf life of the inhaler. Other examples of 
reservoir DPI device are the Easyhaler® (Ranbaxy, UK Ltd), Clickhaler® (Vectura plc, 
Chippenham, UK) and Pulvinal® (Chiesi Farmaceutici SpA, Parma, Italy).  
 
Every DPI device exhibits an internal resistance which determines the inhaled flow rate 
that a patient can achieve when using the device (Harris, 2007). As flow rate will 
inevitably be linked with inhaler performance, it is essential that such factors are 
considered in any in vitro comparative testing of DPIs (Harris, 2007). Successful 
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development of DPI systems requires development on two integrated fronts: device 
engineering and powder formulation engineering (Timsina, Martin et al., 1994). 
 
1.3 Pharmaceutical Engineering of DPI Drug Delivery Systems 
 
The engineering of DPI formulations has relied on ‘top-down’ manufacturing methods, 
where large crystalline drug particles are milled (micronised) to produce fine particles 
with a median geometric diameter 1–5 µm (Telko and Hickey, 2005). These particles 
are then blended with large lactose monohydrate carrier particles to improve powder 
fluidisation (Dunbar, Morgan et al., 2000). Owing to the strong interparticulate cohesive 
and adhesive forces noted with fine drug particles and the large carrier particles, lung 
delivery efficiencies of just 10–30% of the nominal dose are typically observed (Dunbar, 
Morgan et al., 2000). Hence, the process of entrainment and deposition of actives in 
the airways is largely dependent on the balance of interfacial forces between 
components of DPI formulation (Jones, Harris et al., 2008). The control and 
understanding of the interfacial properties of DPI formulations are critical to enable the 
formation of DPI drug product with defined quality and functionality (Edge, Muller et al., 
2008). 
 
Whilst it is known that the surface properties of the drug will dramatically affect DPI 
product performance, the primary design concept in drug particle manufacturing for 
DPIs remains particle size with limited understanding of the effects of processing on 
drug surface properties. Hence, to control the specific performance and stability 
properties of DPI dosage forms, the central design principle in DPI manufacturing must 
focus on tailoring the mesoscopic design of particle interfaces to enable careful control 
of particle-particle interactions and, therefore, product performance.  
 
Current micronisation practises, adopted to generate respirable-sized drug particles, 
provide little hope in controlling particle size, morphology and surface properties 
(Hickey, Mansour et al., 2007). Therefore, there is a requirement of particle processing 
technologies that enable the control of these properties of particles to enable the 
formation of designer particles for inhalation. 
 
 
 
 
 Chapter 1: Introduction  16 
 
 
1.3.1 Interparticulate Forces 
 
Particle interactions that occur as consequence of long-range attractive forces, with 
intermolecular binding energies less than 40 kJ.mol-1, are much weaker than short-
range interactions, such as ionic or covalent bonding (Johnson, 1996). These long-
range forces can be classified as either cohesive, between particles of similar size and 
the same chemical structure, or adhesive, between particles of different materials 
(Johnson, Kendall et al., 1971; Tabor, 1976). Hence, a powder is said to be cohesive 
when the component particles tend to stick to one another; the interaction forces 
between these particles are termed ‘cohesive forces’. Similarly, a particle is adhesive 
when it readily adheres to the surface of an object of larger dimensions; the interaction 
forces are then termed ‘adhesive forces’. When gravitational forces acting upon these 
particles become negligible then either the cohesive or adhesive forces become 
dominant (Tabor, 1976), which occurs when the dimensions of the particulate materials 
become smaller than 10 µm (Deryaguin, Krotova et al., 1978). Respirable powders 
employed typically in DPI formulations fall into this category, and much work has been 
done to fully understand the cohesive and adhesive forces that exist in such systems  
(Cline and Dalby, 2002; Begat, Morton et al., 2004). 
 
The interactions between particles may be a result of a number of concurrently acting 
forces or mechanisms such as van der Waals, electrostatic, capillary forces and solid 
bridging (McFarlane and Tabor, 1950; Johnson, Kendall et al., 1971). Since 
pharmaceutical solids are often insulators, particles are likely to retain a charge during 
the powder handling process (Staniforth and Rees, 1982). Charged particles will exert 
electrostatic forces on adjacent particles. However, uncharged particles also interact 
with each other due to dispersion forces (van der Waals forces) (Castellanos, 2005).  
 
When condensation occurs on solid-solid interfaces, particulate interactions due to 
capillary forces arise. These forces, resulting from the surface tension of the adsorbed 
liquid layer, may dominate over other forces if sufficient liquid is condensed on the 
solid-solid interface (McFarlane and Tabor, 1950; Price, Young et al., 2002). 
 
1.3.1.1 van der Waals Forces 
 
The omnipresent van der Waals forces are the major force of interaction between 
uncharged particles in a dry environment (Lifshitz, 1955). The van der Waals forces are 
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the summation of the attractive forces which arise due to the formation of temporary 
dipole moments between molecules as a result of random fluctuations in their 
surrounding electron cloud (Lifshitz, 1955). 
 
The van der Waals forces ( VDWF ) between two ideally smooth spheres in a vacuum 
can be described by Hamaker (Hamaker, 1937) : 
⎟⎟⎠
⎞
⎜⎜⎝
⎛
+= 21
21
212 dd
dd
s
HFVDW   Equation 1.3 
 
where H  is the Hamaker constant (Equation 1.4), s  is the separation distance 
between the spheres and 1d  and 2d  are the diameters of the two spheres. The 
Hamaker constant is given by: 
dvvH 2,121
2 λπ=    Equation 1.4 
 
where 1v  and 2v  are the number of atoms per unit volumes of particle 1 and 2 and 
d
2,1λ  
is the constant of dispersion: 
2
2,1 4
3 hFad −=λ     Equation 1.5 
 
where h  is Planok’s constant,  F  is the vibration frequency of the interacting 
electronic oscillators and a  is the polarisability of the molecules. 
 
The adhesive force between a sphere (diameter 1d ) and a plane composed of the 
same material and separated by distance s  is described by:  
 
2
111
6s
dHFVDW =     Equation 1.6 
 
whereas the adhesion between a sphere (diameter 1d ) and a plane composed of 
different materials and separated by distance s  is expressed by: 
 
  12
2211
6
d
s
HH
FVDW =    Equation 1.7 
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where 11H  and 22H  are the Hamaker constant for the particle and the plane surface, 
respectively.  
 
Equations 1.3, 1.6 and 1.7 demonstrate the importance of the separation distance, s , 
in determining the van der Waals forces between two solid objects. It is clear that these 
will retard rapidly with increasing separation distance, so it is not surprising that van der 
Waals forces exert their influence only over a narrow range of approximately 10 nm 
(Hamaker, 1937). 
 
1.3.1.2 Capillary Forces 
 
At approximately 50-60% relative humidity, the partial water vapour pressure in the 
atmosphere may be sufficient for the water to condense onto particle surfaces and 
when two surfaces are brought into contact, this may produce a water bridge between 
contiguous surfaces (McFarlane and Tabor, 1950; Hiestand, 1966). The formation of a 
capillary bridge results in an increased force of adhesion between the particles, due to 
the surface tension force of the water and meniscus formed between contacting 
surfaces (McFarlane and Tabor, 1950). The magnitude of this capillary force ( cF ) 
between two identical smooth spheres (radius r ) can be calculated as:  
 
απγ cos2 rF wc =    Equation 1.8 
 
where wγ  is a surface tension of water and α  is a contact angle between water and 
the spheres. In the case of a sphere (radius r ) adhering to a surface, the capillary 
force resulting from the condensation of water in the interface can be calculated as: 
 
)cos(cos2 βαπγ += rF wc   Equation 1.9 
 
where α  and β  are the contact angles of the water with the surface and particle, 
respectively. 
 
Capillary forces become the dominant adhesion forces when the relative humidity is 
above 65-75% (Hiestand, 1966; Price, Young et al., 2002).  
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1.3.1.3 Electrostatic Forces 
 
During powder handling, particles become charged by contact or friction with other 
particles or surfaces. This process is known as triboelectrification (Staniforth and Rees, 
1982). If two charged particles are brought together, they will have an electrostatic 
force (either attractive or repulsive, depending whether the particles are like or 
oppositely charged) which can be described by Coulomb’s law (Coulomb, 1785): 
 
2
21
4 s
qqFEL πε=    Equation 1.10 
 
where ELF  is the electrostatic force,  1q  and 2q  are the electrical charges on the two 
particles, ε  is the permitivity and s  is the separation distance between the particles. 
 
An uncharged particle may become charged if an image charge is induced upon it by 
the approach of a charged particle (Onsager and Samaras, 1934). The resultant 
electrostatic force may be shown by: 
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where s  is the separation distance between charged and uncharged particles. This 
equation may be modified to describe the adhesion of a charged particle to a flat 
earthed conducting surface via the formation of an image charge by making the 
assumption that r  → ∞ : 
2
2
16 s
qFEL πε=    Equation 1.12 
 
Contact between two uncharged particles with different work functions will appear in 
the flow of electrons from the particle with the lower work function to the particle with 
the higher work function until an equilibrium is established (Tabor, 1976). The resultant 
force of attraction ( wF ) can be described as: 
 
( )
s
UrF w
2Δ= πε    Equation 1.13 
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where r  is the radius of the particles and UΔ  is the potential difference arising from 
the difference in work functions. 
 
Equations 1.10 to 1.13 show that electrostatic forces are significantly dependent on the 
electrical properties of the particles involved and the separation distance between them. 
Under normal environmental conditions, electrostatic forces are at least ten times 
smaller than van der Waals forces (Tabor, 1976). This leads to increase van der Waals 
forces, which are thereafter largely responsible for the strength of the adhesion, 
especially if the electrostatic charge dissipates (Johnson, 1996). 
 
1.3.1.4 Mechanical Interlocking 
 
Generally, pharmaceutical particles exhibit irregular shapes and microscopically rough 
surface topography. Thus, the contact and resulting adhesion between two such 
particles can result in the interlocking of asperities, thereby leading to an increase in 
interparticulate interactions (Jayasing, Pilpel et al., 1970; Adolfsson, Olsson et al., 
1997). In addition, if roughness causes particle-particle contact to only occur over a 
small surface area, the interparticulate forces acting on this small area will produce an 
extremely high pressure (Fuller and Tabor, 1975). This may exceed the yield value of 
the material, resulting in increased mechanical interlocking and van der Waals forces.  
 
1.3.2 Factors Affecting Interparticulate Forces 
 
Many factors can affect the magnitude of the adhesion between particles. These relate 
to characteristics of the particles themselves, their process history and the conditions 
under which they are stored. The following sections briefly review some of the more 
important of these factors.  
 
1.3.2.1 Particle Size 
 
According to the equations shown in Section 1.3.1, van der Waals (the major force 
responsible for adhesion) are directly proportional to the particle diameter ( d ), whilst 
gravitational forces are proportional to diameter cubed ( 3d ). Thus, as particle size is 
reduced, the adhesion forces experienced by a particle become more and more 
significant when compared to the gravitational forces to which they are exposed (Visser, 
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1995). For particle smaller than approximately 10 µm, adhesive forces dominate 
gravitational forces, which explain the cohesiveness and poor flowability of fine 
respirable powders. 
 
1.3.2.2 Particle Shape 
 
Van der Waals and electrostatic forces both decrease as a function of the square of the 
separation distance between particles (Equations 1.3, 1.6, 1.7 and 1.10 to 1.12). Hence, 
the increase of this distance would reduce particulate interaction. Additionally, the 
range over which the latter exerts the influence is only ~10 nm. Thus, any effect of 
particle shape on interparticulate distance may significantly influence particle 
interactive forces (Johnson, Kendall et al., 1971). For instance, small, non-interlocking 
surface asperities which increase the separation distance between particles will reduce 
the force of adhesion upon contact (Johnson, Kendall et al., 1971). When the asperities 
are of the order of 1 µm, the separation distance will be large, thereby limiting the van 
der Waals attractions to almost zero (Castellanos, 2005). Alternatively, flat elongated 
particles which pack as shown in Figure 1.2A will experience increased interparticulate 
adhesion due to their reduced separation distance and increased interparticulate 
contact area. The packing of such particles depends on their process history, however, 
in the absence of handling, they tend to be loosely packed together (Figure 1.2B), 
giving rise to higher separation distance and reduced area of contact leading to a 
reduction in their adhesive interactions (Valverde, Ramos et al., 1998).  
 
 
                     
 
 
 
Figure 1.2: Packing arrangements for flat elongated particle (Zeng, Martin et al. 2001): 
(A) Closely packed orientation, typically found after powder handling. (B) Loosely 
packed orientation 
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1.3.2.3 Surface Roughness of Particles 
 
The effect of roughness on adhesion is dependent on the relative size of the roughness 
and the contact geometry between adhering particles (Fuller and Tabor, 1975). As 
shown in Figure 1.3A, if the roughness of a substrate is of a smaller scale than the 
adhering particle, the contact area between the particle and the surface will be 
decreased and the separation distance increased when compared to adhesion to a flat 
surface (Figure 1.3B), resulting in decreased interparticulate forces (Johnson, Kendall 
et al., 1971; Fuller and Tabor, 1975; Johnson, 1996). When the roughness of substrate 
is on a larger scale than the adhering particle, the situation is reversed (Figure 1.3C). In 
addition, mechanical interlocking can occur, resulting in increased interparticulate 
forces. 
                
 
Figure 1.3: The effects of roughness on particle-surface adhesion. (A) Surface 
roughness on a smaller scale the particle size. (B) A smooth surface. (C) Surface 
roughness on a larger scale than particle size 
 
For most pharmaceutical powders, adhesion occurs between two rough particles or a 
rough particle and a rough surface, so the examples shown in Figure 1.3 (where the 
particle is smooth) are a simplification of the situation (Zeng, Martin et al., 2001). 
 
1.3.2.4 Particle Deformation 
 
Attractive forces can generate deformation at the contact site of the adhering surface 
(Krishnan, Busnaina et al., 1994). The extent of any deformation is dependent on the 
elastic properties of the particles, the magnitude of the attractive forces and the 
magnitude and duration of any external forces applied to the particles (Johnson, 1996). 
For certain materials such as polymer-like materials, the duration of contact is also 
important as deformation will increase with time resulting in increased adhesion, a 
phenomenon known as aging (Krupp, 1967). However, in the context of DPI 
formulations, deformation does not lead to greater adhesion but may influence particle 
re-entrainment upon aerosolisation (Johnson, 1998). 
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1.3.2.5 Surface Free Energy 
 
The surface free energy from a solid material is described as the energy required to 
produce a unit area of surface and is analogous to the surface tension of a liquid 
(Johnson, Kendall et al., 1971). Unlike liquids, the molecules of a solid are not free to 
move, therefore, surface free energy is not uniform over a surface and depends on the 
history of the material (Johnson, 1998). The quantity of work required to separate two 
surfaces of two materials is called the work of adhesion ( aW ) and is related to the 
surface free energy of the surfaces by the following equation: 
 
)( CDDCsa AW γγγ −+=   Equation 1.14 
 
where sA  is the area of surface produced by the separation, 
Cγ  and Dγ are the free 
energies per unit surface area of solids C and D in air, respectively; and CDγ  is the  
free energy of the C-D interface per unit area. Therefore, the work of cohesion ( cW ) (i.e. 
the work requires to separate two surfaces of the same material) is shown by: 
 
C
sc AW γ2=     Equation 1.15 
 
The thermodynamic work of adhesion and cohesion is directly related to the force of 
adhesion and cohesion and is critically dependant on the surface free energies of the 
interacting particles (Johnson, Kendall et al., 1971). 
 
1.3.2.6 Relative Humidity 
 
Interparticulate forces are influenced by relative humidity via two opposing mechanisms. 
On the one hand, the relative humidity increases particulate interaction because of the 
capillary forces when a significant amount of water is condensed on the surface of the 
interacting system (McFarlane and Tabor, 1950; Price, Young et al., 2002). On the 
other hand, the conductivity of both interactive particles will be increased and will 
accelerate the dissipation of electrostatic charges on the particles (Byron, Peart et al., 
1997). Hence, water at high relative humidity can condensate at the contact points 
between particles, resulting in the formation of liquid bridges and an increase in 
capillary forces (Price, Young et al., 2002; Young, Price et al., 2003b).  
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1.3.3 Particle Physical State 
 
Many materials can form solids that are crystalline or amorphous, depending on the 
states of growth. Therefore, it is completely important to know the physical properties of 
solids. 
 
1.3.3.1 The Crystalline State 
 
Crystals are solids in which the atoms are arranged in a periodic repeating pattern that 
extends in three dimensions (Myerson, 2002). The simplest repeating unit in a crystal is 
described as a unit cell. Each unit cell is defined in terms of lattice points. It was 
observed in 1848 by Bravais that there are 14 possible point lattices which can be 
constructed (Myerson, 2002). Also, these point lattices can be divided into seven 
categories, which differ in the three unit-cell edge lengths and three internal angles, as 
shown in the Figure 1.4. 
 
                 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
Figure 1.4: The Bravais lattices modified from 
http://chemed.chem.purdue.edu/genchem/topicreview/bp/ch13/unitcell.php 
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Crystals are nucleated and grown from supersaturated solutions. A saturated solution 
is a thermodynamic equilibrium between the solid phase and the liquid phase at a 
specified temperature (Mullins, 1992). This requirement for a supersaturated solution is 
critical for nucleation and crystal growth.   
 
Nucleation happens spontaneously in a homogeneous solution or induced by a 
heterogeneous process. These processes are named primary homogeneous 
nucleation and heterogeneous nucleation, respectively. Young and Berkeley 
discovered that agitation, mechanical shock, friction extreme pressures and 
temperature cooling can increase the degree of nucleation (Young, 1911; Berkeley, 
1912). A supersaturated solution may nucleate at a lower supersaturation when 
crystals of the solute are already present or added. These crystals, typically described 
as seeds, perform as nucleation centres for crystal growth. Such a process can be 
referred as secondary nucleation (Botsaris, 1976). 
 
The external appearance of a crystal is referred to crystal habit (Mullins, 1992). Despite 
the fact that crystals can be classified to seven general systems, the relative sizes of 
the faces of a particular crystal can greatly vary. This variation is called a modification 
of habit. The crystals may grow more rapidly, or be stunted in one direction; an 
elongated growth of the habit gives a needle-shaped crystal and a stunted growth 
brings a flat plate-like crystal (Mullins, 1992). A description of the morphology of a 
crystal requires the characterisation of each crystal face present, their relative 
dominance, specific angles between the faces, relative areas and shape factors. These 
are used to describe the macroscopic geometry of a crystal. However, knowing the 
internal structure of a crystal unit cell is not adequate to represent the external habit of 
the resulting crystals formed. External habit is not only controlled by its internal 
structure, but also by the conditions in which the crystal has been grown. The rate of 
crystal growth, the solvent used, and the impurities present in the solution may have a 
substantially influence on the crystal habit (Strickland-Constable, 1968; Laudise, 1970). 
 
1.3.3.2 Polymorphism 
 
Polymorphism is the name used to describe the phenomenon of chemical species 
having more than one crystal structure (Brittain, Bogdanowich et al., 1991). When a 
material crystallises into different polymorphs, the chemical nature of the species 
remains identical. However, due to the alteration in the crystal unit cell, physical 
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properties including density, melting point, solubility and hygroscopicity may vary 
(Brittain, 1997). During crystallisation, inhibiting polymorphism may be particularly 
crucial. This can sometimes be achieved by optimising and controlling the 
crystallisation conditions (e.g. solution temperature, solvents) as well as storage 
condition (e.g. temperature and relative humidity), in preventing the formation of 
undesired polymorphs. For example, cimetidine, a specific competitive histamine H2-
receptor antagonist, has seven known polymorphs (Danesh and Chen, 2000). Two of 
them are of particular interest to the pharmaceutical industry, with one being used in 
tabletting (form A) and other in suspensions (form B). While form A can be re-
crystallised from non-aqueous solvents at room temperature, form B requires slow 
cooling from a hot aqueous solution. Also, lactose is known to have two anomeric 
forms namely, α and β. Both are simultaneously present in aqueous solution with an α/β 
ration close to 40/60, but only the α-lactose monohydrate crystallises spontaneously 
below 93.5°C (Nickerson, 1974). 
 
1.3.3.3 The Amorphous State  
 
A solid in the amorphous state is also known as a supercooled liquid in which the 
molecules are arranged in a random behaviour as in the liquid state (Yu, 2001). 
Substances such as glass and many synthetic plastics are amorphous in nature. They 
are different from crystalline solids in that they have to flow when subjected to sufficient 
pressure over a period of time, and they do not exhibit melting points (Hancock and 
Zografi, 1994). 
 
An amorphous state is identified by the absence of three-dimensional long range order 
which exists in a crystalline state (Hancock, Shamblin et al., 1995). Rapid cooling, fast 
evaporation or precipitation may happen in the formation of amorphous solids in a 
glassy or rubbery state (Hancock, Shamblin et al., 1995). Amorphous areas on solid 
particles may also be generated from mechanical treatments (Salekigerhardt, Ahlneck 
et al., 1994). The differences in physical properties between crystalline and amorphous 
material have been found to have a significant effect on the stability and performance 
of DPI formulations (Buckton, 1997). Molecules within an amorphous region are 
randomly arranged, and demonstrate a higher surface energy than the crystalline 
material (Ambarkhane, Pincott et al., 2005). Moreover, amorphous materials have 
different mechanical properties in comparison to crystalline materials, where 
amorphous materials are softer and subject to greater deformation under stress 
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(Andronis, Yoshioka et al., 1997). The degree of molecular mobility within a particular 
amorphous material will be related on a number of factors, including temperature and 
solvent vapour pressure (Hancock and Zografi, 1994). The sorption of a solvent into an 
amorphous region would increase molecular mobility and thus lower the glass 
transition temperature ( gT ) (Buckton and Darcy, 1996). If the partial pressure of the 
solvent is high enough to lower the gT  below the experimental temperature, the region 
may recrystallise and remove the solvent (Hancock and Zografi, 1994). It is important 
to note that a system is a thermodynamic process and not a kinetic process. It will not 
reach a true equilibrium until the system re-crystallises, but the process may take time. 
In pharmaceutical applications, dosage forms must have a specific functionality that 
requires a high-energy processing such as milling or micronisation. This process leads 
to the formation of molecular defects, dislocation and the creation of amorphous areas 
within the crystalline material (Begat, Young et al., 2003). In general, amorphous 
materials are thermodynamically unstable and will experience re-crystallsation if the 
right conditions and the kinetics are favourable (Buckton and Darcey, 1999). The 
amorphous regions will directly affect the stability of a formulation as the surface 
energetics will become unpredictable, leading to batch-to-batch variations in the 
stability and aerosolisation properties of the powder blend (Feeley, York et al., 1998).  
 
1.3.4 Particle Engineering  
 
To generate respirable drug particles, different processes have been widely used, for 
example, micronisation, spray drying, spray freeze drying, supercritical fluid technology, 
and crystallisation.  
   
1.3.4.1 Micronisation 
  
Inhalation products such as DPIs, pMDIs and suspension nebulisers consist of 
micronised drug in either agglomerated or blended form. Such particles are generally 
produced by batch crystallisation, followed by filtering, drying and micronisation 
(Shekunov, Feeley et al., 2003). The particle size reduction can be achieved by 
pressure, attrition, impact, or shear. Vibration milling, ball milling and jet-milling are 
well-established techniques used to manufacture dry powders for inhalation. Although 
milling can be carried out on a dry or wet basis, dry grinding is more generally 
employed as it is less labor-intensive. In the jet-milling process, the starting material 
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has many impact events before a significant quantity of the required particle size 
fraction is achieved and separated from the larger particles by inertial impaction 
(Steckel, Rasenack et al., 2003). This classification ensures that the particle size 
distribution required for respiratory drug delivery can be obtained.  
 
Particles produced by micronisation are adversely affected by such a high energy 
process and the resultant particles have been shown to increase surface rugosity, 
surface free energy, electric charge and most significantly with a degree of crystalline 
disorder (Ticehurst, Rowe et al., 1994; Feeley, York et al., 1998). These disordered 
regions are thought to be on the particle surfaces and are metastable (Begat, Young et 
al., 2003). Under certain conditions, for example, elevated temperature or humidity, 
these amorphous surface regions on particles may undergo a re-crystallisation process, 
inducing solid crystal bonding and particle agglomeration (Price and Young, 2005). The 
material is also subjected to chemical decomposition and water sorption. All physical 
and chemical changes are highly undesirable, and can affect the in-vitro and in-vivo 
performance of the respiratory formulation (Rasenack, Steckel et al., 2004). 
 
1.3.4.2 Spray Drying 
 
Spray drying has been employed as a routine technique for the production of 
pharmaceutical particles for decades (Broadhead, Rouan et al., 1992). A typical spray-
drying process comprises four steps: (a) atomisation of feed solution into a spray; (b) 
spray-air contact involving flow and mixing; (c) drying of sprayed droplets at elevated 
temperatures; and (d) separation of dried product from the air (Masters, 1985). A 
feeding solution is atomised into droplets that dry rapidly in the spray drying process 
due to their high surface area and contact with the drying gas (Masters, 1985). The 
process conditions, for instance, flow rate, pump rate, aspiration rate and heat 
significantly influence the drying time of droplets (Chawla, Taylor et al., 1994; Li, Seville 
et al., 2005; Shur, Nevell et al., 2008). This drying time can start from a few seconds to 
less than 100 minutes (Masters, 1985). The temperature experienced by the droplets is 
lower than the temperature of the drying air due to evaporative cooling, which has 
enabled the processing of labile molecules such as proteins and genes (Seville, 
Kellaway et al., 2002; Li, Seville et al., 2005). The dried powder is protected from 
overheating by rapid removal of the drying zone. Finally, the final product can be 
removed from the air stream by the use of cyclones or filters (Masters, 1985). 
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The particles from the spray-drying process are commonly spherical and hollow as a 
result of the rapid evaporation of the solvent on the droplets surface and solidification 
of the surface (Broadhead, Rouan et al., 1992). The hollow structure of spray-dried 
particles can provide benefits in terms of the aerodynamic diameter, therefore, the 
overall density is low, allowing the formation of larger particles to reach the 
aerodynamic size range for inhalation (Edwards, Hanes et al., 1997; Bosquillon, 
Rouxhet et al., 2004). However, spray-dried products are typically amorphous, which, 
owing to their metastable state, precludes their use in conventional carrier-based DPI 
drug products. 
 
1.3.4.3 Spray Freeze Drying 
 
The technique of spray freeze drying involves the atomisation of an aqueous drug 
solution via a two-fluid or an ultrasonic nozzle into a chamber filled with a cryogenic 
liquids, for example, liquid nitrogen or halocarbon refrigerant (Maa, Nguyen et al., 
1999). The spraying process can be run beneath or above the surface of the cryogenic 
liquid, depending on the position of nozzle (Leuenberger, Plitzko et al., 2006). Since 
the normal boiling point for such a liquid is very low, the droplets are quickly frozen. It 
has been established that these droplets may begin to freeze during the time of flight 
through the cold vapour phase and then entirely freeze upon contact with cryogenic 
liquid (Mumenthaler and Leuenberger, 1991; Maa, Nguyen et al., 1999). Once the 
spraying process is completed, the whole content can be lyophilized with conventional 
freeze drying (Rogers, Nelsen et al., 2003). After spray freezing, the frozen solvent is 
removed, as in the case of freezing with cryogenic liquids, by vacuum or atmospheric 
freeze drying. Limitations to this technique contain the fact that it is time consuming. 
Additionally, the nature of the process has safety issues involved with spraying into 
cryogenic fluids and it is expensive (Mumenthaler and Leuenberger, 1991). 
Furthermore, the metastable state of spray-freeze-dried particles may lead to drug 
product instability once such particles are incorporated into a given dosage form.   
 
1.3.4.4 Supercritical Fluid (SCF) Technology  
 
Supercritical fluids (SCFs) are gases and liquids at temperatures and pressures above 
their critical points which include critical temperature ( cT ) and critical pressure ( cP ) 
(Shekunov and York, 2000). In the area of the critical point, the SCFs occur as a single 
phase with several advantageous properties of both liquids and gases (Palakodaty, 
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York et al., 1998). The SCFs obtain density values which are able to reach salvation 
power, whilst the viscosity of solutes in SCFs is lower than in liquids (Kajimoto, 1999). 
The diffusivity of solutes in SCFs is completely higher than in liquids, hence, it is 
capable of facilitating mass transfer without difficulty (Eckert, Knutson et al., 1996). 
Most importantly, SCFs are highly compressible, particularly near the critical point, and 
their densities and thus salvation power can also be controlled by variation in 
temperature and pressure (Savage, Gopalan et al., 1995). According to the 
pharmaceutical applications, SCF is akin to supercritical CO2 (SC CO2) because of its 
low critical temperature (31.1˚C), moderate pressure (73.8 bar), non-toxic inert nature 
and low cost (Savage, Gopalan et al., 1995).  
 
Particle engineering by SCFs can be separated into three different groups (York, 1999). 
The first method involves dissolving or solubilising the drug in a SCF followed by rapid 
expansion of the SCF solution through a heated orifice to minimise the density of the 
solution, thereby decreasing the salvation power of the SCF (York, 1999). The 
reduction of the salvation power leads to the precipitation of the drug (Pasquali, Bettini 
et al., 2006). This process is referred to as the “rapid expansion of supercritical 
solution” (RESS) (Pasquali, Bettini et al., 2006). The second method is similar to RESS 
because they both involve using SC CO2 as a solvent rather than an anti-solvent. The 
process has been named as “precipitation from gas saturated solution” (PGSS). For 
this PGSS system, the SCF is firstly dissolved in molten solute, following with the step 
of transferring the supercritical solution from an orifice into a chamber to allow a rapid 
expansion under ambient conditions (Jung and Perrut, 2001). Particle formation from 
PGSS utilises the high solubility of CO2 in certain materials such as polymers, which 
result in plasticisation, decreased viscosity, and depressed melting and glass-transition 
points. The essential benefit is to apply this procedure with blending, coating and 
encapsulation, which occur without the use of organic solvents (Jung and Perrut, 2001). 
The challenge of PGSS is the controlling of particle size because the high melt 
viscosity may stop the formation of fine particles. The third method is the most common 
method and different variants of technique have been developed. This typical 
technique employs a similar concept to the use of anti-solvent in solvent-based 
crystallisation processes (Palakodaty, York et al., 1998). The high solubility of SC CO2 
in organic solvents leads to volume expansion when the fluids make contact. This 
contributes to the reduction in solvent density and parallel fall in salvation capacity 
(York, 1999). Such reduction may cause increased level of supersaturation, solute 
nucleation and particle formation (York, 1999). The assorted names such as GAS 
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(gaseous anti-solvent), ASES (aerosol solvent extraction system), SEDS (solution 
enhanced dispersion by SCF), and PCA (precipitation by compressed anti-solvent) 
have been assigned to different applications via this technique (Jung and Perrut, 2001). 
For example, Steckel et al. used ASES process on particle properties of budesonide 
and found that the process condition in ASES may influence the aerodynamic 
properties, although other physico-chemical parameters appear to be similar (Steckel, 
Pichert et al., 2004). The principal disadvantage of this process is the lack of control for 
particle formation. In batch procedure conditions, it has been shown that the level of 
saturation is not maintained (Jung and Perrut, 2001).  
 
1.3.4.5 Controlled Crystallisation  
 
The separation of a solid substance from solution by changing the physical or chemical 
properties of the material concerned is termed crystallisation (Shekunov and York, 
2000). A compound may crystallise from a solution when its solubility in a particular 
solvent is exceeded and the solution becomes supersaturated. Supersaturation can be 
accomplished in many ways, for instance, the evaporation of the solvent, cooling the 
solution or by producing additional solute as a result of chemical reaction or a change 
in the solvent system (Mullins, 1992). Controlled crystallisation has advantages over 
both micronisation and spray drying in that it may generate particles with high 
crystallinity and of predetermined size, size distribution and shape (Rasenack, Steckel 
et al., 2004; Westmeier and Steckel, 2008). For diagnosis of asthma and bronchial- 
related disorder, Abbas and Srour found that the generated NaCl particles with size 
ranging from approximately 1 µm to sub-micron range were achieved by 
sonocrystallisation with optimal conditions of temperature (<5˚C), ultrasonic power 
output (~35W) and salt concentration (~32g/100g water) (Abbas, Srour et al., 2007). 
Controlled crystallisation is an important technique, which may aid the generation of 
particles suitable for drug delivery to the lungs. 
 
1.4 Solution Atomisation and Crystallisation by Sonication (SAX) 
 
1.4.1 SAX Process 
 
The solution atomisation and crystallisation by sonication (SAX) process consists of 
three interdependent processes: (a) the production of aerosol droplets of the solute 
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from a carrier solvent using a suitable aerosol generator; (b) the collection of the highly 
supersaturated droplets in a crystallisation vessel containing a non-solvent of the drug; 
(c) the application of ultrasonic waves to a crystallisation vessel to controllably induce 
homogeneous nucleation and crystal growth (Kaerger and Price, 2004). An atomiser in 
the SAX process produces highly supersaturated spherical constructs of the active 
ingredient within a well-defined particle size for controlled crystallisation. The atomised 
droplets are collected in a crystallisation vessel containing a non-solvent of the drug, 
which is preferably miscible with the solvent in which the drug is solubilised (Kaerger 
and Price, 2004). The surface tension of the collecting solution in the crystallisation 
vessel should be low or possibly minimised to prevent structural changes to the droplet 
shape on impingement. The generation of micrometer-sized droplets of drug solution 
leads to rapid vaporisation of the solvent and the production of highly supersaturated 
droplets of the solute molecules. However, rapid crystallisation within these droplets 
does not readily occur because of the dramatic increase in the viscosity, which limits 
the mass transport properties of the solute molecules to form a critical nucleus for 
nucleation and subsequent crystal growth (Kaerger and Price, 2004). To induce 
homogeneous nucleation, such highly supersaturated droplets require a sufficient 
degree of molecular motion within the droplets. This process is aided by the application 
of sonic energy, which increases the molecular motion within the droplets and induces 
nucleation and growth of crystals.  
 
The relative viscosity of these droplets will be drug specific and highly dependent on 
the rate of vaporisation of the drug solvent. The vaporisation process is dependent on a 
number of parameters including vapor pressure of the solvent, dimensions of the initial 
atomised droplet, solute-to-solvent composition, temperature, and flow rate. In the SAX 
process, the degree of vaporisation of the solvent is controlled by the separation 
distance between the atomiser and the non-solvent solution. As a batch process, the 
crystallised particles are filtered from the resulting suspension and dried over silica-gel 
at room temperature (Kaerger and Price, 2004). 
 
By combining these processes and controlling relevant parameters, high-purity micron-
sized sphere-like crystalline particles can be readily produced in a single droplet-to-
particle operation. The major advantage of this low-cost technique relates to the use of 
any suitable aerosol generator, and the whole process can be carried out under 
atmospheric pressure and ambient conditions. Furthermore, it has the potential for 
batch and continuous processing at an industrial scale.  
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1.4.2 Theory of Crystallisation 
 
The crystalline state is different from the amorphous state by the manner in which 
constituent molecules, atoms or ions arrange into a thermodynamically stable 
crystalline lattice. A crystalline lattice presents long-range molecular order with the 
configuration of the molecules, atoms or ions into a fixed and periodic pattern (Mullins, 
1992). 
 
1.4.2.1 Nucleation 
   
Crystals are typically nucleated and grown from a supersaturated solution or from a 
supercooled melt of the solid (Mullins, 1992). Supersaturation is defined as a state in 
which the concentration of substance in a solvent at a specific temperature and 
pressure is higher than the saturated solubility of the drug under such conditions 
(Shekunov and York, 2000). Supersaturation can be expressed as concentration 
driving force cΔ :  
*ccc −=Δ    Equation 1.16 
or as a supersaturation ratio S : 
     *c
cS =    Equation 1.17 
or as a relative supersaturation σ : 
*c
cΔ=σ    Equation 1.18 
 
where c  is actual concentration and *c  is equilibrium saturated concentration at a well-
defined temperature and pressure. In general, the solubility of a drug increases with 
increasing temperature (Shekunov and York, 2000). 
 
The formation of a supersaturated or supercooled state alone is not a sufficient cause 
for a system to induce nucleation (Shekunov and York, 2000). Prior to crystal growth, 
there must exist a number of agglomerated molecules that act as growth centres 
(Botsaris, 1976). These critical nuclei may occur spontaneously at certain conditions of 
supersaturation. This problem can be avoided by secondary nucleation, where artificial 
seed crystals are introduced into the supersaturated solution. Seed crystals can either 
catalyse the formation of other nuclei or act as a growth centre for crystal growth 
(Botsaris, 1976).  
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According to primary nucleation, it can be divided into two categories. On the one hand, 
foreign particles such as impurities or the material of the vessel provide the breeding 
ground for nuclei formation (Mullins, 1992). This process is termed heterogeneous 
primary nucleation. On the other hand, a sufficient number of molecules can 
spontaneously agglomerate to form a nucleus, and such number of molecules can vary 
between ten to several thousands (Mullins, 1992). This process is referred to as the 
homogeneous primary nucleation.  
 
The free energy changes associated with the process of homogeneous nucleation may 
be described as follows. In Figure 1.5, the diagram shows the free energy of nucleation 
explaining the existence of a critical nucleus. The overall Gibbs free energy ( GΔ ) 
results from the addition of the surface excess free energy sGΔ , which is the difference 
between the energy on the surface and inside a sphere with radius r, and the volume 
excess free energy vGΔ , which is the difference in energy between the bulk and 
particles in solution. The total Gibbs free energy GΔ  can be expressed as: 
 
vs GGG Δ+Δ=Δ    Equation 1.19 
                               vGrr Δ+= 32 3
44 πγπ   Equation 1.20 
 
where vGΔ  is the free energy change of the transformation per unit volume and γ  is 
the surface tension (Mullins, 1992). 
 
The value of sGΔ  is dependent on the surface of the sphere, which increases as a 
function of 2r , whereas vGΔ  proportionally increases to 3r . Thus, for small r  with a 
small number of molecules in the lattice, sGΔ  increases more dramatically than vGΔ . 
However, upon reaching a critical radius ( critr ) shown in Equation 1.21, vGΔ  increases 
faster than sGΔ  and it becomes thermodynamically more attractive to increase the size 
of the nucleus instead of re-dissolving. At this critical point, nucleation ceases and 
crystal growth begins (Myerson, 2002).  
v
crit G
r Δ
−= γ2    Equation 1.21 
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Figure 1.5: Free energy diagram of nucleation showing free energy versus cluster size  
 
The number of nuclei formed per unit time, known as the rate of nucleation ( J ), can be 
expressed in the form of an Arrhenius equation, which is commonly used for 
determining the rate of thermodynamically activated processes: 
 
kT
Gcrit
AeJ
Δ−
=     Equation 1.22 
 
where k  is the Boltzmann constant. The Gibbs-Thomson relationship (Mullin 1992) 
which relates the solubility to the particle size may be written as: 
 
kTr
VS mγ2ln =     Equation 1.23 
 
where mV  is the molecular volume. Combining equations 1.21, 1.22, 1.23, the result is 
thus: 
 
⎥⎥⎦
⎤
⎢⎢⎣
⎡ −= 233
23
)(ln3
16
STk
VAJ mEXP
πγ
  Equation 1.24 
 
The rate of nucleation, therefore, depends on temperature, supersaturation and surface 
free energy. Furthermore, it can be concluded that the majority of obtained nuclei will 
exhibit the lowest possible surface free energy of the material because an increase in 
surface tension would led to a decrease in the rate of nucleation. 
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Nucleation can often be induced by agitation, mechanical shock, friction and extreme 
pressure within the solutions or melts (Young, 1911). The effects of electric and 
magnetic fields, spark discharge and ultrasonic irradiation have previously been 
studied, and are slowly finding significant applications in industrial crystallisation 
(Mullins, 1992). 
 
1.4.2.2 The Influence of Ultrasonication on Nucleation 
   
Ultrasonication has been applied to initiate nucleation and crystallisation in 
supersaturated solutions on the laboratory scale (Kaerger and Price, 2004; Abbas, 
Srour et al., 2007). However, there still remains a degree of uncertainty on how the 
arrangement of molecules in a crystalline structure during nucleation and crystallisation 
is linked to ultrasonic waves. 
 
Ultrasound is the name given to sound waves having frequencies higher than those to 
which the human ear can respond ( f > 20 kHz) (Ruecroft, Hipkiss et al., 2005). Being 
a sound wave, it is transported by solids, liquids and gases with elastic behaviour. The 
movement of molecules in a vibrating body is a vibration around a mean rest-position, 
and energy is transported by transmission to adjoined particles (Ruecroft, Hipkiss et al., 
2005). This movement produces compressed areas, followed by an area of enhanced 
mean molecular distance. In gases and liquids, particles oscillate in the direction of 
producing longitudinal waves (Lorimer and Mason, 1987). However, in solids, the shear 
elasticity can also support tangential stresses and allow perpendicular movement of the 
particles and transversal waves (Ruecroft, Hipkiss et al., 2005).  
 
If an acoustic field is applied to a liquid, it creates an additional acoustic pressure ( aP ) 
to the ambient hydrostatic pressure ( hP ). If 
∗A  is the amplitude of the wave, the 
acoustic pressure can be described as: 
 
 
)2sin( ftAPa π∗=    Equation 1.25 
 
where t  is the time and f  the frequency of the wave (Lorimer and Mason, 1987).  
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The corresponding energy ( I ) transmitted to the liquid (per second per cm2) can be 
determined by: 
sf V
AI ρ2
2∗
=     Equation 1.26 
 
where fρ  is the density of the fluid and sV  the velocity of sound in the liquid. 
Molecules vibrating under the action of a sound wave additionally experience a viscous 
interaction, which decreases the amplitude of the sound wave. The lost energy is 
represented in bulk heating and the energy loss can de described by:  
 
laeII
∗−= 20*     Equation 1.27 
 
where *I  is the intensity of the wave at a pre-set distance l , 0I  the intensity at the 
source and ∗a  the absorption coefficient. The absorption coefficient ∗a  of a liquid is 
described by the Kirchoff equation, where: 
 
2fa ∝∗     Equation 1.28 
 
From equation 1.28, increasing in frequency leads to a greater degree of absorption. 
Because this energy, which is lost within the system, is converted into heat, it has to be 
taken in account either by continuous cooling or by applying the energy in intervals 
when using a high frequency system. 
 
A sound wave induces areas of high and low pressure. If the pressure in a specific 
area is sufficiently low, the critical distance between molecules will be exceeded. This 
leads to the formation of cavitations (Lorimer and Mason, 1987) . In general, there are 
two different kinds of cavitations – stable and transient cavitations (Lorimer and Mason, 
1987). Stable cavities are bubbles, which form and oscillate around a mean radius in a 
sound field and exist for many acoustic cycles (Ruecroft, Hipkiss et al., 2005). Thus, 
the amount of expansion must be the same as the contraction. A transient cavity exists 
for only a few acoustic cycles. During its existence, it grows in the low pressure part of 
a frequency cycle. The constant growth of the bubble is caused by diffusion into the 
cavity. Upon reaching a critical bubble size, the hydrostatic pressure combined with the 
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acoustic pressure leads to implosion of the cavity, creating an area of high pressure 
and temperature (Lorimer and Mason, 1987). 
 
The mechanical influence of ultrasonic treatment on the erosion of solid material, and 
the increase in the degree of nucleation and crystallisation, induced by the application 
of acoustic wave energy to supercooled melts have been well studied (Lorimer and 
Mason, 1987; Kaerger and Price, 2004; Ruecroft, 2007). There is a general agreement 
that nucleation triggered by sonication leads to the formation of smaller particles 
(Ruecroft, 2007). The increase of the amplitude of applied ultrasonic waves has also 
been found to decrease the particle size (Abbas, Srour et al., 2007). However, the 
scientific principle behind the influence of sonication on nucleation has still to be fully 
understood. Virtually, all theories agree that the effect of ultrasonic waves during 
nucleation is not due to the transmission of sound waves but due to effects caused by 
cavitation (Ruecroft, Hipkiss et al., 2005).  
 
Two theoretical approaches have been established on the influence of cavitation on 
nucleation and crystal growth (Lorimer and Mason, 1987). In considering bulk 
nucleation behaviour within supercooled melts, Sobolev described that the pressure 
inside a cavity during an adiabatic expansion increased the degree of supercooling 
which led to homogenous nucleation (Sobolev, 1989). However, earlier work by Hem 
indicated that nucleation only occurred during the collapse of cavitations inside the 
areas of elevated temperature and pressure (Hem, 1967).  
 
1.4.2.3 Crystal Growth 
 
If a nucleus grows to a critical size, the supersaturated system is thermodynamically 
driven to increase the particle size via crystal growth. The various mechanisms of 
crystal growth have received several theoretical explanations (Mullins, 1992; Davey 
and Garside, 2000). The most plausible explanation is based on a thermodynamic 
viewpoint, where molecules attach to a growing crystal surface at the site of highest 
surface free energy (Burton and Cabrera, 1951). This will predominantly occur on a 
ledge, where there are two-unsaturated bonds, or at a kink site on a ledge, where there 
will be three-unsaturated bonds (Mullins, 1992). The areas between two ledges, known 
as a terrace, will have the lowest surface free energy with only a single unsaturated 
bond. As a result, growth proceeds in a layer-by-layer process, where the growth of a 
new layer only occurs upon growth of the previous layer (Mullins, 1992). The rate-
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limiting step for crystal growth is the formation of a two-dimensional nucleus for growth 
of a new surface later. The process, which is more commonly described as a two-
dimensional nucleation and growth, is dependent on the degree of supersaturation for 
the formation of a stable two-dimensional nucleus (Mullins, 1992). At low degrees of 
supersaturation, 2-D nucleation and crystal growth do not proceed. 
 
However, the presence of defects and dislocations on the surface of a growing crystal, 
which may displace the molecular arrangement between two crystal planes, provides 
an area of increased surface free energy for crystal growth (Frank, 1949). The three-
dimensional character and unmovable nature of the dislocation source provide an ever 
winding source of high surface free energy sites for growth around the centre of the 
dislocation. This growth process is more commonly known as a screw dislocation 
growth process (Frank, 1949), which dominates at low levels of supersaturation. 
 
Since a nucleus exhibits the lowest possible surface free energy, it is expected that 
crystals preferably grow on faces where the overall surface free energy of the particle 
can be reduced. This is called the Wulff condition (Mullins, 1992). However, the 
observed habit of crystal growth from solution is often quite different from theoretical 
predictions. Hartman and Perdik related the crystal morphology to the internal crystal 
structure and concluded that the morphology of a crystal is governed by a chain of 
strong bonds (periodic bond chain – PBC) which run though the structure (Hartman 
and Perdok, 1955). As a result, crystals preferably grow in the direction of the bonds. 
Therefore, faces which have the PBCs as a vector will grow faster. This analysis has 
been shown to result in a typical crystal habit for each material and crystal structure. 
 
1.5 Aims of the Study 
 
Technologies for modifying particles in order to achieve a greater control of size and 
surface properties of particles for DPI formulations have been investigated for a 
number of years. However, these processes are inefficient and difficult to control to 
ascertain particles of defined physical properties. There continues to remain a need to 
develop novel particle processing technologies for the successful control of the surface 
characteristics and surface geometry of active drug materials. 
 
The key aim of this study is to investigate whether the SAX technology enables the 
production of respirable particles for both binary and combined DPI dosage forms, with 
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defined physicochemical functionality. The outline of the thesis in relation to the key 
aim is shown in Figure 1.6. 
 
 
Figure 1.6: Flow diagram of the structure of the thesis in relation to the key aim of the 
project 
 
In Chapter 2, the drugs and excipients will be generally characterised in the term of 
physical properties of particles. Chapter 3 of this study is related to the development of 
the lab-scale SAX system by using the principle from the first SAX generation (Kaerger 
and Price, 2004). For developing the SAX system, many important factors have been 
involved in the controlling conditions such as pressure, carrier solvents, non-solvents 
and temperatures. In Chapter 4, SAX process has been applied to generate the single 
crystalline drug particles. Furthermore, all produced materials have been characterised 
for the physical properties and formulated in DPI formulations to investigate to in-vitro 
performance.  
 
The role of combined inhalation products containing β2-agonist plus ICS can help 
improve the clinical effectiveness for asthma and COPD patients. The improved clinical 
outcome on application of combination products is thought to be related to synergistic 
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actions of the different agents at receptor, cellular and molecular levels. For this effect 
to occur, both drugs need to be present on the same cell in the airways. Current DPI 
formulation technologies are not efficient and effective to enable both actives to be 
delivered to the same site of action at the cellular level. One method of achieving this 
may be through engineering of single geometric particles that contain both actives in 
the appropriate concentrations. Therefore, in Chapter 5, the combined drug particles of 
fluticasone propionate and salmeterol xinafoate with the high-dose ratio have been 
produced via SAX process. Moreover, the physical characterisation of such combined 
drug particles and their formulation performance will also be examined. For Chapter 6, 
similar method for producing combined particles of budesonide and formoterol 
fumarate dihydrate will be used to evaluate the low-dose ratio of this combination 
product. The study gained from this research work will help elucidate how SAX may be 
used to generate respirable particles. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 2: General Physical Characterisation 42 
 
 
Chapter  2: General Physical Characterisation 
 
In Chapter 1, the importance of the physicochemical properties of components of 
inhalation dosage forms was highlighted. Physicochemical properties such as particle 
size, shape and crystallinity can have a dramatic effect on interparticulate forces within 
inhalation dosage forms and drug product performance. This chapter, therefore, 
describes the comprehensive physicochemical characterisation of the materials used 
throughout this study. 
 
2.1 Materials  
 
Table 2.1 shows the details of materials applied for this study. All solvents were 
supplied by Fisher Scientific UK (Loughborough, UK) and were of at least analytical 
grade. Water for the overall study was prepared by reverse osmosis (MilliQ, Molsheim, 
France). 
 
Table 2.1: Sources of materials used in this study 
 
Materials Manufacturers 
Micronised budesonide Scior, Milan, Italy 
Micronised fluticasone propionate Merck Generics, Potters Bar, UK 
Micronised formoterol fumarate dihydrate Scior, Milan, Italy 
Micronised salmeterol xinafoate Merck Generics, Potters Bar, UK 
Lactose monohydrate - Lactohale Friesland Foods DOMO – Borculo, 
The Netherlands 
 
 
It should be noted that, unless otherwise specified, for the remainder of this thesis, 
budesonide, fluticasone propionate, formoterol fumarate dihydrate and salmeterol 
xinafoate will be abbreviated to Bud, FP, FFD and SX, respectively.  
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2.2 Temperature-Controlled Dissolution of Carrier Lactose 
 
The carrier lactose used in this study was subjected to a temperature-controlled 
dissolution process known as etching in order to reduce the proportion of intrinsic fines. 
This technique is described in detail elsewhere (El-Sabawi, Price et al., 2006), but will 
be briefly described here.  
 
The carrier lactose (Lactohale) used in this study was sieved to obtain the 63-90 µm 
size fraction using stainless steel sieves (Endecotts Limited, London, UK) and an 
Analysette 3 PRO vibratory sieve shaker (Fritsch GmbH, Idar-Oberstein, Germany) set 
to an amplitude of 1 mm.  
 
Saturated aqueous lactose solution of 400 ml was prepared and continuously stirred at 
the constant temperature of 20°C in a water-jacketed vessel. Approximately, 100 g of 
63-90 µm Lactohale was added to the saturated lactose solution and etched by 
increasing the temperature to 25°C. From knowledge of the solubility versus 
temperature profile of lactose, this combination of variables was calculated to dissolve 
10% of the initial mass of lactose (El-Sabawi, Price et al., 2006). After 24 hours of 
stirring at 25°C, the etched lactose was removed by filtration and washed several times 
with lactose saturated ethanol. Finally, it was spread out and allowed to air dry under 
ambient laboratory conditions (20-25°C and 30-40% RH) for seven days before using. 
 
2.3 Scanning Electron Microscopy 
 
2.3.1 Introduction 
 
Drug and carrier morphology plays an important role on drug delivery in dry powder 
formulations (Timsina, Martin et al., 1994). Scanning electron microscopy (SEM) is 
used to characterise particle morphology of materials because particle morphology can 
affect formulation performance (Adi, Traini et al., 2008). SEM produces magnified 
images by using electrons instead of light waves (Brittain, Bogdanowich et al., 1991). 
An electron gun emits a beam of high energy electrons and this beam travels 
downward through a series of magnetic lenses designed to focus the electrons to a 
very fine spot. At the bottom, a set of scanning coils moves the focused beam back and 
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forth across the specimen, row by row. As the electron beam hits each spot on the 
sample, secondary electrons are knocked out from its surface. A detector counts these 
electrons and sends the signals to an amplifier. The final image is built up from the 
number of electrons emitted from each spot on the sample. Given the large amount of 
electrical energy, analysis is carried out in a vacuum and samples must be conductive. 
Non-conductive samples are coated with a thin layer of gold, a conducting material. 
 
2.3.2 Method 
 
Samples were fixed to sticky carbon tabs mounted on aluminium stubs and excess 
powder removed with a puff of air. The resulting particles were then coated with gold 
using a splutter coater (model S150B, Edwards High Vacuum, Sussex, UK) and 
examined using a scanning electron microscope (model JSM6310 or JSM6480LV, 
Japanese Electron Optics Ltd., Tokyo, Japan) at 10 kV. 
 
2.3.3 Results and Discussion 
 
2.3.3.1 Micronised Drugs 
 
It can be observed from Figure 2.1 that inspection of SEM images of the four 
micronised drugs shows the different shape of particles produced from the 
micronisation process. Bud particles (Figure 2.1A and B) were more round with varying 
size range of particles, whereas FFD (Figure 2.1C and D), FP (Figure 2.1E and F), and 
SX (Figure 2.1G and H) particles shared a similar plate-like shape. The plate-like 
shapes of FFD and FP were also wider, whereas particles from SX had the narrow 
plate-like shapes. Most particles of FFD FP and SX exhibited in the form of 
agglomerates, while Bud particles tended to be more dispersed, suggesting that FFD, 
FP and SX powders were more cohesive. This may be attributable to post-
micronisation conditioning of these Bud particles, which they may have been exposed 
to organic and/or water vapours to induce recrystallisation of surface amorphous 
domains, thus reducing powder cohesiveness.  
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Figure 2.1: Representative SEMs of the four micronised drugs at x3000 and x7000 
magnifications for A, B = Micronised Bud; C, D = micronised FFD;  E,F = Micronised 
FP; G, H = Micronised SX 
C D
E F
G H
A B
 
Chapter 2: General Physical Characterisation 46 
 
 
2.3.3.2 Lactose 
 
Scanning electron micrographs of the lactose samples before and after etching are 
shown in Figure 2.2. For lactohale (Figure 2.2A and B), the coarse carrier particles 
exhibited the tomahawk shape typical of lactose monohydrate, whilst the intrinsic fines 
had a more round, irregular morphology. This suggests that intrinsic fines may be 
formed by the breakage from larger tomahawk-shaped crystals during powder 
processing, rather than during the crystallisation of the material. Further investigation 
reveals that the etched-lactohale sample (Figure 2.2C and D) contained fewer fine 
particles, both adhered and unadhered to the surface of the coarser particles. From 
these SEM results, it may be suggested that the method of temperature-controlled 
dissolution for carrier lactose can successfully apply to generate the smooth surface 
with less intrinsic fine particles. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.2: SEMs of the two lactose at x3000 and x7000 magnifications for: A, B = 
lactohale; C, D = etched lactohale 
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2.4 Particle Size Analysis 
 
2.4.1 Introduction 
 
It is well known that the particle size distribution of the drug and excipient in a carrier-
based DPI formulation is crucial as they can affect both fluidisation properties of the 
formulations and the deposition profile in the lungs (Shur, Harris et al., 2008). Many 
different techniques for the measurement of a particle size distribution are available, for 
instance, sieving, microscopy, and impaction (Brittain, Bogdanowich et al., 1991). The 
technique chosen for use in this study is laser diffraction (low angle laser light 
scattering) as the ability of this method to rapidly and accurately measure the particle 
size of an ensemble of particles has led to a widespread use within the field of 
inhalation science (de Boer, Gjaltema et al., 2002; Guchardi, Frei et al., 2008).  
 
Particle size analysis by laser diffraction is based on the principle that the light is 
scattered by particles in its path (Shekunov, Chattopadhyay et al., 2007). With smaller 
particles, the scattering light shows larger angles (Bosquillon, Lombry et al., 2001). A 
beam of coherent, monochromatic laser light, is directed at the particles to be sized 
and then, the pattern and intensity of the scattered light detected. When a sample with 
a polydisperse particle size distribution is analysed, the resultant scattering pattern is 
achieved by integration of the scattering patterns of the particles. This pattern can then 
be used to derive a volume-weighted distribution of volume equivalent diameters by 
applying one of several mathematical models which describes the scattering of light by 
particles and the comparison of experimental and theoretical diffractograms (Shekunov, 
Chattopadhyay et al., 2007). 
 
These phenomena can be described by the Fraunhoffer diffraction or Mie theory. Mie 
theory requires knowledge of the refractive index of the particles and makes the 
assumption that they are smooth spheres (Mie, 1908). The Mie theory states that the 
induction of light scattering is triggered by the difference between the refractive indices 
of the particle and the surrounding medium (Mie, 1908). It can be difficult to apply Mie 
theory for the derivation of the particle size distribution of pharmaceutical materials, 
due to their variable shape, roughness and unknown refractive index. In these 
situations and when particle size is significantly greater than the wavelength of the light, 
it can be considered more appropriate to apply the Fraunhofer approximation to derive 
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the particle size distribution (Shekunov, Chattopadhyay et al., 2007). This technique 
only describes the diffraction of light at the contour of the particle and makes the 
assumptions that only forward light scattering occurs and the particle size is much 
larger than the wavelength of the light (Shekunov, Chattopadhyay et al., 2007). 
Therefore, the Fraunhofer approximation is applied to derive particle size distribution. 
 
2.4.2 Method 
 
Particle sizing was carried out in wet cell with a small quantity of the particles being re-
dispersed in a 0.1% w/v of lecithin (BDH Ltd., Poole, UK) in cyclohexane by sonicating 
for 5 minutes. The resultant suspension was then diluted down to 50 ml in the cuvette 
and particle size measured using a HELOS laser diffraction sensor (Sympatec GmbH, 
Clausthal-Zellerfeld, Germany). The particle size analysis was performed using 
WINDOX 4.0 software (Sympatec GmbH, Clausthal-Zellerfeld, Germany). Size 
distribution and values presented are the average of three determinations. 
 
2.4.3 Results and Discussion    
 
2.4.3.1 Micronised Drugs 
 
Inspection of the particle size distribution of the micronised drugs (Figure 2.3) shows 
the cumulative distribution of micronised Bud, micronised FFD, micronised FP and 
micronised SX. The cumulative distribution for such four micronised drugs all indicated 
narrow distribution. As seen from Figure 2.3, micronised FP had a slightly broader 
distribution than micronised Bud, FFD and SX. In addition, the data were summarised 
using the d10, d50 and d90 values shown in Table 2.2. It is apparent that d50 values of 
micronised Bud, FFD, FP and SX are 2.21, 2.42, 3.28 and 2.13 µm, respectively. From 
the results of d50 values, these four micronised drug particles confirm the suitable size 
range for a DPI formulation. 
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Figure 2.3: Particle size distribution of four micronised drugs 
 
 
Table 2.2: Summary particle size statistics of the micronised drugs 
 
 d10% (µm) ± SD d50% (µm) ± SD d90% (µm) ± SD
Micronised Bud 0.95 ± 0.00 2.21 ± 0.01 4.06 ± 0.00 
Micronised FFD 1.07 ± 0.00 2.42 ± 0.00 4.36 ± 0.01 
Micronised FP 1.41 ± 0.00 3.28 ± 0.00 5.98 ± 0.00 
Micronised SX 0.86 ± 0.00 2.13 ± 0.00 4.09 ± 0.01 
 
 
2.4.3.2 Carrier Lactose 
 
Inspection of the particle size distribution of the carrier lactose before and after etching 
(Figure 2.4) reveals that the cumulative distribution patterns of both were similar. The 
particle size statistics of 63-90 µm of lactohale before and after etching are also shown 
in the table 2.3 by using the d10, d50 and d90 values. The d50 values of the lactose before 
and after etching appear in the size of 90.05 and 82.15 µm. It can be suggested that 
the etching process did not generate the dramatic change in the size of lactose 
particles. During etching process, the surface rearrangement of the lactose particles 
can happen and it is possible that this process may cause a slightly smaller particle 
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size and smoother surface on lactose particles with less level of fine lactose material 
via the d10. 
                     
        
 
 
 
 
 
 
 
 
 
 
 
Figure 2.4: Particle size distribution of 63-90 µm of lactohale before and after etching
   
 
Table 2.3: Summary particle size statistics of 63-90 µm of lactohale before and after 
etching 
 
 d10% (µm) ± SD d50% (µm) ± SD d90% (µm) ± SD
Lactohale 53.07 ± 0.19 90.05 ± 0.14 134.99 ± 0.07 
Etched lactohale 45.36 ± 0.17 82.15 ± 0.21 124.38 ± 0.44 
                              
2.5 Differential Scanning Calorimetry 
 
2.5.1 Introduction 
 
Differential scanning calorimetry (DSC) is used to investigate the identity and 
crystallinity of many pharmaceutical materials (Buckton, 1997). DSC measures energy 
differences associated with chemical and physical changes in the sample including 
crystallisation, melting, and decomposition in relation to changing temperature 
(Duncanhewitt and Grant, 1986). This is achieved by measuring the heat flow required 
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to maintain the sample and reference at the same temperature during heating and 
cooling (Buckton, 1997). There are two types of DSCs in common use. In a power 
compensated DSC, the temperatures of the sample and reference are controlled 
independently using separate furnaces (Wendlandt, 1986). Temperature differences of 
the sample and reference are made identical by varying the power input to the two 
furnaces; this energy difference is calculated as a function of sample temperature. In a 
heat flux DSC, which was used in this study, a single furnace is utilised so the sample 
and reference are heated by a single source. Enthalpy changes in the sample cause a 
difference in its temperature relative to the reference (Wendlandt, 1986). 
 
2.5.2 Method 
 
Study material thermal properties were investigated using a differential scanning 
calorimeter (DSC 2920, TA Instruments, Surrey, UK) calibrated with indium standards. 
For most materials, approximately 1-5 mg of the sample was accurately weighed into 
an aluminium pan and crimped with a lid to form a hermetic seal. The sample and 
reference (identical, but empty, hermetically sealed pan) were heated at the rate of 
10°C.min-1 from 30°C to 350°C. The calorimeter head was flushed with dry nitrogen gas 
at 0.2 L.min-1 during all measurements.  
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2.5.3 Results and Discussion   
 
2.5.3.1 Micronised Drugs 
 
The DSC thermogram of the micronised Bud sample (Figure 2.5A) shows an 
endothermic response at ~262°C, which is typical of the melt with decomposition seen 
for crystalline Bud (Velaga, Berger et al. 2002). The thermogram relating to micronised 
FFD (Figure 2.5B) was more complicated with three endothermic peaks at ~113°C, 
~129°C and ~144°C. The literature does not contain a FFD thermogram for comparison. 
However, it is known that FFD may be thermally dehydrated. Formoterol anhydrous 
polymorph A melts at the range 125-129°C (Jarring, Larsson et al. 2006) and formoterol 
anhydrous polymorph B melts at the range 143-148°C (Jarring, Larsson et al. 2006). 
Therefore, the first endothermic peak represented dehydration and the second peak at 
~129°C showed the melting of anhydrous polymorph A. The third peak was the melting 
of anhydrous of polymorph B.        
 
The micronised FP thermogram in Figure 2.5C was similar to Bud with a single 
endothermic peak at ~290°C. For SX thermogram (Figure 2.5D), the peak was also 
complex. Endothermic peaks were detected at ~126°C and ~141°C and an exothermic 
peak at ~132°C appeared in the DSC thermogram. The first endothermic event at 
~126°C represents the melting of SX form I, which recrystallises to SX form II at ~132°C 
before melting again at ~141°C. Micronisation of SX form I is thought to induce the 
formation of trace seeds of SX form II, which enables this recrystallisation to occur 
(Beach, Latham et al., 1999; Tong, Shekunov et al., 2003).            
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Figure 2.5 (continued on next page): DSC thermograms of the four micronised drugs 
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Figure 2.5 (continued from previous page): DSC thermograms of the four micronised 
drugs 
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2.5.3.2 Carrier Lactose 
 
The thermograms of the lactohale carrier before and after the dissolution process are 
very similar (Figure 2.6), confirming that this process did not bring about any changes 
in the lactose crystal structure. In comparison with literature, thermograms also 
confirmed that the materials were α–lactose monohydrate (Angberg 1995). The 
endothermic peaks at ~140°C exhibited dehydration and the endotherms between 210 
and 215°C showed the melting of α–lactose (Angberg 1995).         
 
 
 
 
 
 
  
 
 
 
 
 
Figure 2.6: DSC thermograms of the lactohale before and after etching 
 
2.6 X-Ray Powder Diffraction 
 
2.6.1 Introduction 
 
X-ray powder diffraction (XRPD) is used to confirm the identity and crystallinity of the 
study materials (Buckton, 1997). Every crystalline form of a compound has a unique X-
ray powder pattern. XRPD was, therefore, utilised  to identify the respective 
polymorphic forms of the compounds (Suryabarayanan, 1995). More importantly, this is 
necessary as amorphous materials are thermodynamically unstable and have a 
propensity to recrystallise during storage (Buckton, 1997). 
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A parallel and monochromatic X-ray beam incident on a crystalline solid is scattered in 
all directions. At certain angles, the scattered radiation is in phase with itself and so is 
reinforced (Suryabarayanan, 1995). This phenomenon occurs whenever Bragg’s law is 
satisfied: 
     θλ sin2 pdn =    Equation 2.1 
 
where n  is an integer (the order of reflection), λ is the wavelength of the X-rays, pd  is 
the distance between the planes of the crystal and θ  is the angle between the incident 
X-rays and the crystal surface (Suryabarayanan, 1995). 
 
Every crystalline solid leads to the diffraction of X-rays at a unique combination of 
angles, enabling identification of the material and its polymorph. In addition, amorphous 
materials do not create scattering at well defined angles, allowing them to be 
distinguished from crystalline samples. XRPD can be able to detect amorphous content 
at the lower limit of approximately 10% w/w (Buckton, 1997). 
 
2.6.2 Method 
 
XRPD spectra were obtained using a Phillips analytical X-ray powder diffractometer 
(Cambridge, UK) with a CuK α  source (
°= A5418.1λ ) operated at 40 kV and 25 mA. A 
single sweep between diffraction angles (2θ ) 5˚ and 50˚ with a step size of 0.02˚ and 
step time of 13 seconds was employed for each measurement. 
 
2.6.3 Results and Discussion 
 
2.6.3.1 Micronised Drugs 
 
The presence of distinct peaks in the XRPD spectra of the four micronised drugs 
(Figure 2.7) suggests that they had a predominately crystalline structure. Additionally, 
the spectra are comparable with previously published data for these materials, 
confirming their identity as Bud (Steckel, Pichert et al. 2004), FFD (Apperley, Harris et 
al. 2003; Jarring, Larsson et al. 2006), FP form I (Louey, Van Oort et al. 2004), and SX 
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form I (Beach, Latham et al. 1999; Tong, Yu Shekunov et al. 2001; Shekunov, Feeley 
et al. 2002; Murnane, Marriott et al. 2008). 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
Figure 2.7 (continued on next page): XRPD spectra of the four micronised drugs used 
in this study 
 
 
 
 
 
            Micronised Bud 
 
 
 
 
 Micronised FFD 
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   Micronised FP 
 Micronised SX 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.7 (continued from previous page): XRPD spectra of the four micronised drugs 
used in this study 
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2.6.3.2 Carrier Lactose 
   
As shown in Figure 2.8, the XRPD spectrum of the lactohale carrier was unchanged by 
the etching process, confirming that this procedure did not bring about any change to 
the lactose crystal structure. Once again, the presence of distinct peaks confirmed that 
both materials were largely crystalline and, in comparison with the previously published 
data, spectra also confirmed the identity as lactose monohydrate (El-Sabawi, Price et 
al., 2006). 
 
 
 
  
  
  
 
 
 
 
 
Figure 2.8: XRPD spectra of lactohale carrier before and after dissolution process 
 
2.7 Dynamic Vapour Sorption 
 
2.7.1 Introduction 
 
Dynamic vapour sorption (DVS) is generally used to investigate the effect of humidity 
on the water sorption and desorption of materials (Buckton, 1997). The 
hydrophilic/hydrophobic nature of materials may affect interparticulate forces, therefore, 
DVS is widely applied to investigate the stability and crystallinity of a material at 
elevation conditions of relative humidity (% RH) (Young, Edge et al., 2005). 
 
A DVS instrument employs a Cahn microbalance housed within a temperature-
controlled incubator. The twin pans of the microbalance (one for the sample, one as a 
reference) are contained within glass cells perfused with nitrogen, the relative humidity 
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of which is controlled by a mass flow controller that mixes dry and water saturated gas 
(Buckton and Darcey, 1999).  
 
The instrument can be used to measure changes in sample mass upon exposure to 
varying humidity. Amorphous materials are thermodynamically unstable, which enables 
their detection by DVS as they absorb water molecules from the atmosphere during the 
experiment (Pfeiffer-Brodka, Langguth et al., 2003). This relates to the plasticisation of 
the amorphous phase, progressively lowering its glass transition temperature until it 
falls below the experimental temperature. At this point, molecules in the amorphous 
phase have sufficient mobility to align and so recrystallise, resulting in the expulsion of 
the absorbed vapour, which can be seen as a rapid loss of mass on the DVS trace 
(Buckton, 1997). The presence of amorphous materials can be deduced from DVS 
traces showing >1% mass increase or rapid mass loss with increasing humidity 
(Buckton, 1997).  
 
2.7.2 Method 
 
DVS experiments were performed with a DVS-1 instrument (Surface Measurement 
Systems Ltd., London, UK). An appropriate amount of sample (see Table 2.4) was 
weighed into the sample pan and its mass continually recorded during exposure to two 
humidity cycles of 0-90% RH in 10% RH steps at 25°C. Equilibrium mass, as defined 
by a specific change in mass to time ratio (dm/dt, see Table 2.4), was achieved for ten 
minutes before progression to the next step of the cycle.  
 
Table 2.4: DVS sample masses and equilibrium conditions for various materials 
 
 
 
 
 
Material Approximate Sample Mass (mg) Equilibrium dm/dt (%)
Micronised drugs 50 0.0002 
Lactohale 100 0.0005 
Etched Lactohale 100 0.0002 
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Micronised Bud 
2.7.3 Results and Discussion 
 
2.7.3.1 Micronised Drugs 
 
None of the DVS moisture sorption isotherms of the micronised drugs (Figure 2.9) 
showed >1% w/w mass increase or a mass loss during the first sorption cycle, 
indicating very low levels of amorphicity. Bud, FP and SX each had a mass increase of 
~0.1% w/w at 90% RH.  
 
FFD showed a rapid increase in mass by ~0.13% w/w at 10% RH followed by only 
~0.15% w/w mass increase between 10% and 90% RH. This suggests that reversible 
partial dehydration of the formoterol fumarate dihydrate may occur at very low 
humidities, but once rehydrated, the material shows similar adsorption properties to the 
other drugs, although it is thought that FFD is stable at low humidities and ambient 
temperatures (Jarring, Larsson et al. 2006). However, at 50% RH of the first cycle 
sorption, the sorption isotherm tended to drop down from 0.2% to 0.15% mass 
decrease and then the mass change came up to 0.25% at 90% RH. This event 
suggests that the process of recrystallisation may happen after FFD is rehydrated.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.9 (continued on the next two pages): DVS moisture sorption isotherms at  
25°C for the four micronised drugs 
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Micronised FP 
Micronised FFD 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.9 (continued from previous page): DVS moisture sorption isotherms at 25°C 
for the four micronised drugs 
 
 
 
 
 
 
 
 
 
Chapter 2: General Physical Characterisation 63 
 
 
Micronised SX 
Lactohale 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.9 (continued from previous page): DVS moisture sorption isotherms at 25°C 
for the four micronised drugs 
 
2.7.3.2 Carrier Lactose 
 
The DVS moisture sorption isotherms for the lactose carrier (Figure 2.10), both before 
and after etching, did not show >1% w/w mass increase or a mass loss during the first 
sorption cycle, so no amorphous material was detected. Lower levels for the etched 
lactose may be related to the decrease in surface area due to the removal of fines and 
the reduction in surface roughness of the coarse carrier. 
 
 
 
 
 
   
 
 
 
 
 
 
 
 
 
Figure 2.10 (continued on next page): DVS moisture sorption isotherms at 25°C for the 
carrier lactose before and after etching 
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Figure 2.10 (continued from previous page): DVS moisture sorption isotherms at 25°C 
for the carrier lactose before and after etching 
 
2.8 Conclusions 
 
The physicochemical characterisation of the materials was investigated using an array 
of analytical methods. Moreover, similarities and differences in the physical properties 
of such materials were also investigated. The supplied micronised drugs were similar to 
each other in terms of particle size and shape. The differences between materials 
characterised using DVS, DSC and XRPD were observed. Similar techniques were 
also used to investigate the physicochemical properties of the carrier lactose. The 
process of etching lactose did not affect the anomeric form of the material, however, 
the fines content of the etched lactose was lower than that of the as-supplied material. 
Importantly, the physicochemical characterisation of the pharmaceutical materials 
shown in this chapter will be compared to those of SAX-engineered particles in the 
following chapters.  
 
 
 
 
Etched Lactohale 
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Chapter 3: Particle Engineering using the SAX Process 
 
3.1 Introduction 
 
Particle processing technologies are vital for the generation of fine particles in the 1–5 
µm particle size range for delivery to the lungs. This can be implemented by a number 
of constructive and destructive methods although pharmaceutical scientists tend to 
employ the latter (Feeley, York et al., 1998). The most common destructive method 
used is air jet milling, which shatters large crystalline particles to reduce their size 
(Malcolmson and Embleton, 1998). Such pharmaceutical processing is inefficient and it 
remains difficult to control key physicochemical properties of the resultant particles, 
which may lead to downstream problems with drug product performance and stability 
(Vogel and Peukert, 2004). As a result, particle engineering processes have been 
widely explored to generate particles for inhaled drug delivery systems with defined 
functionality (Broadhead, Rouan et al., 1992; York, 1999; Li, Seville et al., 2005). Most 
techniques such as spray drying (Broadhead, Rouan et al., 1992; Li, Neill et al., 2003), 
spray freeze drying (Maa, Nguyen et al., 1999) and supercritical fluid technology (Jung 
and Perrut, 2001)  have been applied.  
 
Recently, Kaerger and Price showed that the novel development of a solution 
atomisation and crystallisation by sonication (SAX) technology enabled significant 
control in the engineering of respirable sized particles (Kaerger and Price, 2004). The 
SAX process, as described by Kaerger and Price (Kaerger and Price, 2004), consists 
of three key stages that included: solution atomisation to produce aerosol droplets of 
the solute from a carrier solvent using a suitable aerosol generator; generation of highly 
supersaturated droplets by evaporation of carrier solvent from aerosol droplet; and 
collection of droplets in a crystallisation vessel containing an appropriate non-solvent 
with the application of ultrasonic waves to the crystallisation vessel. The choice of non-
solvent is dependent on the material that is to be processed and should preferably be 
miscible with the carrier solvent in which the drug is solubilised. Furthermore, the 
surface tension of the non-solvent should be low or minimised to prevent structural 
change of the droplets upon collection in the crystallisation vessel. 
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The formation of crystalline particles on collection of highly supersaturated droplets 
may be kinetically restricted due to the level of viscosity within the droplets. To 
enhance the molecular mobility to induce crystallisation, the SAX process utilises 
ultrasonic energy, which is understood to reduce the metastable zone width for 
nucleation (Lorimer and Mason, 1987; Ruecroft, 2007). Ultrasonic energy provides 
sufficient kinetic energy for the formation of a stable cluster of molecules for crystal 
growth, which is achieved through the formation of cavitations on application of 
ultrasonic energy (Ruecroft, 2007). The implosion of cavitations generates areas of 
extremely high pressure and temperature over a short time interval, which induces an 
increase in the diffusion of the drug molecules within the viscous droplets and a 
concomitant decrease in the activation energy barrier for the formation of a stable 
nucleus or nuclei for crystal growth (Lorimer and Mason, 1987). Crystallised particles 
are subsequently collected from the non-solvent by filtration of the resulting suspension. 
Product isolation from the non-solvent by means of filtration is inefficient and may have 
detrimental effects on the morphology and flowability of SAX-processed particles. This 
remains a key difficulty of the first generation SAX process. Hence, more robust and 
efficient means of powder isolation are required. 
 
The early studies by Kaerger and Price showed that the SAX technology had ‘dial-a-
particle’ potential, where key process parameters could be modified and controlled to 
generate particles of desired functionality (Kaerger and Price, 2004). However, despite 
being able to produce micron-sized crystalline particles, the first generation SAX 
process was not robust and efficient. Furthermore, the system was difficult to 
manipulate to generate different types of particles in sufficient quantities.  
 
This chapter explores the further development of the SAX process as a technology that 
possesses ‘dial-a-particle’ properties. Key factors that affect the size, shape and 
morphology of the resultant particles are also investigated. The SAX-produced particles 
are characterised using scanning electron microscopy (SEM), particle size analysis, 
differential scanning calorimetry (DSC) and X-ray powder diffraction (XRPD) to ensure 
the suitable physical properties of the particles, which are related to appropriate 
conditions that result in the generation of particles with defined properties. 
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3.2 Materials  
 
Micronised budesonide was obtained from the suppliers listed in Chapter 2. All organic 
solvents were of at least analytical grade and were supplied by Fisher Chemicals 
(Loughborough, UK). Water was prepared by MilliQ from reverse osmosis (Molsheim, 
France). Nylon filter membranes from Whatman International Ltd. (Maidstone, UK) with 
pore size 0.45 µm were used in the study. 
 
3.3 Methods 
 
3.3.1 The SAX Apparatus Set-Up 
 
The SAX process consists of three interdependent steps (Kaerger and Price 2004). 
These three main steps include atomisation, generation of highly supersaturated 
droplets and collection of droplets in a non-solvent. In the process of atomisation, small 
aerosol droplets of the drug solution are generated using an appropriate atomiser. This 
step is followed by the collection of the highly supersaturated droplets in a 
crystallisation vessel containing a non-solvent of the drug. The final step is the 
crystallisation; the application of ultrasonic energy in a crystallisation vessel is used for 
inducing homogeneous nucleation and crystal growth.  
 
3.3.1.1 Laboratory-Scale SAX System  
 
The laboratory-scale SAX (lab-scale SAX) process was predominately fabricated from 
glass as shown in Figure 3.1 and 3.2. The key strategy for particle production using the 
SAX process involved the controlled production of supersaturated droplets. Such 
droplets were then collected and exposed to ultrasonic energy to help induce 
nucleation and crystal growth of crystalline particles with defined morphology and size. 
The lab-scale SAX process used a pneumatic atomiser (Büchi Mini Spray Dryer B-191, 
Flawil, Switzerland), operated with compressed air consumption at 600 L.h-1, to 
produce micron-sized droplets from the drug solution; the system operated under at 
positive N2 air pressure with vertical laminar flow. This increased the evaporation rate 
of the solvent inside droplets, which aided the formation of supersaturated droplets for 
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producing crystalline drug particles. In addition, the air flowed through a ‘bubbler’ tube 
containing small holes, which enabled the deposition of the droplets in the non-solvent. 
 
The separation distance between the atomiser and non-solvent was set in order to 
have the sufficient evaporation of the droplets for generating of highly supersaturated 
droplets. The appropriate separation distance at 60 cm between the atomiser and the 
surface of the non-solvent was, therefore, selected in this process. Under these 
conditions, the highly supersaturated droplets were removed from the airflow and into 
the non-solvent using a ‘bubbler’ immersed in the non-solvent. The temperature of the 
non-solvent in which the droplets were collected was controlled using a temperature-
controlled vessel (Haake K20 from Thermo Haake, Karlsruhe, Germany). Finally, the 
ultrasonic energy was supplied using an ultrasonic probe immersed in the non-solvent 
set at 20 kHz (Sonic processor P100, Sonic system, Somerset, UK). The probe 
induced nucleation through the mechanism of cavitation and created crystalline 
particles in the collecting vessel.  
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Figure 3.1: The image of the lab-scale SAX experimental set-up 
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Figure 3.2: Schematic diagram of the lab-scale version of the SAX experimental  
set-up 
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3.3.1.2 Isolation of SAX-Processed Particles from the Non-solvent using 
Supercritical Fluid-Carbon dioxide (SCO2) Solvent Extraction 
 
A supercritical fluid can be defined as a substance existing as a single fluid phase 
above its critical temperature ( cT ) and pressure ( cP ) (Kajimoto, 1999). Supercritical 
fluids exhibit interesting physicochemical properties that can vary between liquid-like 
and gas-like characteristics. These features enable supercritical fluids to possess 
higher diffusivity, and lower surface tensions and viscosities than liquid solvents (York, 
1999). Furthermore, the densities of supercritical fluids can be varied between gas-like 
and liquid-like values in a controlled manner by changing the temperature and pressure 
conditions, which enhance their salvation power and mass transfer rates compared 
with those of liquids (Eckert, Knutson et al., 1996). Carbon dioxide (CO2) is the most 
widely used supercritical fluid solvent because it has easily accessible critical 
parameters ( cT  = 31.1˚C; cP  = 73.8 bar) and is generally regarded as having safe 
(GRAS) status (Jung and Perrut, 2001). Moreover, it is also relatively inexpensive and 
non-toxic.  
  
Supercritical fluids have been widely employed for the extraction of compounds such 
as hydrocarbons, oils, nutraceuticals and pharmaceuticals (Eckert, Knutson et al., 1996; 
York, 1999; Sievers, Milewski et al., 2000; Jung and Perrut, 2001). The objective of 
supercritical fluid extraction (SFE) is to isolate specific compounds by removal of the 
solvent (Sievers, Milewski et al., 2000). For this to be achieved, the compound to be 
extracted should be insoluble in the supercritical fluid. In some cases, the material to 
be isolated is a solid that is suspended in a liquid. In this situation, the liquid solvent 
must be completely soluble in SCO2 to enable the removal of the liquid, whereas the 
solids must have completely insolubility in the supercritical fluid to aid isolation of the 
solid material. It must be noted that this process is not a particle formation or 
crystallisation step, and is purely related to the extraction of the solid component 
suspended in the liquid non-solvent. 
 
A schematic representation of the SFE rig applied in this study is shown in Figure 3.3. 
The extraction of the non-solvent hexane and isolation of SAX particle were carried out 
using a 150 ml volume extraction vessel. The supercritical fluid delivery system 
consisted of a liquid CO2 pump (P-500, Thar Technologies, Inc., Pittsburgh, PA, USA) 
and a heat exchanger, which provided SCO2 to the bottom of the extraction column 
through a 0.2 µm porous membrane at a flow rate of 10 g.min-1. This porous membrane 
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maximised the mass-transfer efficiency during extraction. The suspension of SAX 
particles in the non-solvent was charged into a 150 ml extraction vessel, to which SCO2 
was delivered via the liquid CO2 pump into the bottom of the extraction vessel at a 
constant flow rate of 10 g.min-1. The extraction temperature maintained constant at 
40°C within an air-heated oven (Thar, Inc.), whilst the automated backpressure 
regulator BP-1580-81 (Thar, Inc.) maintained a constant working pressure of 100 bar 
during the run. The effluent SCO2 was vented from the top of the column. The 
extraction process was run for a total of 3 h, and then the vessel de-pressurised slowly 
at a rate of 2 bar.min-1. Following completion of the extraction process, dried 
particulates were removed from the vessel and stored over silica gel.   
 
 
 
Figure 3.3: Schematic of SFE system 
 
3.3.2 Characterisation  
 
All SAX-produced particles were characterised using scanning electron microscopy 
(SEM), particle size analysis, differential scanning calorimetry (DSC), and X-ray 
powder diffraction (XRPD). The details of the characterisation are described in Chapter 
2.  
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3.4 Results and Discussion 
 
3.4.1 The Lab Scale Development of the SAX Process 
 
Based on the original SAX system developed by Kaerger and Price, a laboratory scale 
system has been developed. This section highlights studies carried out to investigate 
the influence of process parameters such as atomisation pressures, carrier solvents, 
non-solvents and crystallisation temperatures on the physicochemical properties of 
resultant particles. 
 
3.4.1.1 The Effect of Operating the SAX System under Negative or Positive 
Pressure 
 
Budesonide particles produced from the lab-scale SAX process by spraying a 3% w/v 
budesonide in acetone through a pneumatic atomiser at a sprayed rate of 0.8 ml.min-1 
over a separation distance of 60 cm are shown in Figure 3.4. These particles were 
collected in hexane set at 5˚C, using either negative or positive air pressure set at 30 
L.min-1. Under both operation conditions, the crystallisation vessel was exposed to 
sonic energy to induce nucleation and crystal growth. 
 
Budesonide particles collected from the system with the negative air pressure of 30 
L.min-1 (Figure 3.4A) possessed an orthorhombic crystalline habit with smooth surfaces. 
Budesonide particles generated under the positive air pressure as shown in Figure 
3.4B were similar to those particles produced under the negative pressure, but were 
smaller. This is supported by particle size distribution analysis shown in Figure 3.5. By 
applying the negative air pressure within the system, the data exhibited a broad size 
distribution. On the contrary, the cumulative particle size distribution for the particles 
produced from the positive air pressure system indicated that the size of the materials 
was significantly smaller than those produced under the negative pressure. The under 
size particle size data of such materials are also confirmed by Table 3.1. The d10%, d50% 
and d90% of the material produced under the negative pressure were 1.61 ± 0.05, 14.43 
± 0.3, and 22.77 ± 0.54 µm, respectively. However, the d10%, d50% and d90% of the 
material produced under the positive air pressure were at 0.99 ± 0.02, 5.79 ± 0.08 and 
10.36 ± 0.43 µm, respectively. The significant difference of the results from the shape 
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and size of SAX-budesonide particles can be related to the evaporation rate of the 
carrier solvent in the droplets, which may be affected by the different air-flow systems 
within the SAX process. The positive air pressure may have aided greater evaporation 
of the carrier solvent, which may have resulted in the formation of small supersaturated 
droplets. Upon exposure of these droplets to sonic energy, the formation of small 
crystalline budesonide particles would be generated in this system. 
 
 
 
 
 
 
 
 
 
 
Figure 3.4: Scanning electron micrographs of budesonide particles generated using: (A) 
negative air pressure; (B) positive air pressure in the lab-scale SAX process 
 
                          
 
Figure 3.5: Particle size distribution of budesonide particles produced from different 
types of air pressures in the lab-scale SAX process 
 
 
A B 
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Table 3.1: Summary particle size statistics of budesonide particles generated using 
negative and positive air pressures in the lab-scale SAX process 
 
 
 
The DSC thermographs shown in Figure 3.6 both present a single endothermic peak, 
which suggests that SAX-produced budesonide particles from both negative and 
positive air flow pressures were of the same crystalline polymorph. The endothermic 
transition of SAX-budesonide particles from the negative air pressure clearly exhibited 
the melting temperature at 259.9˚C, which is typical of the endothermic melting 
transition for crystalline budesonide (Jones, Young et al., 2008). In addition, the 
endothermic peak of such particles produced with the positive air flow in the system 
also indicated the clear peak at 257.9˚C. In order to confirm the crystallinity of particles, 
XRPD was employed. The XRPD patterns in Figure 3.7 show sharp diffraction peaks 
associated with crystalline materials in both SAX-budesonide particles from the 
negative and positive pressures. The XRPD spectra are comparable with previously 
published data, confirming the identity as budesonide (Jones, Young et al., 2008). The 
results from DSC and XRPD reveal that the lab-scale SAX process could generate 
budesonide crystalline particles by applying either negative or positive air flow pressure 
in the SAX process. However, the positive air flow provided much smaller particles.  
 
       
 
d10% (µm) ± SD d50% (µm) ± SD d90% (µm) ± SD 
Negative pressure 1.61 ± 0.05 14.43 ± 0.30 22.77  ± 0.54 
Positive pressure 0.99  ± 0.02 5.79 ± 0.08 10.36  ± 0.43 
 
Chapter 3: Particle Engineering using the SAX Process 76 
 
 
                                
 
Figure 3.6: DSC thermograms of budesonide particles generated using  
different types of air pressures in the lab-scale SAX process 
 
                             
 
Figure 3.7: X-ray powder diffraction patterns of budesonide particles produced using  
different types of air pressures in the lab-scale SAX process 
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3.4.1.2 The Influence of Different Carrier Solvents on the Physicochemical 
Properties of SAX-Engineered Particles 
 
The electron micrographs in Figure 3.8 reveal budesonide particles prepared by 
spraying drug solution of (A) a 2.5% w/v budesonide in ethanol and (B) a 3% w/v 
budesonide in dichloromethane. Solutions of budesonide in ethanol and budesonide in 
dichloromethane were prepared in different concentrations in order to be close to their 
solubility limits. Then such solution was sprayed through a pneumatic atomiser at a 
sprayed rate of 0.8 ml.min-1 to generate supersaturated droplets with having the 
positive air pressure of 30 L.min-1 in this SAX system. These highly viscous droplets 
were collected in hexane set at 5˚C with sonication. Particles produced from ethanol 
exhibited planar crystalline particles with smooth and flat surface (Figure 3.8A), 
whereas SAX-budesonide particles produced from dichloromethane possessed a more 
spherical morphology. Moreover, particles produced from dichloromethane appeared to 
be encrusted with nano-sized budesonide particles (Figure 3.8B). The striking 
differences in morphology of SAX-budesonide particles prepared from different carrier 
solvents may be attributed to the different vapour pressures of the carrier solvent. For 
example, ethanol, with a vapour pressure of 44.6 mm.Hg at 25˚C, resulted in more 
planar particles, whilst the more volatile dichloromethane, with a vapour pressure of 
353.21 mm.Hg at 25˚C, led to the formation of more spherical shaped particles. 
Solvents such as dichloromethane may experience rapid evaporation from the droplets 
containing the drug solute, resulting in highly viscous droplets, which were able to 
retain their spherical morphology upon collection. The highly corrugated nature of 
budesonide particles produced using dichloromethane may be a result of the volatility 
of the dichloromethane during evaporation of the solvent from the droplets, which may 
be the reason for the processing of shell like particles. Low vapour pressure solvents 
such as ethanol may not have sufficient time to form the level of viscosity to prevent the 
deformation of the droplet upon collection. These data suggest that by using different 
solvents, particularly with varying vapour pressures, it may be possible to introduce a 
control on particle morphology and surface geometry, which may further enhance 
control of surface interfacial properties of resultant particles (Adi, Traini et al., 2008). 
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Figure 3.8: SEMs of budesonide particles prepared from: (A) a 2.5% w/v budesonide 
in ethanol; (B) a 3% w/v budesonide in dichloromethane from the lab-scale SAX 
process 
 
In addition, Figure 3.9 shows that SAX-produced particles from different types of 
solvents had a slight variation in the size of the resultant particles. As described in 
Table 3.2, the particle size data for the ethanol-processed particles, expressed by d10%, 
d50% and d90%, were 1.39 ± 0.03, 12.8 ± 0.26 and 20.91 ± 0.39 µm, respectively, 
whereas the results of d10%, d50% and d90% from dichloromethane were 1.11 ± 0.03, 
10.56 ± 0.03  and 22.81 ± 1.30 µm, respectively. Hence, there was no significant effect 
of carrier solvents on particle size of SAX-processed materials for the same 
atomisation conditions. 
                          
 
Figure 3.9: Particle size distribution of budesonide particles prepared from 
 different solvents in the lab-scale SAX process 
A B 
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Table 3.2: Summary particle size statistics of budesonide particles prepared from 
different solvents 
 
DSC thermograms of the particles generated from different solvents are shown in 
Figure 3.10. Budesonide particles produced from ethanol as a carrier solvent exhibited 
an endothermic peak at 259.9˚C and the endothermic peak of particles from 
dichloromethane appeared at 258.0˚C. These endothermic peaks corresponded to the 
melting endotherm of crystalline solid of budesonide. In addition, XRPD diffractograms 
of SAX-budesonide particles produced from the different carrier solvents are also 
shown in Figure 3.11. Both samples prepared from ethanol and dichloromethane 
illustrated characteristic sharp diffraction peaks associated with highly crystalline 
materials, and the results confirmed that the same polymorphic form was formed 
regardless of carrier solvents used. These data suggest that the lab-scale SAX process 
is able to generate budesonide crystalline particles with defined size, shape and 
morphology through the use of different carrier solvents. 
                            
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.10: DSC thermographs of budesonide particles prepared from  
different solvents in the lab-scale SAX process 
 
d10% (µm) ± SD d50% (µm) ± SD d90% (µm) ± SD 
2.5% w/v budesonide in 
ethanol 1.39 ± 0.03 12.8 ± 0.26 20.91 ± 0.39 
3% w/v budesonide in 
dichloromethane 1.11 ± 0.03 10.56 ± 0.30 22.81 ± 1.30 
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Figure 3.11: X-ray powder diffraction patterns of budesonide particles prepared from 
different solvents in the lab-scale SAX process 
 
3.4.1.3 The Influence of Different Non-Solvents on the Physicochemical 
Properties of SAX-Engineered Particles 
 
The effect of spraying a 3% w/v of budesonide in dichloromethane through a 
pneumatic atomiser (a spray rate of 0.8 ml.min-1) into a non-solvent of either water or 
hexane at 5˚C was investigated. Under both conditions, each non-solvent was exposed 
to the same sonication frequency. 
 
The shape and morphology of budesonide particles produced upon collection in water 
and hexane at 5˚C are shown in Figure 3.12A and B. Particles crystallised in water 
indicated an irregular shape of planar particles fused together, and the surface of 
particles appeared rough (Figure 3.12A). By changing the non-solvent from water to 
hexane, particles shown in Figure 3.12B exhibited a marked difference in shape. SAX-
budesonide particles crystallised in hexane possessed a more spherical morphology 
and appeared to be encrusted with nano-sized budesonide particles on the surface. 
These differences in shape of SAX-budesonide particles may be related to the different 
physico-chemical properties of the non-solvent, for example, the surface tension of the 
liquids, solubility of the drug in the non-solvent and the miscibility of the carrier solvent 
with the non-solvent, which may have led to a change in overall shape or deformation 
of the droplet. 
 
Chapter 3: Particle Engineering using the SAX Process 81 
 
 
The greater surface tension of water (72.8 mN/m) in comparison to hexane (18.4 mN/m) 
may have influenced the morphology of the resultant SAX-budesonide particles. The 
droplets of budesonide generated by atomisation may have impacted at the air-liquid 
interface of the water non-solvent, which may have resulted in the loss of the droplets 
spherical shape, thereby resulting in the crystallisation of planar crystals. Such 
impaction of droplets may have been limited when droplets were collected in a non-
solvent of hexane, which possesses a lower surface tension than water. As a result, 
the spherical nature of the droplets would have been maintained, which would result in 
the crystallisation of spherical particles.  
 
           
           
  
 
 
 
 
 
 
Figure 3.12: Scanning electron micrographs of budesonide particles collected in  
(A) water and (B) hexane from the lab-scale SAX process 
 
The particle size distribution of SAX-budesonide particles produced using different non-
solvents is shown in Figure 3.13. The cumulative particle size distribution of SAX-
budesonide particles collected from hexane was slightly broader, with d10%, d50% and 
d90% values of 1.11 ± 0.03, 10.56 ± 0.30 and 22.81 ± 1.30 µm, respectively (see Table 
3.3). The d10%, d50% and d90% values of SAX-budesonide particles obtained from water 
were 1.25 ± 0.05, 8.44 ± 0.03 and 14.92 ± 0.21 µm, respectively. Hence, there was no 
significant difference on the size of SAX-processed particles when either hexane or 
water was used as non-solvents. However, these data suggest that careful 
consideration of the non-solvent is required to generate particles with different shapes 
and surface morphologies.  
 A  B
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Figure 3.13: Particle size distribution of budesonide particles obtained from  
different non-solvents from the lab-scale SAX process 
 
 
Table 3.3: Summary particle size statistics of budesonide particles collected from  
different non-solvents from the lab-scale SAX process 
 
The DSC thermograms of budesonide particles collected from two non-solvents are 
presented in Figure 3.14. SAX-produced budesonide particles obtained from water 
showed the sharp endothermic peak at 253.84˚C and hexane appeared at 257.97˚C, 
which corresponded to the melting endotherm of budesonide. The slightly lower onset 
of the melt of such material produced using water as a non-solvent may be associated 
with residual solvent content, which may have shifted the melt of the material.  
 
The XRPD diffractograms of SAX-budesonide particles generated from the different 
non-solvents are shown in Figure 3.15. Both samples, prepared from two different 
types of non-solvents, presented the same pattern of sharp diffraction peaks 
associated with highly crystalline materials. Furthermore, these data suggest that both 
 
d10% (µm) ± SD d50% (µm) ± SD d90% (µm) ± SD 
Water 1.25 ± 0.05 8.44 ± 0.03 14.92 ± 0.21 
Hexane 1.11 ± 0.03 10.56 ± 0.30 22.81 ± 1.30 
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sets of materials are of the same polymorphic form, which is not affected by the non-
solvents used.  
                             
 
Figure 3.14: DSC thermograms of budesonide particles obtained from  
different non-solvents from the lab-scale SAX process 
 
                             
 
Figure 3.15: X-ray powder diffraction patterns of budesonide particles collected from  
different non-solvents from the lab-scale SAX process 
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3.4.1.4 The Effect of Crystallisation Temperatures on the Physicochemical 
Properties of SAX-Processed Materials 
 
A 3% w/v solution of budesonide in dichloromethane was sprayed through a pneumatic 
atomiser (a spray rate of 0.8 ml.min-1), which was crystallised in hexane using 
sonication at 20˚C and 5˚C. Figure 3.16A exhibits SAX-budesonide particles 
crystallised at 20˚C and these particles appear less spherical and more corrugated, 
whereas particles crystallised at 5˚C possess a spherical morphology with defined 
surface geometry (Figure 3.16B). Furthermore, the particle size distribution of SAX 
particles collected from hexane at 20˚C and 5˚C is shown in Figure 3.17. The size 
distribution of SAX-budesonide particles collected at 20˚C from hexane was slightly 
broader than those particles obtained at 5˚C. As can be seen in Table 3.4, the particle 
size data of material crystallised in hexane at 20˚C expressed by d10%, d50% and d90% 
were 1.19 ± 0.04, 13.8 ± 0.88 and 24.49 ± 0.59 µm, respectively. The d10%, d50% and 
d90% values of SAX-budesonide particles crystallised in hexane at 5˚C were 1.11 ± 0.03, 
10.56 ± 0.30 and 22.81 ± 1.30 µm, respectively. Hence, crystallisation temperatures did 
not have a significant effect on the size of resultant particles.   
 
 
 
 
 
 
    
 
 
 
Figure 3.16: Scanning electron micrographs of budesonide particle collected from 
temperature-controlled vessels at (A) 20˚C and (B) 5˚C in the lab-scale SAX process 
 
 
A B
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Figure 3.17: Particle size distribution of budesonide particles collected from 
temperature-controlled vessels at 20˚C and 5˚C in the lab-scale SAX process 
 
 
Table 3.4: Summary particle size statistics of budesonide particles obtained from 
temperature-controlled vessels at 20˚C and 5˚C in the lab-scale SAX process 
 
 
The effect of crystallisation temperatures on particle morphology is interesting and may 
be related to kinetics of crystallisation as a function of temperature. The crystallisation 
kinetic at 20˚C would be significantly more rapid than at 5˚C. Hence, the slower 
crystallisation at 5˚C would provide sufficient time for the droplet to crystallise as a 
spherical particle and enable the outer topography of the particle to form. However, the 
rate of crystal growth did not seem to affect the size of the resultant particle. These 
data suggest that the control of crystallisation temperature may enable intricate control 
of particle surface geometry. Furthermore, these data suggest that the morphological 
features of SAX particles occur within the solution and not prior to collection. 
 
 
d10% (µm) ± SD d50% (µm) ± SD d90% (µm) ± SD 
Temperature at 20˚C 1.19 ± 0.04 13.80 ± 0.88 24.49 ± 0.59 
Temperature at 5˚C 1.11 ± 0.03 10.56 ± 0.30 22.81 ± 1.30 
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The DSC thermograms in Figure 3.18 show the particles collected in hexane at 
different temperatures. These SAX-budesonide particles controlled in the vessel at 
20˚C revealed the endothermic peak at 259.59˚C; at 5˚C, such particles indicated the 
endothermic peak at 257.97˚C, which corresponded to the melting of the crystalline 
solid of budesonide. The XRPD diffractograms for SAX-budesonide particles produced 
from two different temperatures are shown in Figure 3.19. The resulting particles 
demonstrated the similar X-ray patterns associated with highly crystalline materials. It 
can be confirmed that the same polymorphic form was produced regardless of the 
temperatures used. These data suggest that the lab-scale SAX process can generate 
budesonide crystalline particles. Additionally, by controlling the temperatures in the 
controlled vessels, the morphology of particles can be manipulated. 
                               
               
 
 
 
 
 
 
 
 
 
 
 
Figure 3.18: DSC thermograms of budesonide particles collected from temperature-
controlled vessels at  20˚C and 5˚C in the lab-scale SAX process 
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Figure 3.19: XRPD patterns of budesonide particles collected from temperature-
controlled vessels at 20˚C and 5˚C in the lab-scale SAX process 
 
3.4.2 The Influence of Material Isolation by SCO2 Extraction on Physicochemical 
Properties of SAX Particles 
 
One of the key concerns with the SAX process has been the isolation of processed 
material from the non-solvent. This was traditionally achieved using vacuum filtration, 
which is an inefficient process when dealing with large quantities of material. As a 
result, the use of SCO2 solvent extraction was evaluated. 
 
The SAX set-up was purged with a constant air-flow of dry nitrogen at 30 L.min-1 to 
enable evaporation of the solvent from the atomised droplets. Following this, a solution 
of budesonide (3% w/v) prepared in dichloromethane was atomised using a pneumatic 
atomiser (Buchi, Fawali, Switzerland) at a constant air-flow rate of 800 L.h-1. The 
generated aerosol droplets were then allowed to pass through a column to aid solvent 
evaporation from the aerosol droplets, thereby forming highly supersaturated droplets. 
These droplets were then collected in a crystallisation vessel containing the non-
solvent (n-hexane), which was exposed to ultrasonic energy using an ultrasonic probe 
resonating at 20 kHz, to induce nucleation and crystal growth. In this way, one batch of 
SAX processed-budesonide particles was isolated using either membrane filtration or 
SCO2 solvent extraction. 
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Optical images of SAX particles were isolated using vacuum filtration (Figure 3.20A) 
and SCO2 extraction (Figure 3.20B). As can be seen from the images, particles 
obtained by using vacuum filtration in the collecting method seemed to be more 
agglomerated and tended to have difficulty in preparing DPI formulations. However, the 
particles gained from SCO2 extraction presented a highly flowable powder which was 
easy to handle in terms of formulation preparation. The reason for the difference in 
physical property may be related to the isolation method. During vacuum filtration, 
negative air flow provides the driving force for the filtration process. Therefore, filtrated 
particles may have compacted together and caked. In contrast, the SCO2 extraction 
process utilises CO2 in the supercritical phase to remove the solvent and enables dry 
powder isolation. The greater diffusivity and lower surface tension of supercritical fluids 
enable efficient drying of powders. Furthermore, the SCO2 is percolated into the 
extraction vessel, which prevents the material from caking. For this reason, SAX 
particles isolated using SCO2 extraction exhibit excellent flow properties and are 
suitable for preparation of DPI formulations.  
 
                                                          
 
 
 
 
 
    
 
 
 
    
 
 
Figure 3.20: Optical images of SAX particles isolated using (A) vacuum filtration and (B) 
SCO2 extraction 
 
 
 
 
 
 A B
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The particle morphology and shape of SAX-processed materials isolated using either 
membrane filtration or SCO2 solvent extraction are shown in Figure 3.21A and B. 
Furthermore, the particle size distribution of both materials is shown in Figure 3.22. It is 
evident from Figure 3.21 that isolation by SCO2 solvent extraction did not affect the 
morphology or size of the resultant particles. Furthermore, Figure 3.22 shows that the 
particle size distribution of the materials was similar. Hence, the SCO2 solvent 
extraction process did not induce further crystal growth or damage.  
 
 
 
 
 
 
 
 
 
 
 
Figure 3.21: Scanning electron micrographs of budesonide particles isolated using (A) 
membrane filtration and (B) SCO2 solvent extraction 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.22: Particle size distribution of materials isolated using different isolation 
methods 
 
 B A 
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DSC thermograms of particles, collected using membrane filtration and SCO2 solvent 
extraction, are shown in Figure 3.23. The thermograms of both materials were similar 
to both crystalline and micronised budesonide, which suggests that the SCO2 isolation 
process did not influence the crystallinity or polymorphic form of the drug.  
 
The ability to isolate using SCO2 solvent extraction enables improved efficiency in 
product isolation and allows material to be directly employed in formulations without 
secondary processes such as sifting.    
         
                
 
 
 
 
 
 
 
 
 
 
 
Figure 3.23: DSC thermograms of materials isolated using different isolation methods 
 
3.5 Conclusions 
 
A variety of factors has been shown to influence the SAX process in manipulating the 
physical properties of active pharmaceutical particles. In development of the lab-scale 
SAX system, all factors, including air flow pressures, carrier solvents, non-solvents, 
and temperatures were shown to have a significant effect on the particle engineering 
process. All factors had a significant influence on the evaporation rate of the small 
supersaturated droplets, which is critical to generating crystalline particles with defined 
shape, size and morphology.   
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The control of the lab-scale SAX process by adjusting these factors is critical to any 
further development of the SAX apparatus. In the following chapters, these critical 
parameters are controlled and manipulated in the processing of SAX particles of both 
single actives and combination drug particles. 
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Chapter 4: Functionality and In-vitro Formulation Performance 
of SAX-Engineered Budesonide Particles 
 
4.1 Introduction  
 
The objective of pharmaceutical manufacturing is the generation of dosage forms that 
enable the delivery of medicines to the human body via many different routes. Whilst 
current pharmaceutical manufacturing practices remain empirical in nature, the future 
of pharmaceutical manufacturing is the generation of products with well-defined 
properties and functionality. This is the primary goal of pharmaceutical product 
engineering, which is achieved through control of the product ‘property function’ (Price 
and Edge, 2007).  
 
The ‘property function’ was initially defined by Rumpf (Rumpf, 1967) and later Peukert 
(Peukert, 2005) as the relationship between the physicochemical properties of 
particulate systems (i.e. particle size, morphology, surface properties) and product 
properties.  A further consideration in producing products with well-defined properties is 
the ‘process function’, which relates specific process parameters (e.g. unit operations 
such as mills, centrifuges etc.) to the physicochemical properties of the product (Krekel 
and Polke, 1992). Hence, both the process and property functions must be known, 
understood and controlled in order to achieve products with defined functionality and 
properties that have been built into the product by design (Peukert, 2005). 
 
In designing pharmaceutical products with well-defined properties, it is important to 
determine the key functionalities that affect product performance and stability. In the 
case of dry powder inhaler (DPI) dosage forms, surface interfacial interactions play a 
dominant role in product performance. As a result, the drug-drug and drug-excipient 
surface interfacial interactions within DPI formulations are critical in determining the 
dose that reaches the patients’ lung (Kawashima, Serigano et al., 1998; Begat, Morton 
et al., 2004). Whilst it is known that the surface properties of the active pharmaceutical 
ingredient (API) will dramatically affect DPI product performance, the primary design 
concept in API manufacturing for DPIs remains particle size, with limited understanding 
of the effects of processing on API surface properties. Hence, to control the specific 
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performance and stability properties of DPI dosage forms, the central product design 
principle in DPI manufacturing must focus on tailoring the mesoscopic design of 
particle interfaces to enable careful control of particle-particle interactions, and 
therefore, product performance.  
 
Current pharmaceutical manufacturing strategies for DPI dosage forms generally 
involve the engineering of the API into specific crystalline forms. The API crystals are 
then processed into particles in the required particle size range using destructive ‘top-
down’ strategies (e.g. micronisation) and formulated into dosage forms. Although, it is 
possible to control particle size of materials using such processes, the control of 
particle surface properties and morphology is extremely difficult. The inability to control 
surface properties of micronised materials is directly related to variability in batch-to-
batch performance of products, as small differences in batch preparations can result in 
extreme variations in surface properties of processed products. Hence, equivalent 
batches may possess varying property function (Feeley, York et al., 1998).  
Furthermore, the use of high-energy comminution is also known to result in undesirable 
product properties such as disorder of the crystalline lattice of the material, which can 
adversely impact the overall performance and stability of the product (Krycer and 
Hersey, 1981; Buckton, 1997; Begat, Young et al., 2003).               
 
Whilst current research and development exercises are being directed to define and 
understand process functions employed in pharmaceutical product design, there is a 
growing requirement to investigate new technologies to tailor specific functionalities 
and properties into products. Development in the engineering of pharmaceutical 
particulates has primarily focussed on controlled crystallisation strategies such as 
supercritical fluid crystallisation, which have made significant strides in controlling 
particle size, crystallinity and habit of particulates (Shekunov, Feeley et al., 2003). 
However, the inability to specifically control particle morphology and process scale-up 
issues has hampered the introduction of such process technologies into full-scale 
pharmaceutical manufacturing (Price and Edge, 2007). Recent developments in a 
range of ‘bottom-up’ strategies have shown potential in the production of 
pharmaceutical particles of defined property function. These include process 
technologies such as spray drying (Li, Neill et al., 2003), spray freeze drying (Maa, 
Nguyen et al., 1999) and high gravity precipitation (Chiou, Li et al., 2007).    
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The novel processing technology referred to as the solution atomisation and 
crystallisation by sonication (SAX) process shows great promise in enabling greater 
control on particle size, shape, morphology and surface properties, without 
compromising material stability (Kaerger and Price, 2004). The SAX process consists 
of defined stages, which begin with the generation of aerosol droplets of material, with 
defined droplet size distribution using an appropriate atomiser. Following atomisation, 
the carrier solvent evaporates resulting in the formation of highly supersaturated 
droplets, which are then collected in a crystallisation vessel containing a non-solvent of 
the processed material.  
 
The aim of this investigation was to utilise the SAX particle engineering process to 
produce particles of budesonide with defined property function for delivery to the 
airways. 
 
4.2 Materials  
 
Micronised budesonide was obtained from suppliers listed in Chapter 2. All organic 
solvents were of at least analytical grade and were purchased from Fisher Chemicals 
(Loughborough, UK). Water was produced by MilliQ from reverse osmosis (Molsheim, 
France). Etched lactohale was prepared from coarse carrier lactose monohydrate 
(Friesland Foods Domo – Pharma, Zwolle, The Netherlands). 
 
4.3 Methods 
 
4.3.1 The Production of SAX-Produced Budesonide Particles 
 
As described in the previous chapter, a range of critical parameters can be 
manipulated and controlled in the SAX-particle engineering process to produce 
particles of defined functionality. In terms of producing particles for lung delivery, it is 
essential to control particle size, morphology and crystallinity. Based on the 
understanding gained during studies described in Chapter 3, it was discovered that the 
choice of carrier solvents and atomisation method was critical to achieving particles 
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suitable for delivery to the lungs. The following describes different configurations of the 
SAX process that are utilised to produce budesonide particles suitable for pulmonary 
drug delivery. 
 
4.3.1.1 SAX-Produced Budesonide B (SAX B) Particles 
 
SAX B particles were prepared from a 1.5% w/v solution of budesonide in 
dichloromethane, which was atomised using a co-axial two-fluid atomiser with an 
internal mixing principle (SU11, Spraying Systems Co., Illinois, USA). The atomiser 
was operated with a solution feed rate of 2 ml.min-1, air pressure at 2 bar, a separation 
distance of 60 cm and a positive carrier gas of 30 L.min-1. The resulting particles were 
then collected in hexane at 5˚C. The particles were isolated from the hexane using 
SCO2 solvent extraction as described in Chapter 3.  
 
4.3.1.2 SAX-Produced Budesonide C (SAX C) Particles 
 
SAX C particles were generated upon atomisation of a 3% w/v solution of budesonide 
in dichloromethane using a pneumatic atomiser with an orifice of 0.7 mm (Büchi, Flawil, 
Switzerland). The atomiser was operated at a spray rate of 0.8 ml.min-1 with the 
compressed air consumption of the atomiser at 10 L.min-1, a separation distance of 60 
cm and a positive carrier gas of 30 L.min-1. The resulting particles were then collected 
in hexane at 5˚C and, finally, isolated from the non-solvent using SCO2 solvent 
extraction. In addition, a small aliquot of the suspension was isolated using vacuum 
filtration to assess if the SCO2 extraction process affected the physicochemical 
properties of the SAX particles.  
 
All particles were characterised using scanning electron microscopy, particle size 
analysis, differential scanning calorimetry, X-Ray powder diffraction, and dynamic 
vapour sorption. The experimental methodologies for these techniques are described in 
Chapter 2. 
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4.3.2 Formulation Blending  
 
A formulation containing a 0.4% w/w drug (SAX B) was prepared in 4 g batch by 
geometrically mixing the drug and surface-etched carrier lactose in a 15 ml glass 
container for 60 seconds on a Whirlimixer (Fisons Scientific Equipment, Loughborough, 
UK). The resultant blend was further mixed using a Turbula shaker-mixer (Willy A 
Bachofen AG, Basel, Switzerland) at 46 rpm for 45 minutes. Similarly, a formulation 
containing a 0.4% w/w micronised budesonide was also prepared by mixing with the 
same batch of surface-etched lactose. Both formulations were stored at 25˚C and 44% 
RH prior to testing. These materials were investigated as part of study I. 
 
The in-vitro aerosolisation performance of SAX C particles was investigated as part of 
study II. A formulation containing a 0.8% w/w of SAX C was formulated in 4 g batch 
with surface-etched lactose using the same formulation preparation method as study I. 
In order to compare the aerosolisation properties of SAX C particles and conventional 
micronised budesonide, a further formulation containing a 0.8% w/w micronised 
budesonide was prepared with the same batch of surface-etched lactose. 
 
4.3.3 Content Uniformity Determination 
 
Upon blending, the content uniformity of formulations in both studies (I and II) was 
assessed. Each blend was spread over a clean surface and ten samples of 25 ± 1 mg 
taken from random positions. Each sample was dissolved with 15 minutes sonication in 
45% methanol, 35% acetonitrile and 20% water to 100 ml final volume and drug 
concentration assessed by high performance liquid chromatography (HPLC). The 
proportion of drug in each sample was calculated and the content uniformity expressed 
as the coefficient of variation (CV ): 
 
  
x
SDCV 100×=     Equation 4.1 
where x  is the mean drug proportion and SD  is the standard deviation. 
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4.3.4 Capsule Filling 
 
The formulations for both studies I and II were manually loaded into size 3 
hydroxypropyl methylcellulose (HPMC) capsules (Qualicaps, Madrid, Spain). Fill weight 
was 25 ± 1 mg, giving a nominal dose of 100 ± 10 µg drug per capsule for formulations 
used in study I. For study II, the fill weight was 25 ± 1 mg, giving a nominal dose of 200 
± 15 µg drug per capsule. Following filling, capsules were stored in a sealed container 
containing a saturated solution of potassium carbonate (giving a relative humidity of 
44%) for at least 24 hours prior to analysis. 
 
4.3.5 In-Vitro Performance Analysis 
 
4.3.5.1 Next Generation Impactor (NGI) and Multi-Stage Liquid Impinger (MSLI) 
 
Inertial impaction has been the pharmacopoeial and industry standard technique for the 
determination of drug aerosol particle size distribution (Marple, Roberts et al., 2003). 
This is because this method allows the aerodynamic size distribution of the entire 
inhaled dose to be characterised in a way that is specific to the drug (Marple, Roberts 
et al., 2003). An impactor is a device into which the aerosolised formulation is drawn, 
under an airstream at a defined flow rate. It passes through a series of stages which 
consists of a plate containing a number of nozzles or jets with a defined diameter 
located above a flat collection surface. As the aerosol passes from stage-to-stage, the 
jet sizes become progressively smaller. As the airstream passes through each stage, it 
changes direction. Any airborne particles will be subject to two forces: their momentum, 
which acts to keep them travelling in their current direction; and the hydrodynamic 
forces exerted by the air travelling in the new direction (Marple, Roberts et al., 2003). 
Particles with a larger momentum, which is a function of their mass and thus diameter, 
will be less likely to relax into a change in direction of the air flow, and may impact on 
the collection surface, removing them from the airstream (see Figure 4.1).  
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Figure 4.1: The impactor consisting of a nozzle and an impaction plate 
 
For a given nozzle diameter, particles above a certain size (the cut-off diameter) will 
impact on the collection surface. In practice, the efficiency with which particles of 
varying sizes impact in a given stage follows a sigmoidal function. Therefore, the cut-off 
diameter for a given stage is characterised by the aerodynamic diameter at which 50% 
of particles impact )( 50C (Marple, Roberts et al., 2003). The cut-off diameter of a stage 
can be described using Stokes’ law (Marple, Roberts et al., 2003): 
 
5050 4
9 St
QC
WnC
aep
nn ×= ρ
πη
   Equation 4.2 
 
where η  is the viscosity of air, nn  is the number of circular nozzles in the stage, nW  is 
the nozzle diameter, pρ  is the particle density, aeC  is the Cunningham slip correction 
factor, Q  is the volumetric air flow rate and 50St  is the square root of the Stokes’ 
number that gives a 50% chance of particle deposition, which is ~0.49 for a well-
designed impactor.  
 
By passing the aerosolised formulation through an impactor and then recovering and 
quantifying the amount of drug deposited on each stage, the aerodynamic particle size 
distribution can be determined. In order to mimic the anatomy of the respiratory tract, 
impactors also feature an induction port that is placed between the inhaler and the 
stages. This contains a 90˚ bend and acts as a very simple model of the mouth and 
throat, enabling deposition in this area to be approximated. 
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In-vitro formulation performance is assessed using a NGI (Figure 4.2), which is an 
instrument recently designed specifically for pharmaceutical inhaler testing (Marple, 
Roberts et al., 2003). When used for testing DPIs, the NGI employs a metal throat, pre-
separator and eight stages and the last stage is a micro orifice collector (MOC), which 
performs the role of a filter. When operated at a flow rate of 60 L.min-1, the cut-off 
diameters of each NGI stage exhibit as follows: 
 
• Throat and pre-separator:  >12.8 µm 
• Stage 1:    8.06 – 12.8 µm 
• Stage 2:    4.46 – 8.06 µm 
• Stage 3:    2.82 – 4.46 µm 
• Stage 4:    1.66 – 2.82 µm 
• Stage 5:    0.94 – 1.66 µm 
• Stage 6:    0.55 – 0.94 µm 
• Stage 7:    0.34 – 0.55 µm 
• MOC     0.14 – 0.34 µm 
 
The fine particle dose (FPD) can, therefore, be defined as the mass of drug deposited 
on stage 3 and below (<4.46 µm). 
  
 
 
 
 
 
 
 
 
 
 
 
Figure 4.2: Next generation impactor (NGI) adapted from http://www.mspcorp.com 
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Where the NGI relies on particle impaction, Figure 4.3 shows the multi-stage liquid 
impinger (MSLI) that collects particles impinging onto liquid interfaces. The MSLI has 
five liquid impinging stages and the cut-off diameters at a flow rate of 60 L.min-1 of 
stages 1, 2, 3 and 4 are 13, 6.8, 3.1 and 1.7 µm, respectively. Additionally, stage 5 
comprises an integral paper filter to capture the remaining fraction of particle less than 
1.7 µm. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.3: Multi-stage liquid impinger (MSLI) reproduced from  
Microbiol. Mol. Biol. Rev. (May 1966) 
 
4.3.5.2 Study I – In-vitro Inhalation Performance of SAX B  
 
The NGI was used to investigate the performance of micronised budesonide and SAX 
B formulations. The NGI collection cups were immersed in a 1% v/v solution of silicone 
oil (Acros Organics, Geel, Belgium) in hexane and allowed to air dry. The NGI (Copley 
Scientific Ltd, Nottingham, UK) in Figure 4.2 was then assembled with pre-separator 
(containing 15 ml of wash solvent) and connected to a vacuum pump (Gaast, Benton 
Harbour, MI, USA) via a solenoid valve. The flow rate at the inlet to the throat was set 
to 60 L.min-1 using a digital flow meter with model DFM 2000 (Copley Scientific Ltd., 
Nottingham, UK). A Cyclohaler™ was attached to the throat of the NGI using a rubber 
mouthpiece.  A capsule was inserted in the Cyclohaler and pierced by two sharp pins 
within this Cyclohaler to generate two small holes at the respective ends of the capsule. 
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The contents of the capsule were then aerosolised into the NGI by drawing air through 
the apparatus at 60 L.min-1 for 4 seconds (controlled by the solenoid valve). Once the 
contents of ten capsules were aerosolised in this way, the device was disconnected, 
and capsules and each stage washed down into separate known volumes of 45% 
methanol, 35% acetonitrile and 20% water, which were sonicated to aid dissolution. 
The concentration of drug in each solution was investigated by HPLC, from which the 
mass of drug deposited on each stage of the NGI could be determined at stages 1 to 7 
and the MOC. Between experiments, the NGI was washed in water and methanol, 
dried in an oven, and allowed to cool to room temperature before re-use. 
 
Each formulation was tested in triplicate. The emitted dose (ED) was defined as the 
mass of drug recovered from all parts of the NGI. The fine particle dose (FPD) was the 
mass of drug recovered from stage 3 and below of the NGI and the fine particle fraction 
(FPFED) was the FPD expressed as a percentage of the ED.  
 
4.3.5.3 Study II – In-vitro Inhalation Performance of SAX C 
 
A MSLI (Copley Scientific Ltd, Nottingham, UK), shown in Figure 4.3, was used in this 
study. Each stage (1-4) contained 20 ml of wash solvent and MSLI connected to a 
vacuum pump (Gaast, Benton Harbour, MI, USA) via a solenoid valve. The flow rate at 
the inlet to the throat was set to 60 L.min-1 using a digital flow meter with model DFM 
2000 (Copley Scientific Ltd., Nottingham, UK). A Cyclohaler was attached to the throat 
of the MSLI using a rubber mouthpiece, in fact, a capsule was inserted in the 
Cyclohaler and pinned by the two sharp pins within this Cyclohaler to generate two 
small punctures. The contents of the capsule were then aerosolised into the MSLI by 
drawing air through the apparatus at 60 L.min-1 for 4 seconds (controlled by the 
solenoid valve). Once the contents of ten capsules were aerosolised in this way, the 
device was disconnected and capsules and each stage washed down into separate 
known volumes of 45% methanol, 35% acetonitrile and 20% water, which were 
sonicated to add dissolution and allowed to cool. The concentration of drug in each 
solution was investigated by HPLC, from which the mass of drug deposited on each 
stage of the MSLI could be determined. The MSLI was washed in water and methanol, 
dried in a low temperature oven, and allowed to cool to room temperature. 
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Each formulation was tested three times in this way. The emitted dose (ED) was 
defined as the mass of drug recovered from all parts of the MSLI. The fine particle dose 
(FPD) was the mass of drug recovered from stage 3 and below of the NGI and the fine 
particle fraction (FPFED) was the FPD expressed as a percentage of the ED.  
 
4.3.6 High Performance Liquid Chromatography 
 
Drug concentrations were determined by HPLC. The HPLC system consisted of a PU-
980 intelligent HPLC pump, an AS950 intelligent autosampler, a CO-866 column oven 
(all from Jasco, Japan) and a 1050 variable wavelength UV detector (Agilent 
Technologies, Wokingham, UK). Data were collected and analysed using Azur v4.0 
software (Datalys, Saint Martin D’Heres, France). Unknown sample concentration was 
determined from duplicate injections by comparison of peak area with reference peaks 
from external standard solutions of known concentration. 
 
Both two studies were analysed using the same HPLC method. This employed a 4.6 
mm x 250 mm C18 5 µm Hypersil column (Thermo Electron Corporation, Waltham, MA, 
USA) and a mobile phase consisting of 45% v/v methanol, 35% v/v acetonitrile and 
20% v/v water. The flow rate was 1.5 ml.min-1; column temperature was 40˚C with the 
injection volume of 200 µl. Drug retention time was 3.2 minutes, so a run time of 5 
minutes was employed. UV detection wavelength of budesonide was 244 nm.  
 
The relationship between drug concentration (0.1, 0.25, 0.5, 2, 10 and 50 µg.ml-1) and 
peak area for each drug was found to be linear, with linear regression analysis yielding 
a coefficient of determination (R2) of 1.0 in study I and II (Figure 4.4).  
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Figure 4.4: HPLC calibration curves for budesonide in study I and II 
 
 
 
 
 
 
 
 
 Study I 
 y = 85.183x 
 R2 = 1.0000 
 y = 47.335x 
 R2 = 1.0000 
 Study II 
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4.4 Results and Discussion 
 
4.4.1 Characterisation of SAX-Engineered Budesonide Particles 
 
4.4.1.1 Scanning Electron Microscopy 
 
Electron micrographs of budesonide particles obtained from micronised budesonide, 
SAX B and SAX C are shown in Figure 4.5. The SAX-produced budesonide particles 
possessed more defined and uniform morphology than micronised budesonide. 
Micronised budesonide particles were irregular and appeared agglomerated with 
varying size, whereas SAX B and SAX C particles, which were produced from the lab-
scale of SAX process, exhibited uniform shape. SAX B was prepared from a 1.5% w/v 
of budesonide in dichloromethane and the drug solution sprayed by SU11 atomiser. 
These SAX-produced B particles appeared to have a granular shape possessed a 
greater degree of sphericity with more uniform size. SAX C particles were produced 
from a 3% budesonide in dichloromethane through a pneumatic atomiser. These 
particles were spherical and encrusted with nanometre-sized particles.  
 
The different morphologies of micronised and SAX-engineered budesonide were 
related to the different engineering process of the particles. The irregular morphology of 
the micronised budesonide particles is attributed to the highly energetic and destructive 
micronisation process, which relies on fragmentation of crystals to produce small 
particles. Such approach provides a little control of particle morphology, which is a 
significant drawback of the micronisation process. However, it seems possible to 
manipulate particle morphology using the SAX process, whilst maintaining particle size 
control via a single droplet to particle operation. The highly corrugated nature of SAX B 
and C produced using dichloromethane may be a result of rapid evaporation of the 
solvent from the droplet, owing to its highly volatile nature. The differences in 
morphology between particles of SAX B and SAX C may be associated to the 
differences in solution concentrations used to fabricate the respective particles using 
the SAX process. The more concentrated solution of budesonide employed in the 
fabrication of SAX C particles may be responsible for the encrustation of smaller 
particles on the surface of the larger spherical budesonide particles. This may be 
related to the rapid solvent removal from droplets or ‘blow-out’, which may have led to 
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implantation of further seeds for crystallisation on the surface of the droplet resulting in 
the formation of nano-sized budesonide crystallites on the surface of the carrier 
budesonide particle. Furthermore, the high volatility of dichloromethane may in itself 
operate as a pore-forming agent, which may lead to particles of SAX C exhibiting low 
porosity. Such a phenomena has been previously described in the formation of 
particles using the Pulmosphere technology, where fluorocarbons serve a similar 
purpose and aid the formation of hollow/porous particles (Duddu, Sisk et al., 2002). 
These data suggest that by controlling critical parameters such as carrier solvents and 
solution concentrations of the SAX process, the engineering of particles with defined 
property function is possible.  
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Figure 4.5: Representative SEMs of micronised budesonide, SAX B and SAX C 
particles at magnifications of x3000 and x7000 
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SAX C 
SAX B 
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4.4.1.2 Particle Size Analysis 
 
Inspection of the particle size distribution in Figure 4.6 shows the cumulative 
distribution of micronised budesonide, SAX B and SAX C particles. The cumulative 
particle size distribution of the three budesonide particles was different. The particle 
size distribution of SAX C was broader than both micronised budesonide and SAX B 
particles. As supported by the summary data in Table 4.1, it was apparent that the 
volume median diameters (d50) of micronised budesonide, SAX B and SAX C were at 
3.27, 3.07 and 8.68 µm, respectively. In addition, the span of the size distribution which 
was calculated from (d90 – d10)/d50 was shown in Table 4.1, and such data indicated that 
the span of SAX B and C was narrower than micronised budesonide. These data can 
be explained by the fact that the SAX process could generate the aerosol droplets with 
a narrower span of size distribution in comparison with particles gained from 
micronisation process. The particle size of SAX C suggests that the material was not 
suitable for pulmonary drug delivery. However, due to the porous nature and likely low 
density of these particles, they were formulated for aerodynamic particle size 
classification.  
 
 
 
 
 
 
 
 
 
                            
                                                    
 
 
 
Figure 4.6: Particle size distribution of micronised budesonide, SAX B and SAX C 
particles 
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Table 4.1: Summary of particle size data of micronised budesonide, SAX B and SAX C 
particles 
 
 d10% 
(µm) ± SD 
d50%  
(µm) ± SD 
d90% 
(µm) ± SD Span 
Micronised Bud 1.02 ± 0.01 3.27 ± 0.02 8.08 ± 0.04 2.16 
SAX B 1.48 ± 0.01 3.07 ± 0.01 5.86 ± 0.02 1.43 
SAX C  3.04 ± 0.05 8.68 ± 0.12 16.61 ± 0.12 1.56 
 
 
4.4.1.3 Differential Scanning Calorimetry 
 
The DSC thermograms of micronised budesonide, SAX B and SAX C are shown in 
Figure 4.7. Three samples all exhibited a single endothermic peak, which 
corresponded to the melting point of budesonide. Micronised budesonide showed the 
sharp endothermic peak at 261.84˚C and SAX B appeared at 260.86˚C. Additionally, 
SAX C had the endothermic peak at 257.97˚C. These data suggest that processing of 
budesonide by SAX did not change the polymorphic form of the material.  
                              
 
 
 
 
 
 
 
 
 
 
 
                             
Figure 4.7: DSC thermograms of micronised budesonide, SAX B and SAX C particles 
recorded at a heating rate of 10˚C.min-1 
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4.4.1.4 X-ray Powder Diffraction 
 
XRPD diffractograms of budesonide particles from micronised budesonide, SAX B and 
SAX C are shown in Figure 4.8. All particles presented similar diffraction peaks 
associated with crystalline budesonide. It can be confirmed that the materials were of 
the same polymorphic form of budesonide. These results supported that the lab-scale 
SAX process generated crystalline budesonide particles. 
                   
                  
 
 
 
 
 
 
 
 
 
 
 
Figure 4.8: XRPD spectra of micronised budesonide, SAX B and SAX C particles 
 
4.4.1.5 Dynamic Vapour Sorption 
                             
DVS isotherms of micronised budesonide, SAX B and SAX C particles are provided in 
Figure 4.9. The DVS moisture sorption isotherms of all budesonide samples showed 
<1% w/w mass increase or a mass loss during the first sorption cycle, indicating no 
detectable level of amorphous material. According to micronised budesonide, the 
following desorption and the subsequent second sorption cycle suggests that 
approximately 0.007% of water has been retained. Additionally, micronised budesonide 
and SAX C had a mass increase of ~0.1% w/w at 90% RH, and SAX B had a mass 
increase of ~0.2% w/w at 90% RH. All data suggest that no amorphous content was 
detected in all samples. Therefore, crystalline budesonide particles were successfully 
produced via the lab-scale of SAX process. 
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Figure 4.9: DVS isotherms of micronised budesonide, SAX B and SAX C particles 
SAX C 
SAX B 
Micronised Bud  
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4.4.2 Study I: In-Vitro Performance of SAX B  
 
4.4.2.1 SEMs of the Formulations 
 
Figure 4.10 shows representative SEMs of: (A) etched lactohale; (B) the formulation of 
micronised budesonide, formulated by mixing microinised budesonide with etched 
lactohale; and (C) the formulation of SAX B, prepared by mixing SAX B with etched 
lactohale. The formulations of micronised budesonide and SAX B in Figure 4.10B and 
4.10C demonstrated that the etched lactohale, which had the smooth surface, was 
covered with the small drug particles. Etched lactohale (see Figure 4.10A), prepared 
from the method of temperature-controlled dissolution for carrier lactose and sieved the 
size to 63-90 µm, possessed a smooth surface and exhibited the tomahawk shape. In 
addition, such etched lactohale appeared to have less intrinsic fine lactose particles. 
The formulations of micronised budesonide and SAX B were prepared by blending 
such drug particles to the etched lactohale. As a result, the SEMs micrograph B and C 
both exhibited the similar pattern of the small drug particles embedded on the surface 
of the etched lactohale.  
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Figure 4.10: Representative SEMs of: (A) etched lactohale; (B) the formulation of 
micronised budesonide; (C) the formulation of SAX B at magnifications of x900 and 
x2500 
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4.4.2.2 Content Uniformity 
 
The coefficient of variation ( CV ) of the drug content of the two formulations for 
micronised budesonide and SAX B was <6%, which is the upper limit of what is 
commonly acceptable as uniformity for a carrier-based DPI formulation. The micronised 
budesonide blended with etched lactohale showed the CV  at 3.47%, whereas the CV  
of the SAX B formulation was at 2.65%. These results demonstrated that both 
formulations were uniformly blended.  
 
4.4.2.3 Drug Impactor Deposition Measurements 
 
The mean mass data of drug deposited per capsule on each stage of the NGI for 
micronised budesonide and SAX B formulations are shown in Table 4.2 and Figure 
4.11. Table 4.2 also summarises the emitted dose (ED), fine particle dose (FPD), fine 
particle fraction of emitted dose (FPFED) and mass median aerodynamic diameter 
(MMAD).  
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Table 4.2: NGI deposition per capsule of drug aerosolised from micronised Bud and SAX-produced Bud B formulations 
Bud = budesonide; D & C = device and capsules; MP & T = mouthpiece and throat; PS = pre-separator; S = stage 
 
 
Formulations Mean Drug Deposition on Impactor Stages (µg ± SD) 
Mean ED 
(µg ± SD) 
Mean FPD 
(µg ± SD) 
Mean  
FPFED 
(% ± SD) 
MMAD 
(µm ± GSD) 
 D & C MP &T PS S1 S2 S3 S4 S5 S6 S7 MOC 
    
Micronised 
Bud 
19.67 
± 
3.41 
 
11.58 
± 
0.52 
 
38.89 
± 
3.25 
2.52 
± 
0.71 
3.39 
± 
0.82 
2.06 
± 
0.45 
1.32
± 
0.18 
0.48 
± 
0.08 
0.12
± 
0.01 
0.00 
± 
0.00 
0.00 
± 
0.00 
60.37 
± 
3.57 
3.99 
± 
0.70 
6.6 
± 
1.0 
4.48 
± 
1.48 
SAX-produced 
Bud B 
 
22.70 
± 
2.04 
 
5.55 
± 
0.56 
57.93 
± 
2.61 
0.86 
± 
0.14 
1.93 
± 
0.20 
3.06 
± 
0.67 
3.70 
± 
0.73 
1.45 
± 
0.28 
0.21 
± 
0.04 
0.00 
± 
0.00 
0.00 
± 
0.00 
74.69 
± 
4.30 
8.42 
± 
1.70 
11.23 
± 
1.88 
3.41 
± 
1.41 
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Figure 4.11: NGI deposition per capsule of budesonide aerosolised from the 
formulations of micronised budesonide and SAX-produced budesonide B 
 
The ED and FPD of micronised budesonide and SAX B formulations are shown in 
Figure 4.12. As can be seen in Figure 4.12, both ED and FPD aerosolised per capsule 
for SAX B formulation were different from the micronised formulation. The ED of the 
micronised budesonide formulation was 60.37 ± 3.57 µg, whereas the SAX B 
formulation was significantly higher 74.69 ± 4.30 µg (P<0.05). The FPD of the SAX B 
formulation (8.42 ± 1.70 µg) was significantly higher than the micronised formulation 
(3.99 ± 0.70 µg) (P<0.05). Figure 4.13 shows the comparison of FPFED of micronised 
budesonide and SAX B formulations. As shown in Figure 4.13, FPFED aerosolised per 
capsule for SAX B formulation was significantly higher than the micronised formulation 
(P<0.05), with the FPFED increasing from 6.60% for the micronised formulation to 
11.23% for the SAX B formulation. These data suggest that the greater delivery of 
budesonide from the SAX B formulation may be attributed to the corrugated 
morphology of the particles, which may have lowered the contact area between the 
particle and lactose carrier, thereby increasing the liberation of SAX B particles on 
aerosolisation. Such behaviour of corrugated particles as also been shown by Chew 
and Chan (Chew and Chan, 2001).  
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Figure 4.12: The emitted dose and fine particle dose per capsule of budesonide 
aerosolised from the formulations of micronised budesonide and SAX-produced 
budesonide B 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.13: The percent fine particle fraction of emitted dose of budesonide 
aerosolised from the formulations of micronised budesonide and SAX-produced 
budesonide B 
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4.4.3 Study II: In-Vitro Performance of SAX C 
 
4.4.3.1 SEMs of the Formulations 
 
Representative SEMs of: (A) etched lactohale; (B) the formulation of micronised 
budesonide, formulated by blending micronised budesonide with etched lactohale; and 
(C) the formulation of SAX C, formulated by mixing SAX-produced Bud C with etched 
lactohale are all shown in Figure 4.14. The formulations of micronised budesonide and 
SAX C in Figure 4.14B and 4.14C exhibited that the etched lactohale, which had the 
smooth surface, was covered with the small drug particles. The formulations of 
micronised budesonide and SAX C were prepared by blending such drug particles to 
the etched lactohale. Therefore, the SEM micrographs of both B and C exhibited the 
same patterns of small drug particles embedded on the surface of the etched lactose 
crystals. 
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Figure 4.14: Representative SEMs of: (A) etched lactohale; (B) the formulation of 
micronised budesonide; (C) the formulation of SAX C at magnifications of x900 and 
x2500 
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4.4.3.2 Content Uniformity 
 
The coefficient of variation ( CV ) of the drug content of the two formulations for 
micronised budesonide and SAX C was <6%, which is the upper limit of what is 
generally acceptable as uniformity for a carrier-based DPI formulation. The micronised 
budesonide blended with etched lactohale showed the CV  at 0.90 %, whereas the 
CV  of the SAX C formulation was at 2.23 %. These results revealed that both 
formulations were uniformly mixed.  
 
4.4.3.3 Drug Impactor Deposition 
 
The mean mass data of drug deposited per capsule on each stage of the MSLI for 
micronised budesonide and SAX C formulations are shown in Table 4.3 and Figure 
4.15. Table 4.3 also demonstrates the ED, FPD, FPFED and MMAD.  
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Table 4.3: MSLI deposition per capsule of drug aerosolised from micronised Bud and SAX-produced Bud C formulations 
Bud = budesonide; D & C = device and capsules; MP & T = mouthpiece and throat; PS = pre-separator; S = stage 
 
 
 
 
 
 
 
 
Formulations Mean Drug Deposition on Impactor Stages (µg ± SD) 
Mean ED 
(µg ± SD) 
Mean FPD 
(µg ± SD) 
Mean  
FPFED 
(% ± SD) 
MMAD 
(µm ± GSD) 
 
 
D & C 
 
 
Throat 
 
 
S1 
 
 
S2 
 
 
S3 
 
 
S4 
 
 
Filter 
 
    
Micronised 
Bud 
 
40.63 
± 
6.14 
 
5.57 
± 
0.42 
90.55 
± 
15.70 
7.00 
± 
0.79 
7.57 
± 
1.91 
8.25 
± 
0.78 
2.89 
± 
0.86 
121.84 
± 
8.75 
18.71 
± 
3.23 
15.38 
± 
1.58 
3.75 
± 
1.88 
SAX-produced 
Bud C 
 
40.22 
± 
8.13 
 
15.42 
± 
2.39 
89.60 
± 
1.20 
7.10 
± 
1.82 
7.74 
± 
1.06 
7.52 
± 
1.54 
2.52 
± 
0.31 
129.90 
± 
3.54 
17.78 
± 
1.99 
13.68 
± 
1.38 
3.88 
± 
1.86 
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Figure 4.15: MSLI deposition per capsule of budesonide aerosolised from the 
formulations of micronised budesonide and SAX-produced Bud C 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Chapter 4: Functionality and In-vitro Formulation Performance of SAX-
Engineered Budesonide Particles  122 
 
 
As shown in Figure 4.16, both ED and FPD aerosolised per capsule of the micronised 
formulation were not significantly different from the SAX C formulation. The ED of the 
micronised budesonide and the SAX C formulations were 121.84 ± 8.75 µg and  
129.90 ± 3.54 µg, respectively. The FPD of the micronised budesonide and SAX C 
formulations were 18.71 ± 3.23 µg and 17.78 ± 1.99 µg, respectively. The similarities in 
delivery may be related to their mass median aerodynamic diameter (MMAD) 
measurements. The MMAD of SAX C was 3.88 ± 1.86 µm (d50% = 8.68 µm), which was 
similar to the MMAD of 3.75 ± 1.88 µm for the micronised budesonide. The significant 
increase in the fine particle delivery of SAX C particles may be related to a reduction in 
surface contact geometry owing to the morphology of the particles, which would result 
in greater aerosolisation efficiency.  However, it is suggested that the density and the 
size of the nanometer-sized crystals exhibited by SAX C particles may also increase 
the effective contact area due to their number and size. This mechanism of increasing 
adhesion is similar to the manner in which the setae of geckos are able to support the 
weight of the lizard by van der Waals forces. The high surface density of the gecko 
setae is thought to correspond to greater contact area and, therefore, greater adhesion 
(Autumn, Sitti et al., 2002). Similarly, the high surface density of budesonide particles 
at the surface may also correspond to greater adhesion to the lactose.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.16: The emitted dose and fine particle dose per capsule of budesonide 
aerosolised from the formulations of micronised budesonide and SAX-produced 
budesonide C 
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The FPFED of micronised budesonide and SAX C formulations are shown in Figure 
4.17. Micronised budesonide formulation presented a FPFED of 15.38%, and the FPFED 
of SAX C formulation was 13.68%. It is apparent that there was no significant 
difference between the FPFED of micronised budesonide and SAX C formulations 
(p=0.233). These data suggest that owing to the hollow/porous nature of the SAX C 
particles, the aerodynamic diameters of both SAX C and micronised budesonide were 
similar as their aerosolisation properties. These data confirm that the SAX process may 
be utilised to produce hollow particles, which possess smaller aerodynamic diameters 
that enable penetration of particles into the lower airways. There are many particle 
engineering processes that may be applied to fabricate porous particulates. However, 
this is usually achieved by compromising on physical stability of materials, as many of 
these processes result in the generation of amorphous metastable solids. The 
advantage of the SAX process is that particles such as SAX C are predominately 
crystalline and, therefore, likely to remain stable over product shelf-life.   
 
 
 
 
    
 
 
 
 
 
 
 
 
Figure 4.17: The % FPFED of budesonide aerosolised from the formulations of 
micronised budesonide and SAX-produced Bud C 
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4.5 Conclusions 
 
In conclusion, the SAX process has been successfully employed in engineering 
particles of budesonide with the desired property function for delivery to the lungs. The 
SAX-produced budesonide particles were crystalline and these particles displayed no 
polymorphic variations upon processing. The SAX B particles possessed the desired 
physical properties with appropriate particle size for lung delivery. Moreover, in-vitro 
performance analysis suggested that the morphological characteristics of SAX B 
particles may have resulted in the significantly greater delivery than the micronised 
formulation. The SAX C particles were unique as, although the particle size of the 
material was not optimal for delivery to the lungs, the materials’ hollow/porous nature 
resulted in the particles displaying a smaller aerodynamic diameter. As a result, the 
larger SAX C particles showed almost equivalent aerosolisation deposition patterns as 
the smaller micronised particles.  
 
These data show that the SAX process can be used almost as a ‘dial-a-particle’ 
process, where particles with the desired property function can be produced for inhaled 
dosage forms. 
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Chapter 5: Engineering of Crystalline Combination Inhalation 
Particles of a Long-acting β2-agonist and Corticosteroid 
 
5.1 Introduction 
 
Chronic respiratory diseases such as asthma and chronic obstructive pulmonary 
disease (COPD) have become major global epidemics with increasing mortality rates 
(World Health Organisation, 2007). According to the latest World Health Organisation 
(WHO) estimates, approximately 300 million people suffer from asthma (Masoli, Fabian 
et al., 2004) and almost 210 million have COPD (Halbert, Natoli et al., 2006). WHO 
estimates for 2030 suggest that COPD will become the third commonest cause of 
death (Lopez and Mathers, 2006). With limited treatment options to slow the relentless 
progression of these diseases, chronic respiratory diseases constitute a serious public 
health problem in all countries throughout the world (Bousquet, Dahk et al., 2007).     
 
The preferred route of administration of medicaments to treat chronic airway diseases 
is by inhalation via a pressurised metered dose inhaler (pMDI) or dry powder inhaler 
(DPI) (Virchow, Crompton et al., 2008). The delivery of therapeutic agents to the lungs 
affords many advantages, for example, rapid onset of action, enables smaller doses to 
be used and provides a greater efficacy to safety ratio in comparison to systemic 
therapy (Virchow, Crompton et al., 2008). While traditionally a single active 
pharmaceutical ingredient (API) was traditionally administered to the respiratory tract, 
the delivery of multiple drug agents via combined inhalation drug delivery systems has 
gained widespread acceptance by physicians and patients in the management of both 
asthma (Barnes, 2002; Ankerst, 2005; Nelson, 2005) and COPD (Dransfield and Bailey, 
2004).  
 
Medication non-compliance is a significant problem in the treatment of both asthma 
(Bateman, Britton et al., 1998) and COPD (Keating and McCormack, 2007), and has 
been a significant driver for the development of combined inhalation dosage forms 
(Barnes, 2002). These patients have a multitude of drugs to administer on a daily basis, 
which may often lead to the confusion in their treatment regimen (Stempel, Stoloff et al., 
2005). Furthermore, patients tend to forget to take their anti-inflammatory medication 
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because, unlike a bronchodilator, it does not provide immediate relief from acute 
symptoms (Wallin, Sue-Chu et al., 2003). Since the regular use of anti-inflammatory 
drugs is central to treating the underlying disease of asthma and COPD, the 
combination of an anti-inflammatory drug with a long-acting bronchodilator has been 
shown to vastly improve disease management for both patients and physicians (Miller-
Larsson and Selroos, 2006). Although the interest in combined inhalation therapy has 
been primarily driven from a patient compliance stand-point, recent clinical studies 
support the deployment of multiple actives in a single inhalation dosage form to 
improve treatment efficacy and clinical outcome (Nelson, Chapman et al., 2003).   
 
Asthma and COPD are complex disease conditions of the airways that share some 
similarities; both are characterised by air flow limitation and airway inflammation 
(Barnes, Shapiro et al., 2003; Barnes, 2008). However, they are disparate conditions 
since the airflow limitations experienced by people with asthma are fully reversible with 
bronchodilators, whereas in COPD they are not (Dransfield and Bailey, 2004; Cazzola, 
Ando et al., 2007). Furthermore, airway inflammation in COPD is characterised by the 
presence of neutrophils and macrophages (Barnes, Shapiro et al., 2003; Barnes, 2004), 
while the predominant inflammatory cells observed in asthma are eosinophils and mast 
cells (Barnes, Chung et al., 1998). These histological differences in the cellular 
infiltration between asthma and COPD suggest major differences in the chronic 
inflammatory processes involved in each disease condition, which is confirmed by the 
presence of different inflammatory chemokines and cytokines in each condition. 
However, one pro-inflammatory chemokine that plays a key role in the inflammatory 
processes of severe asthma and COPD is IL-8. This chemokine is a potent neutrophil 
chemo-attractant up-regulated in response to inflammatory stimuli such as cigarette 
smoke or bacterial products (Kunkel, Standiford et al., 1991). The recruitment of large 
numbers of inflammatory cells to the lungs in response to increase IL-8 secretion leads 
to the tissue damage that typifies pathophysiologies in cystic fibrosis (Dean, Dai et al., 
1993), asthma (Shute, Vrugt et al., 1997) and eosinophilic pneumonia (Barnes, Chung 
et al., 1998). Such complexities associated with the chronic inflammatory processes in 
each disease condition pose significant challenges in determining a treatment strategy.   
 
In order to manage respiratory disease conditions such as asthma and COPD, 
therapies are required to control symptoms, reduce exacerbations and improve health 
status in patients. The first-line treatments in treating both conditions are long-acting β2-
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agonists (LABA) and inhaled corticosteroids (ICS), which are employed to aid 
bronchodilation and reduce inflammation, respectively (Greening, Ind et al., 1994; Matz, 
Emmett et al., 2001). Inhalation dosage forms combining a LABA and ICS are available 
in both pMDI and DPI platforms (Keating and McCormack, 2007). For the combined 
inhalation products available, the salmeterol xinafoate (SX, LABA) and fluticasone 
propionate (FP, ICS) combination inhalation product (Seretide®/Advair® Inhaler, 
GlaxoSmithKline, UK) has shown a greater efficacy compared with monotherapy with 
the individual components (Nelson, 2005). The product is highly successful and this 
product is currently listed amongst the top ten best-selling pharmaceutical products 
with annual sales of approximately $4.3 billion (Davis, 2008).  
 
Clinical studies have indicated that combination inhaled therapy of LABAs and ICSs 
improves health outcomes in asthma and COPD in comparison to mono-therapy with 
LABA and ICS (Calverley, Pauwels et al., 2003; Bergmann, Lindemann et al., 2004; 
Calverley, Anderson et al., 2007; Cazzola, Ando et al., 2007). Furthermore, 
observational studies suggest that combination inhalation therapy may actually reduce 
mortality in COPD (Sin and Man, 2007). In addition, recent studies have also shown 
that the superior efficacy of combined inhalation therapy with LABAs and ICSs could be 
due to complementary and synergistic interactions (Nelson, Chapman et al., 2003).  
 
The two classes of compounds have very different modes of action and thereby target 
different elements of the disease process. For example, SX, a selective long-acting β2-
adrenoceptor agonist, has almost fifty times the selectivity for the β2-adrenoceptor than 
salbutamol (Cazzola, Testi et al., 2002). The mechanism of action corresponds to the 
binding to the β2-adrenoceptor, thereby activating intracellular adenylyl cyclase, which 
catalyses the conversion of adenosine triphosphate (ATP) to cyclic adenosine 
monophosphate (cAMP). The increased levels of cAMP lead to bronchial smooth 
muscle relaxation (Cazzola, Testi et al., 2002; Keating and McCormack, 2007). In 
contrast, the FP (ICS) is a potent glucocorticosteroid with anti-inflammatory properties 
that are predominately mediated by the glucocorticoid receptor (Dransfield and Bailey, 
2004). Hence, the enhanced clinical benefit of combining both classes of compounds in 
a single inhaler may be related to such additive effects of administering both agents 
simultaneously to the lung because they have complementary modes of action and 
different target aspects of the underlying disease pathophysiology (Barnes, 2002; 
Nelson, 2005). However, the increased clinical efficacy of inhaled therapies combining 
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FP and SX has been reported to be more than just additive effects of co-administering 
both agents, but may be due to synergistic interactions of the two classes of 
compounds at the receptor, molecular and cellular level (Nelson, Chapman et al., 
2003). Several molecular mechanisms have been postulated to explain the synergistic 
action of FP and SX. It is thought that the corticosteroid may provide protection against 
down regulation of the β2-adrenoceptor through up-regulation of β2-receptor gene 
expression, thereby increasing synthesis of respiratory mucosal β2-adrenoceptor 
(Baraniuk, Ali et al., 1997). The LABAs, for example SX, have been shown to prime the 
inactive glucocorticoid receptor through a phosphorylation mechanism that renders the 
receptor more sensitive to steroid-dependent activation (Johnson, 2002).  Furthermore, 
there has been the evidence of enhanced glucocorticoid receptor translocation into the 
nucleus when FP and SX are co-administered, suggesting that SX may amplify the 
anti-inflammatory effects of FP (Usmani, Ito et al., 2005). This synergistic action is 
thought to occur when both drugs reach the same cell together in adequate 
concentrations (Nelson, Chapman et al., 2003). The administration of both drugs from 
a single inhalation dosage form is likely to enhance the probability co-deposition in 
comparison to monotherapy of the individual drug agents. This is primarily related to 
the lower variability in patient inspiratory action when a single inhalation device is 
employed to deliver both actives to the lungs, which prevents different lung deposition 
patterns of both drugs. The delivery of both drugs in a single inhalation is also likely to 
expose regions of the lung to a single aerosol cloud containing both actives, which may 
also enhance the likelihood for co-deposition. Moreover, recent studies have shown 
that the opportunity for synergistic action is further enhanced in the Seretide 
formulation by co-deposition of FP and SX particles in the airways as a result of particle 
co-association within the delivery device (Michael, Snowden et al., 2001; Nelson, 
Chapman et al., 2003; Theophilus, Moore et al., 2006). 
 
Current DPI-combined inhalation dosage forms are physical mixtures of comminuted 
fine drug particles of both actives and coarse carrier particles of lactose monohydrate, 
which are employed within DPI formulations to improve flow properties and metering of 
the highly cohesive drug particles (Hersey, 1975; Malcolmson and Embleton, 1998; 
Edge, Kibbe et al., 2005). During inhalation, the patient’s inspiratory force is employed 
to detach the fine drug particles from the carrier in order to deposit in the deep lung 
(Telko and Hickey, 2005). Hence, the process of entrainment and deposition of both 
actives in the airways is largely dependent on the balance of interfacial forces between 
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components of the formulation (Jones, Harris et al., 2007). As a result, the prospect of 
co-depositing of both actives to the same site of action in the correct dose ratio is 
rather limited and cannot be controlled (Taki, Zeng et al., 2006). Hence, these dosage 
forms are subject to greater variability in fine particle delivery of each active. 
Furthermore, as the actives deployed in DPI dosage forms are micronised using high-
energy mechanical processing, the presence of process-induced structural disorder at 
the surfaces of these particles may perpetuate the variability in dose delivery of both 
actives as a function of product storage conditions. These factors may ultimately limit 
the enhanced clinical efficacy of combination inhalation therapy achieved through 
synergistic action between actives delivered together at the same site of action. Thus, 
there is a requirement of processes that may enable the preparation of combination 
DPI products which will allow both drugs to be delivered more efficiently and 
independently of dose variations.  
 
One approach to circumvent problems associated with the development of combination 
DPI products is to locate separate formulations of both actives in different 
compartments of a single device (Braithwaite and Williams, 2005). Upon inhalation, 
both formulations can be aerosolised in one inhaled air-stream, thereby enabling 
delivery of both actives in one aerosol cloud to the site of action. Another approach 
would be to combine multiple actives into a single particle, an approach previously 
suggested by Westmeier and Steckel (Westmeier and Steckel, 2008). They employed 
a precipitation process to produce combined particles consisting of FP and SX in the 
presence of crystal growth inhibitors. The authors were able to generate combined co-
precipitated particles of FP and SX in the respirable range using a mixture of 
polysorbate and HPMC. However, the product was found to be partly crystalline 
following spray drying and, therefore, this approach would require optimisation 
(Westmeier and Steckel, 2008). The use of the solution atomisation and crystallisation 
by sonication (SAX) process may provide an alternative route of producing crystalline 
combined inhalation particles of FP and SX.  
 
The SAX process consists of three interdependent processes: (a) the production of 
aerosol droplets of the solute from a carrier solvent using a suitable aerosol generator; 
(b) the collection of the highly supersaturated droplets in a crystallisation vessel 
containing a non-solvent of the drug; (c) the application of ultrasonic waves to a 
crystallisation vessel to controllably induce homogeneous nucleation and crystal growth 
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(Kaerger and Price, 2004). An atomiser in the SAX process produces highly 
supersaturated spherical constructs of the active ingredient within a well-defined 
particle size for controlled crystallisation. By combining these processes and controlling 
relevant parameters, high-purity micron-sized sphere-like crystalline particles can be 
readily produced in a single-step (droplet-to-particle) operation. The major advantage 
of this low-cost technique relates to the use of any suitable aerosol generator and the 
whole process can be carried out under atmospheric pressure and ambient conditions. 
Furthermore, it has the potential for batch and continuous processing at an industrial 
scale. 
 
The potential application of the SAX process has been investigated in this study in 
order to produce single crystalline particles containing both FP and SX via a single 
droplet to particle operation.  
 
5.2 Materials  
 
Micronised FP and SX were obtained from sources stated in Chapter 2. All organic 
solvents were of at least analytical grade and were supplied by Fisher Chemicals 
(Loughborough, UK). Water was prepared by MilliQ from reverse osmosis (Molsheim, 
France). Etched lactose was produced from coarse carrier lactose monohydrate as 
indicated in Chapter 2.  
 
5.3 Methods 
 
5.3.1 The Production of SAX-produced FP/SX Particles 
 
Combined SAX FP/SX particles were prepared by atomisation of a 2% w/v solution 
containing FP:SX in the ratio 10:1 in acetone. Atomisation was conducted using a 
SU11 co-axial two-fluid atomiser with an internal mix (Spraying Systems Co., Illinois, 
USA). The atomiser was used at a sprayed rate of 4 ml.min-1 with air pressure at 2.5 
bar in the lab scale of the SAX process over 60 cm of separation distance including 
positive pressure 30 L.min-1 in the system with an ultrasonic probe. The particles were 
collected in perfluorodecalin at 5˚C, and the resulting combined SAX particles of FP/SX 
 
Chapter 5: Engineering of Crystalline Combination Inhalation Particles of  
a Long-acting β2-agonist and Corticosteroid  131 
 
 
were isolated using supercritical CO2 extraction of perfluorodecalin. The process 
conditions for the extraction of perfluorodecalin using supercritical CO2 extraction was 
the same as the extraction of hexane as described in Chapter 3. 
 
5.3.2 Formulation Blending  
 
A formulation, containing 1.6% w/w combined SAX FP/SX particles, was prepared by 
geometric blending with 63 - 90 µm sieve fraction of surface-etched lactose produced 
as described in Chapter 2. The combined SAX particles and coarse ethed-lactose were 
mixed in a 15 ml glass tube for 60 seconds in a Whirlimixer (Fisons Scientific 
Equipment, Loughborough, UK). The resultant blend was further processed using a 
Turbula shaker-mixer (Willy A Bachofen AG, Basel, Switzerland) at 46 rpm for 45 
minutes.  
 
In order to compare the in-vitro inhalation performance of SAX FP/SX and micronised 
FP/SX, a combination formulation containing 1.45% w/w micronised FP and 0.15% w/w 
micronised SX, (ratio 10 to 1), was prepared by geometric blending with 63 - 90 µm 
sieve fraction of surface-etched lactose. The drug and ethched-lactose were mixed in a 
15 ml glass tube for 60 seconds in a Whirlimixer (Fisons Scientific Equipment, 
Loughborough, UK). The resultant blend was then mixed using a Turbula shaker-mixer 
(Willy A Bachofen AG, Basel, Switzerland) at 46 rpm for 45 minutes. Both the 
formulations containing either combined SAX particles of FP:SX or micronised FP and 
SX were stored at 44 % RH and 25 °C for 24 h before formulation testing. 
 
5.3.3 Content Uniformity Determination 
 
The content uniformity of the respective formulations was determined by obtaining ten 
random samples of 25 ± 1 mg from various positions of the powder bed. Each sample 
was dissolved in a solution of 45% methanol, 35% acetonitrile and 20% water, which 
was sonicated for 15 minutes and made up to a 100 ml final volume. Following this, the 
drug concentration was assessed by HPLC. The proportion of drug in each sample was 
calculated and the content uniformity expressed as the coefficient of variation 
(Equation 4.1) 
 
Chapter 5: Engineering of Crystalline Combination Inhalation Particles of  
a Long-acting β2-agonist and Corticosteroid  132 
 
 
5.3.4 Capsule Filling 
 
Each formulation was manually loaded into size 3 HPMC capsules (Qualicaps, Madrid, 
Spain). Fill weight was 25 ± 1 mg, giving a nominal dose of 364 ± 20 µg for FP and 36 
± 2 µg for SX per capsule. In order to investigate the influence of the storage on the 
performance of micronised and SAX FP/SX preparation, formulations were stored at 
different environmental conditions. In Study I, filled capsules of both micronised and 
SAX FP/SX formulations were stored in a sealed chamber containing a saturated 
solution of potassium carbonate (giving a relative humidity of 44%) at 25˚C and re-
tested four weeks later. For Study II, the filled capsules were stored in a sealed 
chamber containing a saturated solution of sodium chloride (giving a relative humidity 
of 75%) at 25˚C, and re-tested at two weeks and four weeks. In Study III, the filled 
capsules were also stored in a sealed chamber containing a saturated solution of 
sodium chloride (giving a relative humidity of 75%) at 40˚C and re-investigated at two 
weeks and four weeks. 
 
5.3.5 In-vitro Performance Analysis 
 
In-vitro formulation performance was assessed using a NGI (Copley Scientific Ltd, 
Nottingham, UK). All NGI collection cups were immersed in a 1% v/v solution of 
silicone oil (Acros Organics, Geel, Belgium) in hexane and allowed to air dry. The NGI 
was then assembled with a pre-separator (containing 15 ml of wash solvent) and 
connected to a vacuum pump (Gast, Benton Harbour, MI, USA) via a solenoid valve. 
The flow rate at the inlet to the throat was set to 60 L.min-1 using a digital flow meter 
with model DFM 2000 (Copley Scientific Ltd., Nottingham, UK). A capsule was inserted 
in the Cyclohaler and punctured by two sharp pins to generate two small holes. Then, a 
Cyclohaler was attached to the throat of the NGI using a rubber mouthpiece. The 
contents of the capsule were then aerosolised into the NGI by drawing air through the 
apparatus at 60 L.min-1 for 4 seconds (controlled by a solenoid valve). Once the 
contents of ten capsules were aerosolised in this way, the device was disconnected. 
The device and capsules, inlet port, pre-separator and each stage of the NGI were 
washed down into separate known volumes of 45% methanol, 35% acetonitrile and 
20% water, which were sonicated to aid dissolution and allowed to cool. The 
concentration of drug in each solution was investigated by HPLC, from which the mass 
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of drug deposited on each stage of the NGI was determined from stages 1 to 7 and on 
the micro-orifice collector (MOC). Between experiments, the NGI was washed in water 
and methanol, dried in an oven, and allowed to cool to room temperature. 
 
5.3.6 High Performance Liquid Chromatography (HPLC) 
 
Drug concentrations were determined by HPLC. The HPLC system consisted of the 
pump, autosampler, column oven, UV detector and analyser as indicated in Chapter 4. 
Unknown sample concentration was determined from duplicate injections by 
comparison of the peak area with reference peaks from external standard solutions of 
known concentration. 
 
The HPLC employed a 4.6 mm x 250 mm C18 5 µm Hypersil column (Thermo Electron 
Corporation, Waltham, MA, USA) and a mobile phase consisting of 45% v/v methanol, 
35% v/v acetonitrile and 20% v/v water. The flow rate was 1.5 ml.min-1; column 
temperature was 40˚C and injection volume was 200 µl. Drug retention times were 3.75 
minutes for FP and 1.30 minutes for SX, so a run time of 5 minutes was employed. UV 
detection wavelengths were 235 nm for FP and 252 nm for SX.  
 
The relationship between drug concentrations of FP and the peak area for each drug 
was found to be linear, with linear regression analysis yielding a coefficient of 
determination (R2) of 0.9999. Similarly, the relationship between the drug 
concentrations of SX and integrated peak area for each drug was found to be linear, 
with linear regression analysis yielding a coefficient of determination (R2) of 0.9992 
(see Figure 5.1). 
 
Chapter 5: Engineering of Crystalline Combination Inhalation Particles of  
a Long-acting β2-agonist and Corticosteroid  134 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.1: HPLC calibration curve for FP 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.1: HPLC calibration curve for FP and SX 
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5.4 Characterisation of SAX-produced FP/SX Particles 
 
5.4.1 Results and Discussion 
 
5.4.1.1 Scanning Electron Microscopy 
 
Representative scanning electron micrographs of micronised FP, micronised SX and 
SAX-produced FP/SX particles are shown in Figure 5.2. The morphology of the SAX-
produced FP/SX particles appeared different from micronised FP and micronised SX. 
Micronised FP and SX particles shared a similar plate-like shape. The plate-like shapes 
of micronised FP were also slightly wider, whereas micronised particles of SX 
appeared to possess a narrow plate-like shape. The combined SAX-produced FP/SX 
particles were spherical in nature and these particles also possessed a defined 
corrugated morphology. Most particles of micronised FP and SX appeared in the form 
of agglomerated particles, whilst the SAX-produced FP/SX particles tended to be more 
dispersed, suggesting that the micronised FP and SX powders were more cohesive. 
This may be attributable to the corrugated morphology of the combined SAX particles, 
which may reduce contact between particles and, therefore, the level of agglomeration.  
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Figure 5.2: Representative SEMs of micronised FP, micronised SX and 
 SAX-produced FP/SX particles at magnifications of x3000 and x7000 
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5.4.1.2 Particle Size Analysis 
 
The particle size distribution of micronised FP, micronised SX and SAX-produced 
FP/SX is shown in Figure 5.3. The cumulative distribution of particles from micronised 
FP and SX was slightly narrower than SAX-produced FP/SX. In addition, the size 
distribution of micronised FP was marginally broader than micronised SX, but slightly 
narrower than SAX-produced FP/SX. These data are summarised in Table 5.1 using 
the d10, d50 and d90 percentiles. It is apparent that the d50 values of micronised FP, SX 
and SAX-produced FP/SX are 3.28, 2.13 and 4.68 µm, respectively. These data 
suggest that the micronised drug particles and SAX-produced FP/SX confirmed the 
suitable size range for  the preparation of DPI formulations (Zeng, Martin et al., 2001). 
Furthermore, the particle size distribution of the SAX-produced combined FP/SX 
particles was mono-modal, which suggests that both FP and SX may have been 
successfully processed into one particle. 
 
                           
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.3: Particle size distribution of micronised FP, micronised SX and  
SAX-produced FP/SX particles 
 
 
 
 
 
 
 
Chapter 5: Engineering of Crystalline Combination Inhalation Particles of  
a Long-acting β2-agonist and Corticosteroid  138 
 
 
Table 5.1: Summary of particle size data of micronised FP, micronised SX and  
SAX-produced FP/SX particles 
 
 
5.4.1.3 Differential Scanning Calorimetry 
 
The DSC thermograms of micronised FP and SX are shown in Figure 5.4. The 
thermogram of micronised FP showed an endothermic peak at ~292°C, related to the 
melting temperature of FP. The thermogram of SX exhibited two endothermic peaks at 
~124°C and ~139°C and exothermic peak at ~130°C. The first large endothermic at 
~124°C represented the melting of SX form I, which re-crystallised to SX form II at 
~130°C before melting again at ~139°C. Micronisation of SX form I has been reported 
to induce the formation of trace seeds of SX form II, which enabled this re-
crystallisation to occur (Beach, Latham et al., 1999; Tong, Yu Shekunov et al., 2001). 
The DSC thermogram of SAX-produced FP/SX revealed three endothermic peaks as 
suggested in Figure 5.5. The two endothermic peaks exhibited at ~122°C and ~138°C, 
which were relevant to the SX peaks. The first endothermic at ~122°C represented the 
melting of SX form I, which re-crystallised to SX form II before melting again at ~138°C. 
Also, the last large endothermic peak appeared at ~294°C, related to the melting point 
of FP. These data suggest that both FP and SX were present in the combined FP/SX 
particles, and the SAX process did not change the polymorphic form of two active 
ingredients.  
 
 
 
 
 
 
 
 
 d10% (µm) ± SD 
 
d50% (µm) ± SD 
 
d90% (µm) ± SD 
 
Micronised FP 1.41 ± 0.01 3.28 ± 0.01 5.98 ± 0.01 
Micronised SX 0.86 ± 0.01 2.13 ± 0.01 4.09 ± 0.01 
SAX FP/SX 1.33 ± 0.01 4.68 ± 0.01 8.53 ± 0.01 
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Figure 5.4: DSC thermograms of micronised FP, micronised SX particles 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.5: DSC thermogram of SAX-produced FP/SX particles 
 
5.4.1.4 X-ray Powder Diffraction 
 
In order to confirm the crystallinity of particles, XRPD was applied in this investigation. 
The XRPD patterns in Figure 5.6 show sharp diffraction peaks associated with 
crystalline materials of micronised FP, micronised SX and SAX-produced FP/SX. The 
XRPD diffractograms shown in this figure, show that the SAX-produced FP/SX had 
292.06 
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  123.91 
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294.13 
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similar X-ray patterns as micronised FP. This was expected as the combined particles 
produced by SAX contained predominately more FP. Moreover, these data confirm that 
the SAX particles were predominately crystalline.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.6: XRPD spectra of micronised FP, micronised SX and SAX FP/SX particles 
 
5.4.1.5 Dynamic Vapour Sorption 
 
The moisture sorption properties of micronised FP, micronised SX and SAX-produced 
FP/SX particles are demonstrated by the DVS isotherms shown in Figure 5.7. The DVS 
moisture sorption isotherms of the all materials showed <1% w/w mass increase or 
mass loss during the first sorption cycle. With respect to micronised FP, there is a 
significant increase in moisture sorption above 60% RH for the first sorption cycle. The 
following desorption and the subsequent second sorption cycle suggests that 
approximately 0.04% of water has been retained. Although the SAX FP/SX sample 
does not undergo such as step change at 60% RH, it also retains a similar amount of 
water. The significant increase in water sorption for SAX FP/SX may be due to the 
larger surface area of the material with respect to the corrugated morphology of the 
particles. These data suggest no indication of material re-crystallisation because the 
sorption profiles of second cycle are similar, which is indicative of a stable crystalline 
material. 
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Figure 5.7: DVS isotherms of micronised FP, micronised SX and  
SAX-produced FP/SX particles 
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5.5 In-vitro Performance of FP/SX Formulations 
 
5.5.1 Results 
 
5.5.1.1 SEMs of the FP/SX Formulations 
 
Representative SEMs of (A) etched lactohale, (B) the formulation containing both 
micronised FP and SX, and (C) the formulation containing combined SAX FP/SX are 
shown in Figure 5.8. The etched lactose exhibited the typical tomahawk shape of 
lactose monohydrate and displayed a smooth surface with limited amount of intrinsic 
fine lactose particles. The formulations containing micronised FP and SX and 
combined SAX FP/SX particles presented particulates deposited on the surface of the 
etched lactose upon blending.  
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Figure 5.8: Representative SEMs of (A) etched lactohale, (B) the formulation of 
micronised physical mixture of FP/SX, and (C) the formulation of SAX-produced FP/SX 
at magnifications of x900 and x2500 
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5.5.1.2 Content Uniformity of FP/SX Formulations 
 
The coefficient of variation (CV) of the drug content of the two formulations containing 
either micronised FP and SX or combined SAX particles of FP/SX  was <6%, which is 
the upper limit of what is commonly acceptable as uniformity for a carrier based DPI 
formulation. These results demonstrated that both formulations were uniformly blended.  
 
5.5.1.3 Study I: In-vitro Performance of FP/SX at 25˚C/44% RH 
 
The in-vitro aerosolisation properties of combination DPI formulations composed of 
either micronised FP/SX or combined SAX FP/SX particles were evaluated using 
inertial impaction testing. The mean mass data of drug deposited per capsule on each 
stage of the NGI for both micronised FP/SX and SAX FP/SX formulations are shown in 
Table 5.2. These two formulations were investigated again after storing at 25˚C/44% 
RH for four weeks. Table 5.2 also shows the mean ED, FPD, FPFED and MMAD upon 
storage. The mean drug deposition data per capsule of both combined formulations at 
the initial time-point and the following storage at 44% RH at 25°C for four weeks are 
shown in Figure 5.9 and 5.10. It is evident from these data that aerosolisation of the 
SAX FP/SX formulation corresponded to higher drug deposition than the micronised 
FP/SX formulation.  
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Table 5.2: NGI deposition per capsule of drug aerosolised from the formulations of micronised FP:SX and 
SAX-produced FP:SX with ratio 10:1 stored at 25˚C/44% RH from different periods of time (week 0 and 4) 
FP = fluticasone propionate; SX = salmeterol xinafoate 
   
 
 
No. Formulations 
Mean Drug Deposition on Impactor Stages 
(µg ± SD) 
Mean ED 
(µg ± SD) 
Mean FPD 
(µg ± SD) 
Mean FPFED 
(% ± SD) 
MMAD 
(µm ± GSD) 
D & C MP &T PS S1 S2 S3 S4 S5 S6 S7 MOC     
 
 
1 
Micronised FP at time 0 
24.97 
± 
2.58 
9.39 
± 
1.24 
273.29 
± 
3.49 
2.90 
± 
0.60 
4.58 
± 
0.26 
6.64 
± 
1.57 
9.52 
± 
0.63 
5.35 
± 
0.22 
2.01 
± 
0.16 
0.87 
± 
0.06 
0.45 
± 
0.06 
315.00 
± 
5.13 
24.83 
± 
1.76 
7.88 
± 
0.46 
2.50 
±  
2.40 
Micronised SX at time 0 
3.56 
± 
0.54 
1.11 
± 
0.03 
32.56 
± 
0.07 
0.41 
± 
0.09 
0.43 
± 
0.05 
0.58 
± 
0.10 
0.81 
± 
0.02 
0.48 
± 
0.08 
0.26 
± 
0.05 
0.19 
± 
0.03 
0.17 
± 
0.03 
36.99 
± 
0.25 
2.48 
± 
0.21 
6.70 
± 
0.53 
2.30  
± 
 3.00 
 
2 SAX-produced FP at time 0 
32.88 
± 
4.11 
19.02 
± 
2.98 
166.37 
± 
1.47 
6.99 
± 
1.29 
10.20 
± 
0.82 
9.05 
± 
0.30 
7.71 
± 
0.45 
4.04 
± 
0.02 
1.83 
± 
0.47 
0.96 
± 
0.17 
0.62 
± 
0.06 
226.78 
± 
3.09 
24.21 
± 
0.53 
10.68 
± 
0.32 
3.60 
 ± 
2.80 
SAX-produced SX at time 0 
3.35 
± 
0.37 
2.36 
± 
0.42 
18.25 
± 
2.19 
0.83 
± 
0.09 
1.17 
± 
0.19 
1.06 
± 
0.10 
0.93 
± 
0.11 
0.49 
± 
0.04 
0.25 
± 
0.05 
0.16 
± 
0.04 
0.16 
± 
0.04 
25.66 
± 
2.44 
3.05 
± 
0.14 
11.96 
± 
1.09 
3.30 
 ±  
3.10 
 
 
3 
Micronised FP  at week 4 
29.95 
± 
1.23 
8.95 
± 
0.98 
273.20 
± 
6.77 
2.09 
± 
0.16 
4.23 
± 
0.20 
7.12 
± 
0.23 
8.59 
± 
0.17 
2.49 
± 
0.08 
0.26 
± 
0.00 
0.02 
± 
0.00 
0.01 
± 
0.00 
306.96 
± 
6.37 
18.49 
± 
0.44 
6.03 
± 
0.15 
3.30 
 ±  
1.90 
Micronised SX at week 4 
3.60 
± 
0.80 
1.22 
± 
0.04 
35.40 
± 
0.67 
0.27 
± 
0.04 
0.35 
± 
0.02 
0.55 
± 
0.02 
0.76 
± 
0.03 
0.26 
± 
0.01 
0.08 
± 
0.02 
0.07 
± 
0.01 
0.08 
± 
0.01 
39.03 
± 
0.71 
1.79 
± 
0.08 
4.60 
± 
0.18 
2.70 
 ±  
2.70 
 
 
4 
SAX-produced FP at week 4 
60.26 
± 
3.34 
17.48 
± 
0.71 
202.60 
± 
6.75 
6.13 
± 
0.93 
14.41 
± 
3.11 
14.67 
± 
3.26 
12.29 
± 
2.00 
3.49 
± 
0.90 
0.40 
± 
0.08 
0.04 
± 
0.02 
0.01 
± 
0.01 
271.53 
± 
16.80 
30.90 
± 
6.24 
11.31 
± 
1.66 
3.90  
±  
1.90 
SAX-produced SX at week 4 
7.42 
± 
0.39 
2.13 
± 
0.06 
20.87 
± 
0.45 
0.67 
± 
0.09 
1.48 
± 
0.32 
1.51 
± 
0.31 
1.35 
± 
0.25 
0.47 
± 
0.04 
0.10 
± 
0.01 
0.09 
± 
0.01 
0.09 
± 
0.01 
28.76 
± 
0.74 
3.61 
± 
0.57 
12.52 
± 
1.72 
3.50 
 ±  
2.60 
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Figure 5.9: NGI deposition per capsule of FP aerosolised from the combination 
formulations of micronised FP:SX (10:1) compared with SAX-produced FP:SX (10:1) at 
25˚C/44% RH from different periods of time (week 0 and 4) 
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Figure 5.10: NGI deposition per capsule of SX aerosolised from the combination 
formulations of micronised FP:SX (10:1) compared with SAX-produced FP:SX (10:1) at 
25˚C/44% RH from different periods of time (week 0 and 4) 
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At the initial time-point, the emitted dose (ED) of the micronised FP/SX formulation was 
315.00 ± 5.13 µg for FP and 36.99 ± 0.25 µg for SX (Figure 5.11). In comparison, 
Figure 5.11 shows that the formulation of SAX processed FP/SX particles showed 
significantly (p<0.05) lower ED of FP (226.78 ± 3.09 µg) and SX (25.66 ± 2.44 µg).  
 
Upon storage at 44% RH for four weeks, the micronised FP/SX formulation did not 
affect the ED of FP, however, a small but significant (p<0.05) increase of the emitted 
dose of SX was observed (Figure 5.11). In contrast, such figure also shows that on 
storage of the SAX FP/SX formulation under the same conditions, the results exhibited 
a significant (p<0.05) increase of the ED of FP, whilst the ED of SX remained 
unchanged. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.11: The emitted dose per capsule of micronised and SAX combined 
formulations stored at 25˚C/44% RH from different periods of time (week 0 and 4) 
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According to Figure 5.12, the FPD of FP and SX upon aerosolisation of the micronised 
FP/SX formulation at the initial time-point were 24.83 ± 1.76 and 2.48 ± 0.21 µg, 
respectively. In comparison, Figure 5.12 demonstrates no significant difference between 
the FPD of FP on aerosolisation of either the micronised FP/SX or the SAX FP/SX 
formulation. However, this figure reveals that the FPD of SX from the SAX FP/SX 
formulation was significantly (p<0.05) greater than that of micronised SX.  
 
Upon storage of both formulations at 44% RH for four weeks, the FPD of both 
micronised FP and SX significantly (p<0.05) decreased, whilst no significant changes in 
the FPD of the SAX material were observed (Figure 5.12). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.12: The fine particle dose per capsule of micronised and SAX combined 
formulations stored at 25˚C/44% RH from different periods of time (week 0 and 4) 
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At the initial time-point, the FPFED of the micronised FP/SX formulation was 7.88 ± 
0.46% for FP and 6.70 ± 0.53% for SX (see Figure 5.13). In comparison, such figure 
exhibits that the formulation of SAX-produced FP/SX particles showed significantly 
(p<0.05) higher FPFED of FP (10.68 ± 0.32%) and SX (11.96 ± 1.09%).  
 
After storage at 44% RH for four weeks, the micronised FP/SX formulation had a 
significant (p<0.05) change in the FPFED of both FP and SX. In contrast, Figure 5.13 
demonstrates that the SAX FP/SX formulation remained unchanged with p<0.05 in 
both FP and SX upon storage under the same condition. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.13: The fine particle fraction of emitted dose (FPFED) per capsule of 
micronised and SAX combined formulations stored at 25˚C/44% RH from different 
periods of time (week 0 and 4) 
 
 
 
The mean normalised mass ratios of FP:SX as a function of recovered dose deposited 
on stages 2 to 5 of the NGI following aerosolisation of both formulations at the initial 
time-point and after storage at 25˚C/ 44% RH for four weeks are shown in Figure 5.14.  
As shown in this figure, the ratio of FP:SX from mean normalised data from stages 2 to 
5 at the initial time-point following aerosolisation of the formulation containing 
micronised FP and SX was greater than one. These data suggest that deposition of 
both drugs was inconsistent and that materials were not deposited in their 10:1 (FP:SX) 
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ratio. As proposed earlier, such an occurrence in-vivo may reduce the potential for 
synergistic action between the actives, as the probability of delivery of both actives to 
the same site of action in the required concentrations will be limited. In contrast, the 
mean normalised ratio of FP:SX following aerosolisation of the SAX formulation on 
stages 2 to 5 was close to unity across stages 2 to 5. These data suggest that 
combined SAX particles of FP/SX may be effectively delivered through the lower 
respiratory system with the constant ratio of both combined drugs, which will increase 
the probability of synergistic effect of the class molecules at the receptor and cellular 
level. As can also be seen in Figure 5.14, at week 4, the ratio of FP:SX at 25˚C/44% 
RH tended to maintain the same pattern as the initial time-point. This suggested that 
FP and SX from SAX formulation were stable and maintained a constant ratio upon 
storage at 25˚C/44% RH for four weeks. In contrast, following aerosolisation of the 
micronised FP and SX formulation upon storage, the deposition of FP and SX varied 
significantly, which may correspond to increase chances of under or over-dosing of the 
class molecules. 
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Figure 5.14: Ratio of FP:SX from mean normalised data of stages 2 to 5 of micronised 
FP:SX (10:1) compared with SAX-produced FP:SX (10:1) stored at 25˚C/44% RH  
from different periods of time (week 0 and 4) 
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5.5.1.4 Study II: In-vitro Performance of FP/SX at 25˚C/75% RH 
 
The mean mass data of drug deposited per capsule on each stage of the NGI for both 
micronised FP/SX and SAX FP/SX formulations upon storage at 25˚C/75% RH for two 
and four weeks are shown in Table 5.3. Table 5.3 also shows the ED, FPD, FPFED and 
MMAD. As can be seen in Figure 5.15 and Figure 5.16, the mean drug deposition per 
capsule of both combined formulations individually compared at week 0, week 2 and 
week 4. These data suggest that aerosolisation of the SAX FP/SX formulation resulted 
in greater drug deposition than the micronised FP/SX formulation.  
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Table 5.3 (continued on next page): NGI deposition per capsule of drug aerosolised from the formulations of micronised FP:SX and  
SAX-produced FP:SX with ratio 10:1 stored at 25˚C/75% RH from different periods of time (week 0, 2 and 4) 
FP = fluticasone propionate; SX = salmeterol xinafoate 
           
 
 
 
No. 
 
Formulations 
Mean Drug Deposition on Impactor Stages 
(µg ± SD) 
Mean ED 
(µg ± SD) 
Mean FPD 
(µg ± SD) 
Mean FPFED 
(% ± SD) 
MMAD 
(µm ±  GSD) 
D & C MP &T PS S1 S2 S3 S4 S5 S6 S7 MOC     
 
 
1 
 
Micronised FP at time 0 
24.97 
± 
2.58 
9.39 
± 
1.24 
273.29 
± 
3.49 
2.90 
± 
0.60 
4.58 
± 
0.26 
6.64 
± 
1.57 
9.52 
± 
0.63 
5.35 
± 
0.22 
2.01 
± 
0.16 
0.87 
± 
0.06 
0.45 
± 
0.06 
315.00 
± 
5.13 
24.83 
± 
1.76 
7.88 
± 
0.46 
2.50 
± 
2.40 
Micronised SX at time 0 
3.56 
± 
0.54 
1.11 
± 
0.03 
32.56 
± 
0.07 
0.41 
± 
0.09 
0.43 
± 
0.05 
0.58 
± 
0.10 
0.81 
± 
0.02 
0.48 
± 
0.08 
0.26 
± 
0.05 
0.19 
± 
0.03 
0.17 
± 
0.03 
36.99 
± 
0.25 
2.48 
± 
0.21 
6.70 
± 
0.53 
2.30 
± 
3.00 
 
 
2 
SAX-produced FP at time 0 
32.88 
± 
4.11 
19.02 
± 
2.98 
166.37 
± 
1.47 
6.99 
± 
1.29 
10.20 
± 
0.82 
9.05 
± 
0.30 
7.71 
± 
0.45 
4.04 
± 
0.02 
1.83 
± 
0.47 
0.96 
± 
0.17 
0.62 
± 
0.06 
226.78 
± 
3.09 
24.21 
± 
0.53 
10.68 
± 
0.32 
3.60 
± 
2.80 
SAX-produced SX at time 0 
3.35 
± 
0.37 
2.36 
± 
0.42 
18.25 
± 
2.19 
0.83 
± 
0.09 
1.17 
± 
0.19 
1.06 
± 
0.10 
0.93 
± 
0.11 
0.49 
± 
0.04 
0.25 
± 
0.05 
0.16 
± 
0.04 
0.16 
± 
0.04 
25.66 
± 
2.44 
3.05 
± 
0.14 
11.96 
± 
1.09 
3.30 
± 
3.10 
 
 
3 
Micronised FP  at week 2 
19.92 
± 
6.01 
6.40 
± 
1.10 
188.46 
± 
35.90 
2.31 
± 
0.17 
3.88 
± 
0.91 
5.51 
± 
0.86 
5.72 
± 
1.05 
2.17 
± 
0.48 
0.98 
± 
0.09 
0.48 
± 
0.10 
0.18 
± 
0.07 
216.08 
± 
39.48 
15.03 
± 
2.52 
6.98 
± 
0.36 
3.00 
± 
2.40 
Micronised SX at week 2 
1.59 
± 
0.22 
0.93 
± 
0.36 
28.19 
± 
5.30 
0.36 
± 
0.08 
0.34 
± 
0.05 
0.52 
± 
0.02 
0.70 
± 
0.11 
0.35 
± 
0.04 
0.25 
± 
0.05 
0.17 
± 
0.02 
0.14 
± 
0.01 
31.96 
± 
5.21 
2.14 
± 
0.09 
6.83 
± 
1.29 
2.30 
± 
3.10 
 
 
4 
SAX-produced FP at week 2 
45.35 
± 
2.14 
19.90 
± 
1.69 
195.92 
± 
7.02 
7.18 
± 
0.58 
15.83 
± 
1.69 
15.90 
± 
1.50 
11.62 
± 
1.11 
4.17 
± 
0.55 
0.98 
± 
0.19 
0.22 
± 
0.05 
0.07 
± 
0.01 
271.79 
± 
13.85 
32.95 
± 
3.09 
12.11 
± 
0.54 
3.90 
± 
2.10 
SAX-produced SX at week 2 
4.44 
± 
0.30 
1.89 
± 
0.09 
18.95 
± 
0.98 
0.73 
± 
0.06 
1.47 
± 
0.09 
1.40 
± 
0.08 
1.16 
± 
0.07 
0.49 
± 
0.04 
0.19 
± 
0.02 
0.15 
± 
0.03 
0.11 
± 
0.01 
26.54 
± 
1.32 
3.50 
± 
0.15 
13.19 
± 
0.12 
3.40 
± 
2.70 
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Table 5.3 (continued from previous page): NGI deposition per capsule of drug aerosolised from the formulations of micronised FP:SX and 
SAX-produced FP:SX with ratio 10:1 stored at 25˚C/75% RH from different periods of time (week 0, 2 and 4) 
FP = fluticasone propionate; SX = salmeterol xinafoate 
           
 
 
 
No. 
 
Formulations 
Mean Drug Deposition on Impactor Stages 
(µg ± SD) 
Mean ED 
(µg ± SD) 
Mean FPD 
(µg ± SD) 
Mean FPFED 
(% ± SD) 
MMAD 
(µm ±  GSD) 
D & C MP &T PS S1 S2 S3 S4 S5 S6 S7 MOC     
 
 
5 
 
Micronised FP at week 4 
27.94 
± 
4.59 
11.42 
± 
0.17 
303.89 
± 
6.29 
2.96 
± 
0.97 
5.27 
± 
1.93 
6.97 
± 
0.88 
6.60 
± 
0.32 
3.19 
± 
0.65 
1.30 
± 
0.35 
0.49 
± 
0.12 
0.28 
± 
0.16 
342.39 
± 
8.88 
18.84 
± 
2.36 
5.50 
± 
0.61 
3.00 
± 
2.40 
Micronised SX at week 4 
2.36 
± 
0.36 
1.41 
± 
0.11 
34.27 
± 
1.02 
0.30 
± 
0.04 
0.37 
± 
0.11 
0.52 
± 
0.11 
0.58 
± 
0.02 
0.30 
± 
0.06 
0.14 
± 
0.03 
0.10 
± 
0.01 
0.10 
± 
0.05 
38.09 
± 
0.81 
1.74 
± 
0.28 
4.57 
± 
0.79 
2.60 
± 
3.00 
 
 
6 
SAX-produced FP at week 4 
69.84 
± 
1.83 
20.19 
± 
0.64 
198.23 
± 
1.81 
7.09 
± 
0.36 
15.17 
± 
0.96 
15.44 
± 
1.21 
11.24 
± 
0.65 
2.25 
± 
0.10 
0.23 
± 
0.03 
0.02 
± 
0.01 
0.00 
± 
0.00 
269.87 
± 
4.23 
29.19 
± 
1.85 
10.81 
± 
0.56 
4.20 
± 
1.90 
SAX-produced SX at week 4 
8.30 
± 
0.31 
2.44 
± 
0.08 
21.35 
± 
0.60 
0.79 
± 
0.06 
1.60 
± 
0.13 
1.59 
± 
0.08 
1.24 
± 
0.08 
0.32 
± 
0.04 
0.20 
± 
0.18 
0.10 
± 
0.01 
0.12 
± 
0.07 
29.76 
± 
0.75 
3.57 
± 
0.31 
12.01 
± 
0.98 
3.60 
± 
2.80 
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Figure 5.15: NGI deposition per capsule of FP aerosolised from the combination 
formulations of micronised FP:SX (10:1) compared with SAX-produced FP:SX (10:1) at 
25˚C/75% RH from different periods of time (week 0, 2 and 4) 
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Figure 5.16: NGI deposition per capsule of SX aerosolised from the combination 
formulations of micronised FP:SX (10:1)compared with SAX-produced FP:SX (10:1) at 
25˚C/75% RH from different periods of time (week 0, 2 and 4) 
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Upon storage of the micronised FP/SX formulation at 25˚C and 75% RH for two weeks, 
the ED of FP decreased significantly (p<0.05) in comparison to the initial time point as 
shown by Figure 5.17. Following storage of the formulation for four weeks under the 
same conditions, the ED of FP increased significantly (p<0.05) in comparison to the 
initial time-point and two week storage at 25˚C and 75% RH. It is evident from Figure 
5.17 that storage of the formulation at two and four weeks at 25˚C and 75% RH did not 
significantly impact the ED of SX. 
 
In contrast, storage of the SAX FP/SX formulation at 25˚C and 75% RH for two weeks 
resulted in a significant (p<0.05) increase in the ED of FP, which did not change 
significantly following storage for four weeks under the same conditions. As observed 
with the micronised FP/SX formulation, the ED of SX was not affected by the storage 
conditions.   
 
  
 
 
 
 
 
 
 
 
 
 
Figure 5.17: The emitted dosed per capsule of micronised and SAX combination 
formulations stored at 25˚C 75% RH from different periods of time (week 0, 2 and 4) 
 
Upon storage at 25˚C and 75% RH for two weeks, the FPD of FP and SX upon 
aerosolisation of the SAX FP/SX formulation were 32.95 ± 3.09 µg for FP and 3.50 ± 
0.15 µg for SX, which were significantly (p<0.05) greater than the FPD of FP (15.03 ± 
2.52 µg) and SX (2.14 ± 0.09 µg) following aerosolisation of the micronised FP/SX 
formulation (Figure 5.18). Following storage at 25˚C and 75% RH for four weeks, the 
FPD of FP and SX following aerosolisation of the SAX FP/SX formulation were 29.19 ± 
1.85 µg for FP and 3.57 ± 0.31 µg for SX, which were significantly greater (p<0.05) 
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than the FPD of FP (18.84 ± 2.36 µg) and SX (1.74 ± 0.28 µg) following aerosolisation 
of the micronised FP/SX formulation as shown by Figure 5.18. 
 
Storage of the micronised FP/SX formulation for two weeks at 25˚C and 75% RH 
resulted in a significant (p<0.05) decrease in the FPD of FP in comparison to the initial 
time-point. Following storage of the formulation under the same conditions for four 
weeks resulted in a significant (p<0.05) decrease in the FPD of FP in comparison to 
the initial time-point, however, there were no significant differences in the FPD of FP 
following two and four week storage. These data suggest that the performance of FP 
following aerosolisation of the micronised FP/SX stored at 25˚C and 75% RH stabilised 
after two weeks. Figure 5.18 also shows that storage of the formulation at 25˚C and 
75% RH for two and four weeks resulted in a significant (p<0.05) decrease in the FPD 
of SX in comparison to the initial time-point. 
 
In contrast, storage of the SAX FP/SX formulation for two weeks at 25˚C and 75% RH 
resulted in a significant (p<0.05) increase in the FPD of FP in comparison to the initial 
time-point. No further change in the FPD of FP was observed after storage for four 
weeks at the same conditions as shown in Figure 5.18. Similarly, the FPD of SX 
increased significantly (p<0.05) after storage at 25˚C and 75% RH for two weeks, but 
did not change significantly after four week storage in comparison to the FPD of SX 
after two week storage. 
 
   
 
 
 
 
 
 
 
 
 
 
Figure 5.18: The fine particle dose per capsule of micronised and SAX combination 
formulations stored at 25˚C/75% RH from different periods of time (week 0, 2 and 4) 
 
Chapter 5: Engineering of Crystalline Combination Inhalation Particles of  
a Long-acting β2-agonist and Corticosteroid  160 
 
 
The %FPFED of FP and SX following aerosolisation of the micronised and SAX FP/SX 
formulation at the initial time-point and storage at 25˚C and 75% RH for two and four 
weeks are shown in Figure 5.19.  
 
Upon storage of the micronised FP/SX formulation at 25˚C and 75% RH for two weeks, 
the %FPFED of FP decreased significantly (p<0.05) in comparison to the initial time-
point. It is evident from Figure 5.19 that the %FPFED of FP also decreased significantly 
(p<0.05) following storage for four weeks in comparison to the initial time-point and two 
week storage under the same conditions. In contrast, the %FPFED of SX did not change 
significantly after two week storage at 25˚C and 75% RH, however, Figure 5.19 shows 
that the %FPFED of SX did decrease significantly (p<0.05) after four week storage at  
25˚C and 75% RH in comparison to the initial time-point.  
 
Storage of the SAX FP/SX formulation at 25˚C and 75% RH for two weeks resulted in a 
significant (p<0.05) increase in the %FPFED of FP in comparison to the initial time-point, 
however, this was not observed upon storage for four weeks under the same 
conditions. In addition, Figure 5.19 shows no significant change in the % FPFED  of SX 
in comparison to the initial time-point following storage of the SAX FP/SX formulation 
for two and four weeks at 25˚C and 75% RH. 
 
 
   
 
 
 
 
 
 
 
 
 
Figure 5.19: The fine particle fraction of emitted dose (FPFED) per capsule of 
micronised and SAX combination formulations stored at 25˚C/75% RH from different 
periods of time (week 0, 2 and 4) 
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The mean normalised mass ratios of FP:SX deposited on stages 2 and 5 of the NGI 
following aerosolisation of the micronised and SAX formulations at initial time-point and 
following storage at 25˚C/75% RH for two and four weeks are shown in Figure 5.20. 
The mean normalised mass ratio of FP:SX deposited on stages 2 to 5 following 
aerosolisation of the micronised FP/SX formulation at the initial time-point was greater 
than one across all stages. These data suggest that the deposition of FP and SX was 
variable and delivered inconsistently across stages 2 to 5. However, the mean 
normalised mass ratio of FP:SX deposited on stages 2 and 5 following aerosolisation of 
the SAX formulation was consistently around one. This implies that FP and SX can be 
affectively delivered through the lower stages of NGI at constant ratio when delivered 
using combined SAX FP/SX particles. Furthermore, the crystallinity of the SAX FP/SX 
material suggests that both performance and delivery are not affected by extreme 
storage conditions. As can be seen in Figure 5.20, the ratio of FP:SX from SAX FP/SX 
formulation at 25˚C/75% RH at week two and four maintained the same pattern with 
the initial time-point, whereas the micronised formulation showed deviations in the 
mass ratio of FP/SX on stages 2 to 5.  
 
These data suggest that upon storage of micronised formulation, the delivery of FP and 
SX is highly variable which can lead to extreme under and overdosing of either active. 
The implications of this would mean the reduced efficacy of the drug product. In 
contrast, the SAX FP/SX preparation delivered both agents together to the lower 
stages of the NGI. Furthermore, the delivery of both actives as combined SAX particles 
was not influenced by storage conditions. 
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Figure 5.20: Ratios of FP:SX from mean normalised data of stages 2 to 5 of micronised 
FP:SX (10:1) compared with SAX-produced FP:SX (10:1) stored at 25˚C/75% RH from 
different periods of time (week 0, 2 and 4) 
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5.5.1.5 Study III: In-vitro Performance of FP/SX at 40˚C/75% RH 
 
The mean mass data of drug deposited per capsule on each stage of the NGI for both 
micronised FP/SX and SAX FP/SX formulations are shown in Table 5.4. These two 
formulations were investigated again after storage at 40˚C/75% RH for two and four 
weeks in order to follow the stability profile of the materials. Table 5.4 also shows the 
ED, FPD, FPFED and MMAD. As can be seen in Figure 5.21 and Figure 5.22, the mean 
drug deposition per capsule of both combined formulations individually compared in bar 
charts of the week 0, week 2 and week 4. The SAX FP/SX formulation had higher drug 
deposition than the micronised FP/SX formulation.  
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Table 5.4 (continued on next page): NGI deposition per capsule of drug aerosolised from the formulations of micronised FP:SX and 
SAX-produced FP:SX with ratio 10:1 stored at 40˚C/75% RH from different periods of time (week 0, 2 and 4) 
FP = fluticasone propionate; SX = salmeterol xinafoate 
          
 
 
 
No. 
 
Formulations 
Mean Drug Deposition on Impactor Stages 
(µg ± SD) 
Mean ED 
(µg ± SD) 
Mean FPD 
(µg ± SD) 
Mean FPFED 
(% ± SD) 
MMAD 
(µm ±  GSD) 
D & C MP &T PS S1 S2 S3 S4 S5 S6 S7 MOC     
 
 
1 
 
Micronised FP at time 0 
24.97 
± 
2.58 
9.39 
± 
1.24 
273.29 
± 
3.49 
2.90 
± 
0.60 
4.58 
± 
0.26 
6.64 
± 
1.57 
9.52 
± 
0.63 
5.35 
± 
0.22 
2.01 
± 
0.16 
0.87 
± 
0.06 
0.45 
± 
0.06 
315.00 
± 
5.13 
24.83 
± 
1.76 
7.88 
± 
0.46 
2.50 
± 
2.40 
Micronised SX at time 0 
3.56 
± 
0.54 
1.11 
± 
0.03 
32.56 
± 
0.07 
0.41 
± 
0.09 
0.43 
± 
0.05 
0.58 
± 
0.10 
0.81 
± 
0.02 
0.48 
± 
0.08 
0.26 
± 
0.05 
0.19 
± 
0.03 
0.17 
± 
0.03 
36.99 
± 
0.25 
2.48 
± 
0.21 
6.70 
± 
0.53 
2.30 
± 
3.00 
 
 
2 
SAX-produced FP at time 0 
32.88 
± 
4.11 
19.02 
± 
2.98 
166.37 
± 
1.47 
6.99 
± 
1.29 
10.20 
± 
0.82 
9.05 
± 
0.30 
7.71 
± 
0.45 
4.04 
± 
0.02 
1.83 
± 
0.47 
0.96 
± 
0.17 
0.62 
± 
0.06 
226.78 
± 
3.09 
24.21 
± 
0.53 
10.68 
± 
0.32 
3.60 
± 
2.80 
SAX-produced SX at time 0 
3.35 
± 
0.37 
2.36 
± 
0.42 
18.25 
± 
2.19 
0.83 
± 
0.09 
1.17 
± 
0.19 
1.06 
± 
0.10 
0.93 
± 
0.11 
0.49 
± 
0.04 
0.25 
± 
0.05 
0.16 
± 
0.04 
0.16 
± 
0.04 
25.66 
± 
2.44 
3.05 
± 
0.14 
11.96 
± 
1.09 
3.30 
± 
3.10 
 
 
3 
Micronised FP  at week 2 
21.80 
± 
1.07 
10.67 
± 
0.54 
315.80 
± 
16.91 
3.94 
± 
0.80 
5.10 
± 
0.50 
6.57 
± 
0.59 
6.57 
± 
0.94 
3.19 
± 
0.46 
1.41 
± 
0.06 
0.58 
± 
0.14 
0.25 
± 
0.13 
354.06 
± 
18.15 
18.56 
± 
1.18 
5.25 
± 
0.32 
3.20 
± 
2.50 
Micronised SX at week 2 
3.23 
± 
1.11 
1.20 
± 
0.04 
32.87 
± 
1.95 
0.42 
± 
0.12 
0.44 
± 
0.04 
0.61 
± 
0.08 
0.68 
± 
0.05 
0.35 
± 
0.05 
0.23 
± 
0.05 
0.12 
± 
0.03 
0.12 
± 
0.04 
37.05 
± 
2.03 
2.11 
± 
0.19 
5.70 
± 
0.64 
2.70 
± 
3.00 
 
 
4 
SAX-produced FP at week 2 
35.63 
± 
3.83 
19.55 
± 
1.08 
202.60 
± 
4.48 
7.50 
± 
0.44 
15.27 
± 
1.12 
13.54 
± 
0.94 
9.96 
± 
0.81 
3.13 
± 
0.20 
0.61 
± 
0.08 
0.13 
± 
0.03 
0.03 
± 
0.01 
272.34 
± 
7.30 
27.41 
± 
1.68 
10.06 
± 
0.42 
4.20 
± 
2.10 
SAX-produced SX at week 2 
4.45 
± 
0.48 
2.45 
± 
0.04 
22.19 
± 
1.24 
0.92 
± 
0.07 
1.74 
± 
0.12 
1.55 
± 
0.09 
1.20 
± 
0.07 
0.49 
± 
0.07 
0.21 
± 
0.03 
0.17 
± 
0.02 
0.12 
± 
0.03 
31.03 
± 
1.44 
3.73 
± 
0.17 
12.04 
± 
0.48 
3.60 
± 
2.80 
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Table 5.4 (continued from previous page): NGI deposition per capsule of drug aerosolised from the formulations of micronised FP:SX and  
SAX-produced FP:SX with ratio 10:1 stored at 40˚C/75% RH from different periods of time (week 0, 2 and 4) 
FP = fluticasone propionate; SX = salmeterol xinafoate 
 
 
 
No. 
 
Formulations 
Mean Drug Deposition on Impactor Stages 
(µg ± SD) 
Mean ED 
(µg ± SD) 
Mean FPD 
(µg ± SD) 
Mean FPFED 
(% ± SD) 
MMAD 
(µm ±  GSD) 
D & C MP &T PS S1 S2 S3 S4 S5 S6 S7 MOC     
 
 
5 
 
Micronised FP at week 4 
28.13 
± 
4.21 
12.29 
± 
1.28 
330.84 
± 
8.12 
3.21 
± 
0.16 
4.90 
± 
0.27 
6.47 
± 
0.20 
6.32 
± 
1.05 
3.11 
± 
0.14 
1.18 
± 
0.10 
0.44 
± 
0.07 
0.14 
± 
0.00 
368.90 
± 
9.11 
17.66 
± 
0.83 
4.79 
± 
0.17 
3.10 
± 
2.30 
Micronised SX at week 4 
2.53 
± 
0.74 
1.17 
± 
0.11 
33.51 
± 
0.44 
0.32 
± 
0.02 
0.35 
± 
0.02 
0.55 
± 
0.03 
0.60 
± 
0.04 
0.32 
± 
0.02 
0.16 
± 
0.03 
0.13 
± 
0.05 
0.11 
± 
0.02 
37.20 
± 
0.24 
1.85 
± 
0.14 
4.98 
± 
0.40 
2.50 
± 
3.00 
 
 
6 
SAX-produced FP at week 4 
56.22 
± 
1.52 
20.82 
± 
1.43 
209.02 
± 
4.04 
7.51 
± 
0.22 
15.44 
± 
0.68 
14.37 
± 
0.92 
9.45 
± 
0.50 
1.67 
± 
0.09 
0.15 
± 
0.01 
0.02 
± 
0.01 
0.00 
± 
0.00 
278.46 
± 
6.66 
25.67 
± 
1.46 
9.22 
± 
0.43 
4.50 
± 
1.90 
SAX-produced SX at week 4 
7.77 
± 
1.10 
2.57 
± 
0.10 
24.46 
± 
0.39 
0.85 
± 
0.02 
1.71 
± 
0.08 
1.63 
± 
0.09 
1.15 
± 
0.06 
0.23 
± 
0.02 
0.03 
± 
0.01 
0.04 
± 
0.02 
0.06 
± 
0.01 
32.72 
± 
0.62 
3.12 
± 
0.19 
9.54 
± 
0.39 
4.40 
± 
2.50 
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Figure 5.21: NGI deposition per capsule of FP aerosolised from the combination 
formulations of micronised FP:SX (10:1) compared with SAX-produced FP:SX (10:1) at 
40˚C/75% RH from different periods of time (week 0, 2 and 4) 
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Figure 5.22: NGI deposition per capsule of SX aerosolised from the combination 
formulations of micronised FP:SX (10:1) compared with SAX-produced FP:SX (10:1) at 
40˚C/75% RH from different periods of time (week 0, 2 and 4) 
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Storage of the micronised FP/SX formulation at 40˚C and 75% RH for two and four 
weeks demonstrated in a significant (p<0.05) increase in the ED of FP in comparison to 
the initial time-point as shown in Figure 5.23. In contrast, this figure revealed no 
significant difference in the ED of SX upon storage of the micronised FP/SX formulation 
at 40˚C and 75% RH for two and four weeks. Storage of the SAX FP/SX formulation at 
40˚C and 75% RH for two and four weeks resulted in a significant (p<0.05) increase in 
the ED of FP and SX in comparison to the initial time-point (see Figure 5.23).  
 
 
   
 
 
 
 
 
 
 
 
 
 
Figure 5.23: The emitted dosed per capsule of micronised and SAX combination 
formulations stored at 40˚C/75% RH from different periods of time (week 0, 2 and 4) 
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The fine particle dose (FPD) of FP and SX after storage of the micronised and SAX 
FP/SX formulations at 40˚C and 75% RH for two and four weeks are shown in Figure 
5.24. Storage of the micronised FP/SX formulation for two and four weeks at 40˚C and 
75% RH resulted in a significant (p<0.05) decrease in FPD of FP and SX in 
comparison to the initial time-point. However, Figure 5.24 suggests that this decrease 
was not observed between two and four week storage. In contrast, storage of the SAX 
FP/SX resulted in a significant (p<0.05) increase in the FPD of FP and SX after two 
week storage at 40˚C and 75% RH in comparison to the initial time-point. However, no 
significant differences in FPD of FP and SX were observed upon four week storage in 
comparison to the initial time-point.    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.24: The fine particle dose per capsule of micronised and SAX combination 
formulations stored at 40˚C/75% RH from different periods of time (week 0, 2 and 4) 
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The %FPFED of FP and SX following aerosolisation of the micronised and SAX FP/SX 
formulations at the initial time-point and storage at 40˚C and 75% RH for two and four 
weeks are shown in Figure 5.25.  
 
Storage of the micronised FP/SX formulation at 40˚C and 75% RH for two and four 
weeks resulted in a significant (p<0.05) decrease in the %FPFED of FP in comparison to 
the initial time-point. In contrast, there was no significant difference in the %FPFED of 
SX following two week storage, however, upon four week storage the %FPFED 
decreased significantly (p<0.05) in comparison to the initial time-point. 
 
Upon storage of the SAX FP/SX formulation at 40˚C and 75% RH for two weeks 
the %FPFED of FP and SX did not change significantly in comparison to the initial time-
point. However, four week storage of the formulation resulted in a significant decrease 
in the %FPFED of FP and SX in comparison to the initial time-point.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.25: The fine particle fraction of emitted dose (FPFED) per capsule of 
micronised and SAX combination formulations stored at 40˚C/75% RH from different 
periods of time (week 0, 2 and 4) 
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The mean normalised mass ratios of FP:SX deposited on stages 2 and 5 of the NGI 
following aerosolisation of the micronised and SAX formulations at initial time-point and 
following storage at 40˚C/75% RH for two and four weeks are shown in Figure 5.26. 
The ratio of FP:SX upon aerosolisation of the SAX FP/SX formulation at 40˚C/75% RH 
at week two tended to consistently remain close to unity, which represents that both FP 
and SX were delivered to stages 2–5 in the ration of 10:1. Furthermore, these trends in 
the deposition of both actives on aerosolisation of the SAX FP/SX did not change as a 
function of formulation storage in comparison to the initial time-point. The deposition of 
both actives did change upon storage of the micronised FP/SX formulation. As shown 
in Figure 5.26, at the initial time-point the FP:SX ratio of the micronised formulation 
remained above unity. However, storage for two and four weeks at 40˚C/75% RH 
resulted in the FP:SX ratio decreasing towards unity. Such trends were not observed 
for the SAX FP/SX formulation. The deposition trends of FP and SX following 
aerosolisation of the micronised FP/SX formulation after storage suggest that product 
storage conditions may alter the delivery of the actives resulting in significant over and 
under dosing of the LABA or ICS.    
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Figure 5.26: Ratios of FP:SX from mean normalised data of stages 2 to 5 of micronised 
FP:SX (10:1)compared with SAX-produced FP:SX (10:1) stored at 40˚C/75% RH 
 from different periods of time (week 0, 2 and 4) 
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5.5.2 Discussion 
 
Many studies have reported that co-administration of an ICS and LABA can interact 
synergistically to improve clinical outcomes in asthma and COPD control (Barnes, 2002; 
Nelson, Chapman et al., 2003; Theophilus, Moore et al., 2006). Current, combined 
inhalation dosage forms are unable to consistently deliver both actives in the required 
concentrations at the receptor, molecular and cellular level to enhance this synergistic 
action. Furthermore, these inconsistencies are likely to perpetuate as function of 
storage. These variations are likely to be associated with the use of mechanical 
blending processes to make current combined products. The SAX process may provide 
a means of engineering particles where both actives are incorporated into individual 
crystalline particles, which may then enhance co-deposition in the airways.  
 
In this way, combined FP/SX particles were fabricated using the SAX process. The 
combined SAX particles exhibited a defined corrugated morphology. This may have 
resulted in the significantly (p<0.05) higher FPFED of FP and SX than the micronised 
FP/SX formulation owing to smaller contact area of the material, which would minimise 
particle adhesion to lactose. Both DSC and XRPD also showed that the SAX FP/SX 
particles were crystalline. The crystalline nature of these particles may also explain the 
better stability profile of the material as measured by in-vitro inhalation performance 
testing as function of storage. These data suggest that the aerosolisation efficiency of 
the SAX FP/SX particles is not compromised upon storage, whereas the micronised 
FP/SX formulation resulted in significant decrease in the delivery of both actives. This 
may be related to the presence of micronisation-induced surface structural disorder of 
the micronised particles, which relax over-time. The consequence of this relaxation is 
that the surface interfacial properties of the materials will change within the formulation, 
which will result in unstable product performance.  
 
The surface interfacial properties of micronised FP and SX will be different with respect 
to each other and lactose, therefore, the delivery of both actives will be highly variable 
and independent of each other as shown in this study. The deposition of FP and SX on 
stages 2–5 following aerosolisation of the micronised FP/SX resulted in inconsistent 
delivery of the actives, which may impact clinical efficacy of the drug product. 
Furthermore, the probability of co-delivery of both actives in the required 
concentrations at the molecular, cellular and receptor level will be limited, which may 
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compromise any potential synergistic action of the molecules. In contrast, upon co-
processing of both actives into one geometric particle, the delivery of both actives was 
consistent and in the desired concentrations. The deposition profile of both actives on 
stages 2 – 5 of the NGI was not affected upon storage, however, there were significant 
under and over dosing of either active following storage of the micronised FP/SX 
formulation. These data suggest that the engineering of combined particles of FP and 
SX using SAX may enable the co-delivery of both molecules at the receptor, molecular 
and cellular level, which may enhance clinical efficacy as a result of enhanced 
synergistic action of the materials. 
 
5.6 Conclusions 
 
These data suggest that combination SAX particles of FP:SX engineered by SAX can 
be produced and successfully delivered through the lower stages of NGI. Under the 
different storage conditions, FPFED data of FP and SX upon aerosolisation of all SAX 
FP/SX formulations were significantly higher than FPFED of FP and SX from the 
micronised FP/SX formulations. The increased performance of the SAX material in 
comparison to the micronised material may be attributed to the corrugated morphology 
of the SAX particles, which may have resulted in reduced drug particle-carrier adhesion, 
thereby increasing drug liberation. Furthermore, SAX FP/SX formulations maintained a 
constant ratio of FP and SX delivery, which was maintained following storage. In 
contrast, aerosolisation of the micronised FP/SX formulations did not show the 
consistency in the delivery of both actives to stages 2 to 5. The decreased performance 
of the micronised material may be attributed to relaxation of process-induced surface 
disorder present on particles, which may have affected their surface interfacial 
interactions and therefore product performance. As the SAX particles may be devoid of 
such process-induced surface disorder, the performance of the material is not affected 
in the same way as micronised material upon storage. This approach presents itself as 
a novel means to produce inhaled combination dosage forms which may lead to offer 
the potential for enhanced clinical efficacy for synergistic interaction. 
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Chapter 6: Pharmaceutical Engineering of a Low-Dose drug in 
Combination with a High-Dose Corticosteroid 
 
6.1 Introduction 
 
Delivery of multiple actives in combined inhaled drug delivery systems has been 
successful in the management of asthma (Barnes, 2002). The recommended strategy 
for the control of asthma is combined inhalation therapy with inhaled corticosteroids 
(ICS) and long-acting β2-agonists (LABA). It has been demonstrated that addition of a 
long-acting β2-agonist (LABA) to an inhaled corticosteroid (ICS) is superior to ICS alone 
in achieving asthma control (Matz, Emmett et al., 2001).  
 
The benefit of paediatric asthma control from treatment with fixed-dose combination 
inhalation therapy with ICS and LABA are limited (Bisgaard, Le Roux et al., 2006). This 
may partly be because paediatric asthma is often an episodic disease with a particular 
strong seasonality, which is associated with few symptoms and near-normal lung 
function for long periods, with intermittent increase in symptoms and exacerbations 
(Pauwels, Sears et al., 2003). Traditional fixed-dosing strategies decided on the basis 
of patient history inevitably lag behind disease activity, and carry a risk of over-
treatment or under-treatment (Bisgaard, Le Roux et al., 2006). Recently, the global 
initiative for asthma have endorsed the use of Symbicort™ for both maintenance and 
relief therapy (SMART®) in asthma (Masoli, Fabian et al., 2004). The SMART approach 
to asthma management challenges the traditional fixed-dosing of ICS/LABA for 
moderate-to-severe persistent asthma in paediatrics, instead emphasising intermittent 
use in addition to the regular low-dose use titrating the steroid dose dynamically to the 
disease activity (Bisgaard, Le Roux et al., 2006). Furthermore, the SMART approach 
requires the patient to only use one inhaler to control and treat their asthma symptoms 
without requirement for a separate short-acting rescue inhaler (Bisgaard, Le Roux et al., 
2006). In a study examining over 2,700 asthma patients, the SMART approach was 
found to substantially reduce the incidence of exacerbations and repeat exacerbations, 
improve lung function, and reduce symptoms to a greater extent than a four-fold higher 
dose of ICS alone (O'Byrne, Bisgaard et al., 2005). 
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Symbicort contains budesonide (ICS) and formoterol (LABA), and is usually available in 
two strengths for maintenance and reliever therapy (100µg/6µg and 200µg/6µg), which 
are typically delivered using a dry powder inhaler (DPI). The preparation of combination 
DPI formulations containing low concentrations of actives can pose significant 
challenges during product development. Current combination therapies are commonly 
prepared by blending both the micronised LABA and ICS together with coarse lactose. 
These preparations are then loaded into a DPI device and actuated by the patient to 
receive both medicaments. However, there is very little control to ensure that both 
drugs are delivered together and in adequate concentrations. Furthermore, there is a 
greater likelihood of variations in dose delivery of the actives as a function of product 
storage conditions. Hence, there is a requirement of processes that may enable 
production of low-dose combination inhaled products that will allow both drugs to be 
delivered more effectively and independently of dose variations.  
 
In the previous chapter, combined FP/SX particles were successfully fabricated using 
the SAX process. The aim of the present study was to employ the solution atomisation 
and crystallisation with sonication (SAX) process to generate individual particles that 
consisted of both the ICS (budesonide) and LABA (formoterol). The aerosolisation 
efficiency of these novel particles was also assessed. 
 
6.2 Materials  
 
Micronised Budesonide (Bud) and formoterol fumarate dihydrate (FFD) were obtained 
from sources stated in Chapter 2. All other materials used in this chapter are listed 
Chapters 2 and 5. 
 
6.3 Methods 
 
6.3.1 The Production of SAX-produced Bud-FFD Particles 
 
SAX-produced Bud-FFD particles were prepared upon atomisation of a 1.5% w/v of 
solution of Bud:FFD in the ratio 36:1 prepared in a co-solvent mixture of methanol and 
dichloromethane (1:12). The solution was sprayed through a SU11 atomiser at a 
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sprayed rate of 4 ml.min-1 with air pressure at 2.5 bar of the atomiser in the lab scale of 
SAX process over 60 cm of separation distance including positive pressure 30 Lmin-1 in 
the system with an ultrasonic probe. The resulting particles were then collected in 
hexane at 5˚C, which were then isolated using supercritical CO2 extraction as 
described in Chapter 3. 
 
6.3.2 Formulation Blending  
 
A formulation, containing 1.6% w/w combined SAX Bud/FFD particles, was prepared 
by geometric blending with 63-90 µm sieve fractions of surface-etched lactose. In order 
to compare the in-vitro inhalation performance of SAX Bud/FFD and micronised 
Bud/FFD, a further carrier-based combination formulation containing 1.56% w/w 
micronised Bud and 0.04% w/w micronised FFD was prepared by geometric blending 
with 63-90 µm sieve fractions of surface-etched lactose. The resultant blend was 
further mixed using a Turbula shaker-mixer (Willy A Bachofen AG, Basel, Switzerland) 
at 46 rpm for 45 minutes.   
 
6.3.3 Content Uniformity Determination 
 
The content uniformity of the formulations was assessed following blending. The blend 
was spread over a clean surface and ten samples of 25 ± 1 mg were taken from 
random positions. The mobile phase in this study was prepared from 60% acetonitrile, 
40% of 5 mM Sodium dihydrogen orthophosphate (set to pH 3) and filtered under 
vacuum through a 0.45 µm membrane. The mobile phase was then sonicated in 
ultrasonic bath for 15 minutes. Each sample was dissolved with 15 minutes sonication 
in mobile phase to 100 ml final volume and drug concentration assessed by high 
performance liquid chromatography (HPLC). The proportion of drug in each sample 
was calculated and the content uniformity expressed as the coefficient of variation 
(Equation 4.1) 
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6.3.4 Capsule Filling 
 
Each formulation was manually loaded into size 3 HPMC capsules (Qualicaps, Madrid, 
Spain). Fill weight was 25 ± 1 mg, giving a nominal dose of 389 ± 20 µg for Bud and  
11 ± 1 µg for FFD per capsule. In order to investigate the influence of storage on the 
performance of micronised and SAX Bud/FFD preparation, formulations were stored at 
different conditions. In study I, filled capsules of both micronised and SAX Bud/FFD 
formulations were stored in sealed chambers containing a saturated solution of sodium 
chloride (giving a relative humidity of 75%) at 25˚C, and re-tested at two weeks and 
four weeks later. In study II, the filled capsules were also stored in a sealed chamber 
containing a saturated solution of sodium chloride (also giving a relative humidity of 
75%) at 40˚C and re-tested at 2 weeks and four weeks later. In order to investigate the 
performance of micronised and SAX Bud/FFD preparation, all formulations were tested 
by using NGI.  
 
In-vitro formulation performance of the micronised and SAX Bud/FFD preparations 
were assessed using a Next Generation Impactor (NGI) using the method described in 
Chapter 5. The device/capsules, mouthpiece/throat, pre-separator and each stage of 
the NGI were washed down into separate known volumes of 60% acetonitrile, 40% 
water, which were sonicated to aid dissolution and allowed to cool. The concentration 
of drug in each solution was investigated by HPLC, from which the mass of drug 
deposited on each stage of the NGI could be determined from stages 1 to 7 and on the 
micro-orifice collector (MOC).  
 
6.3.5 High Performance Liquid Chromatography (HPLC) 
 
Drug concentrations were determined by HPLC. The mobile phase consisted of 60% 
acetonitrile, 40% of 5 mM Sodium dihydrogen orthophosphate (set to pH 3). The flow 
rate was 1.5 ml.min-1, column temperature was 30˚C and injection volume 200 µl. Drug 
retention times were 3.2 minutes for Bud and 9.8 minutes for FFD, therefore, the total 
analysis run time was 12 minutes. The UV detection wavelength used to detect both 
Bud and FFD was 214 nm. The drug concentrations of Bud and FFD and peak area for 
each drug were found to be linear, with linear regression analysis yielding a coefficient 
of determination (R2) of 1 and 0.9999, respectively (see Figure 6.1). 
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Figure 6.1: HPLC calibration curve for Bud and FFD 
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6.4 Characterisation of SAX-produced Bud-FFD Particles 
 
6.4.1 Results and Discussion 
 
6.4.1.1 Scanning Electron Microscopy 
 
Representative scanning electron micrographs of micronised Bud, micronised FFD and 
SAX-produced Bud/FFD particles are shown in Figure 6.2. Both micronised Bud and 
FFD particles were irregular in shape and exhibited particles of different shapes and 
sizes, which were extensively agglomerated. These features are a result of the 
destructive micronisation process, which does not allow adequate control of particle 
shape and morphology. In contrast, the combined SAX Bud/FFD particles appeared 
more uniform in shape and morphology. Furthermore, these micrographs suggest that 
both Bud and FFD may have been successfully processed into individual particles. This 
is to be expected as the SAX operation utilises a droplet-to-particle approach to 
fabricate crystalline particles.  
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Figure 6.2: Representative SEMs of micronised Bud, micronised FFD and               
SAX-produced Bud-FFD particles at magnifications of x3000 and x7000 
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6.4.1.2 Particle Size Analysis 
 
The cumulative particle size distribution of micronised Bud, micronised FFD and SAX-
produced Bud/FFD is shown in Figure 6.3. The particle size distribution of SAX-
produced Bud/FFD suggests that particles of the material were larger than micronised 
Bud and FFD. Table 6.1 shows that d50 values of micronised Bud, FFD and SAX-
produced Bud/FFD are 2.21, 2.42 and 4.17 µm, respectively. It can be suggested from 
the results of d50 values that the micronised drug particles and SAX-produced Bud/FFD 
particles were suitable for pulmonary drug delivery.  
 
                            
                     
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.3: Particle size distribution of micronised Bud, micronised FFD and  
SAX-produced Bud-FFD particles 
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Table 6.1: Summary of particle size data of micronised Bud, micronised FFD and  
SAX-produced Bud-FFD particles 
 
 d10% (µm) ± SD d50% (µm) ± SD d90% (µm) ± SD
Micronised Bud 0.95 ± 0.00 2.21 ± 0.01 4.06 ± 0.00 
Micronised FFD 1.07 ± 0.00 2.42 ± 0.00 4.36 ± 0.01 
SAX-produced Bud-FFD 1.23 ± 0.01 4.17 ± 0.04 8.66 ± 0.05 
 
 
6.4.1.3 Differential Scanning Calorimetry 
 
The DSC thermograms of micronised Bud and FFD are shown in Figure 6.4. The DSC 
thermogram of micronised Bud exhibited an endothermic response at ~261°C, which is 
typical of the melt with decomposition seen for crystalline budesonide (Jones, Young et 
al., 2008). The thermogram relating to micronised FFD is more complicated, with three 
endothermic peaks at ~113°C, ~129°C and ~144°C. It is understood that FFD may be 
thermally dehydrated. Formoterol anhydrous polymorph A melts at the range 125-
129°C (Jarring, Larsson et al. 2006) and formoterol anhydrous polymorph B melts at 
the range 143-148°C. Therefore, the first endothermic peak represents dehydration 
and the second peak at ~129°C shows the melting of anhydrous polymorph A. The 
third peak is the melting of anhydrous of polymorph B.  
 
The DSC thermogram of SAX-produced Bud/FFD exhibited a single endothermic at 
~261°C, as shown in Figure 6.5. This peak only confers to the presence of budesonide 
and not formoterol. However, owing to the significantly lower concentration of 
formoterol in the SAX combined particles, the presence of the material may not be 
detectable by DSC.  
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Figure 6.4: DSC thermograms of micronised Bud, micronised FFD particles 
 
 
 
 
 
 
    
 
 
 
 
 
 
 
 
 
Figure 6.5: DSC thermograms of SAX-produced Bud-FFD particles 
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6.4.1.4 X-ray Powder Diffraction 
 
To confirm the crystallinity of particles, XRPD analysis of micronised Bud, micronised 
FFD and SAX-Bud/FFD was conducted. The XRPD patterns in Figure 6.6 show sharp 
diffraction peaks associated with crystalline materials of micronised Bud, micronised 
FFD and SAX-produced Bud/FFD. The diffractograms suggest that the XRPD of SAX-
produced Bud/FFD had similar peak and patterns to micronised Bud. Again, owing to 
the lower concentration of FFD in the combined SAX particles, it was not possible to 
detect the presence of FFD.  
 
 
 
                              
 
 
 
 
 
 
 
 
 
 
Figure 6.6: XRPD spectra of micronised Bud, micronised FFD and                          
SAX-produced Bud-FFD particles 
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6.4.1.5 Dynamic Vapour Sorption 
 
The DVS isotherms of micronised Bud, micronised FFD and SAX-produced Bud/FFD 
particles are shown in Figure 6.7. As shown in this figure, the DVS moisture sorption 
isotherms of micronised FFD showed a sharp loss in mass during the first sorption 
cycle upon exposure to 60% RH, which suggested that the materials contained 
undetectable amorphous material form. The small hysteresis in the 2 cycles for 
micronised Bud and SAX produced Bud/FFD suggests that these materials are 
crystalline in nature. As shown in the DVS trace for SAX FP/SX in Chapter 5, Figure 
5.7, the increase in %mass uptake for the SAX materials appears to be related to an 
increase in surface area for moisture adsorption.  
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Figure 6.7: DVS isotherms of micronised Bud, micronised FFD and  
SAX-produced Bud-FFD  
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6.5 Formulation Performance of Micronised and SAX Bud/FFD 
Combination DPI Formulations 
 
6.5.1 Results  
 
6.5.1.1 SEMs of the Bud-FFD Formulations 
 
Representative SEMs of (A) etched lactohale, (B) the formulation of micronised 
physical mixture of Bud/FFD, and (C) the formulation of SAX-produced Bud/FFD with 
etched lactohale are shown in Figure 6.8. The etched lactose, from the method of 
temperature-controlled dissolution as described in Chapter 2, exhibited less intrinsic 
fine particles of lactose. However, after preparing the formulations, the formulations 
from micronised physical mixture of Bud/FFD and, also, SAX-produced Bud/FFD 
presented the small drug particles deposited on the surface of the etched lactohale.  
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Figure 6.8: Representative SEMs of (A) etched lactohale, (B) the formulation of 
micronised physical mixture of Bud-FFD, and (C) the formulation of SAX-produced 
Bud-FFD at magnifications of x900 and x2500 
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6.5.1.2 Content Uniformity of Bud-FFD Formulations 
 
The coefficient of variation (CV ) of the drug content of the two formulations containing 
either micronised budesonide and formoterol or combined SAX particles of Bud/FFD  
was <6%, which is the upper limit of what is commonly acceptable as uniformity for a 
carrier-based DPI formulation. These results demonstrated that both formulations were 
uniformly blended. 
 
6.5.1.3 Study I: In-vitro Formulation Performance of Combination Formulations of 
Bud/FFD following Storage at 25˚C/75% RH 
  
The in-vitro inhalation performance of combination based DPI formulations comprising 
of micronised Bud and FFD and combined SAX particles of Bud/FFD was investigated 
using a Cyclohaler with a next generation impactor (NGI). In addition, the performance 
of both formulations was assessed following storage of the materials for 2 and 4 weeks 
at 25˚C/75% RH. The mean mass data of drug deposited per capsule on each stage of 
the NGI for both micronised Bud/FFD and SAX Bud/FFD formulations are shown in 
Table 6.2 along with the ED, FPD, FPFED and MMAD. Stage-by-stage deposition of 
both formulations before and after 2 and 4 week storage is shown in Figure 6.9 and 
6.10, respectively. These data suggest that, upon aerosolisation for the SAX Bud/FFD 
formulation, more budesonide and formoterol were delivered to the lower stages of the 
impactor than the formulation containing micronised budesonide and formoterol.  
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Table 6.2 (continued on next page): NGI deposition per capsule of drug aerosolised from the formulations of  micronised Bud:FFD and 
SAX-produced Bud:FFD with ratio 36:1 stored at 25˚C/75% RH in different periods of time (week 0, 2 and 4) 
Bud = budesonide; FFD = formoterol fumarate dihydrate 
 
  
 
 
 
 
Formulations 
Mean Drug Deposition on Impactor Stages 
(µg ± SD) 
Mean ED 
(µg ± SD) 
Mean FPD 
(µg ± SD) 
Mean 
FPFED 
(% ± SD) 
MMAD 
(µm ± GSD) 
 D & C MP &T PS S1 S2 S3 S4 S5 S6 S7 MOC     
Micronised Bud at week 0 
49.39 
± 
10.84 
12.38 
± 
2.01 
245.91 
± 
6.31 
4.79 
± 
0.59 
11.98 
± 
0.55 
16.09 
± 
0.62 
16.10 
± 
2.71 
8.34 
± 
0.41 
3.40 
± 
0.28 
2.31 
± 
0.42 
1.37 
± 
0.23 
322.69 
± 
9.34 
47.62 
± 
2.75 
14.75 
± 
0.63 
2.60 
± 
2.50 
Micronised FFD at week 0 
0.65 
± 
0.28 
0.16 
± 
0.02 
6.93 
± 
0.40 
0.07 
± 
0.02 
0.13 
± 
0.03 
0.19 
± 
0.06 
0.18 
± 
0.06 
0.07 
± 
0.02 
0.02 
± 
0.01 
0.01 
± 
0.01 
0.00 
± 
0.00 
7.77 
± 
0.25 
0.48 
± 
0.14 
6.19 
± 
1.87 
3.20 
± 
2.00 
SAX-produced Bud at week 0 
66.92 
± 
13.04 
23.29 
± 
0.68 
154.86 
± 
14.75 
8.94 
± 
0.74 
18.73 
± 
4.67 
21.59 
± 
0.87 
19.88 
± 
0.70 
8.84 
± 
0.48 
2.86 
± 
0.91 
2.49 
± 
0.14 
1.44 
± 
0.17 
262.89 
± 
20.23 
57.08 
± 
0.91 
21.78 
± 
1.40 
3.00 
± 
2.60 
SAX-produced FFD at week 0 
1.11 
± 
0.39 
0.37 
± 
0.04 
5.15 
± 
0.59 
0.12 
± 
0.03 
0.26 
± 
0.10 
0.34 
± 
0.03 
0.36 
± 
0.03 
0.17 
± 
0.01 
0.06 
± 
0.01 
0.03 
± 
0.01 
0.01 
± 
0.01 
6.88 
± 
0.81 
0.97 
± 
0.06 
14.19 
± 
0.92 
2.90 
± 
2.40 
Micronised Bud  at week 2 
42.14 
± 
2.09 
13.30 
± 
2.74 
258.78 
± 
3.26 
4.58 
± 
0.25 
10.02 
± 
0.47 
12.25 
± 
0.52 
11.21 
± 
1.51 
4.94 
± 
0.13 
2.36 
± 
0.26 
1.01 
± 
0.25 
0.81 
± 
0.16 
319.26 
± 
5.74 
32.58 
± 
0.69 
10.21 
± 
0.24 
2.90 
± 
2.50 
Micronised FFD at week 2 
0.73 
± 
0.08 
0.18 
± 
0.03 
6.91 
± 
0.22 
0.06 
± 
0.01 
0.11 
± 
0.02 
0.18 
± 
0.01 
0.18 
± 
0.03 
0.06 
± 
0.01 
0.01 
± 
0.01 
0.00 
± 
0.00 
0.00 
± 
0.00 
7.69 
± 
0.16 
0.43 
± 
0.04 
5.56 
± 
0.60 
3.40 
± 
1.80 
SAX-produced Bud at week 2 
60.71 
± 
7.10 
25.52 
± 
3.60 
196.97 
± 
7.46 
10.35 
± 
0.31 
21.71 
± 
0.85 
17.76 
± 
1.28 
16.51 
± 
1.51 
6.92 
± 
1.42 
3.21 
± 
0.17 
1.82 
± 
0.58 
1.10 
± 
0.05 
301.87 
± 
10.37 
47.32 
± 
2.24 
15.69 
± 
0.85 
3.40 
± 
2.70 
SAX-produced FFD at week 2 
0.97 
± 
0.06 
0.40 
± 
0.05 
5.88 
± 
0.12 
0.15 
± 
0.01 
0.30 
± 
0.03 
0.28 
± 
0.02 
0.27 
± 
0.02 
0.12 
± 
0.03 
0.05 
± 
0.01 
0.03 
± 
0.01 
0.00 
± 
0.00 
7.47 
± 
0.20 
0.74 
± 
0.05 
9.87 
± 
0.64 
3.40 
± 
2.00 
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Table 6.2 (continued from previous page): NGI deposition per capsule of drug aerosolised from the formulations of  micronised Bud:FFD and 
SAX-produced Bud:FFD with ratio 36:1stored at 25˚C/75% RH in different periods of time (week 0, 2 and 4) 
Bud = budesonide; FFD = formoterol fumarate dihydrate 
 
 
Formulations 
Mean Drug Deposition on Impactor Stages 
(µg ± SD) 
Mean ED 
(µg ± SD) 
Mean FPD 
(µg ± SD) 
Mean 
FPFED 
(% ± SD) 
MMAD 
(µm ± GSD) 
 D & C MP &T PS S1 S2 S3 S4 S5 S6 S7 MOC     
Micronised Bud at week 4 
35.83 
± 
4.49 
13.99 
± 
1.83 
239.51 
± 
29.93 
5.24 
± 
0.19 
11.43 
± 
0.38 
13.98 
± 
1.15 
13.73 
± 
0.43 
6.31 
± 
0.10 
2.92 
± 
0.13 
1.25 
± 
0.21 
0.79 
± 
0.13 
309.16 
± 
31.01 
38.99 
± 
0.79 
12.72 
± 
1.60 
2.90  
± 
 2.50 
Micronised FFD at week 4 
0.60 
± 
0.07 
0.22 
± 
0.03 
6.78 
± 
0.96 
0.06 
± 
0.01 
0.13 
± 
0.02 
0.21 
± 
0.01 
0.23 
± 
0.02 
0.09 
± 
0.01 
0.03 
± 
0.01 
0.00 
± 
0.00 
0.00 
± 
0.00 
7.74 
± 
1.02 
0.55 
± 
0.03 
7.24 
± 
0.91 
3.10  
±  
1.80 
SAX-produced Bud at week 4 
52.05 
± 
3.09 
27.88 
± 
1.15 
197.35 
± 
2.07 
10.14 
± 
0.31 
19.08 
± 
0.29 
15.37 
± 
1.03 
13.01 
± 
0.98 
5.64 
± 
0.89 
2.32 
± 
0.41 
1.15 
± 
0.15 
0.55 
± 
0.09 
292.49 
± 
4.03 
38.04 
± 
1.09 
13.01 
± 
0.24 
3.70  
± 
 2.60 
SAX-produced FFD at week 4 
0.49 
± 
0.04 
0.44 
± 
0.01 
7.35 
± 
0.63 
0.25 
± 
0.03 
0.42 
± 
0.17 
0.35 
± 
0.07 
0.28 
± 
0.09 
0.14 
± 
0.07 
0.04 
± 
0.07 
0.02 
± 
0.03 
0.00 
± 
0.00 
9.30 
± 
1.00 
0.83 
± 
0.23 
8.85 
± 
1.96 
3.90  
±  
2.10 
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Figure 6.9: NGI deposition per capsule of Bud aerosolised from the combination 
formulations of micronised Bud:FFD (36:1) compared with SAX-produced Bud:FFD 
(36:1) at 25˚C/75% RH in different periods of time (week 0, 2 and 4) 
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Figure 6.10: NGI deposition per capsule of FFD aerosolised from the combination 
formulations of micronised Bud:FFD (36:1) compared with SAX-produced Bud:FFD 
(36:1) at 25˚C/75% RH as a function of storage time (week 0, 2 and 4) 
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Upon aerosolisation of the micronised Bud/FFD formulation at the initial time-point, the 
ED of budesonide was significantly greater (p<0.05) than that of budesonide 
aerosolised from the SAX Bud/FFD formulation as shown by Figure 6.11. However, 
there was no statistical difference in the ED of FFD upon aerosolisation of either 
formulation. Upon storage at 25˚C and 75% RH for two and four weeks, the ED of 
budesonide and formoterol were not dramatically affected upon aerosolisation of both 
formulations. An exception to this observation was the slight but significant (p<0.05) 
increase in the ED of budesonide following aerosolisation of the SAX Bud/FFD 
formulation following storage at 25˚C and 75% RH for two and four weeks in 
comparison to the initial time-point. In addition, it is evident from Figure 6.11 that the 
ED of FFD increased following four week storage of the SAX Bud/FFD formulation at 
25˚C and 75% RH. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.11: The emitted dose per capsule of micronised and SAX combination 
formulations stored at 25˚C/75% RH in different periods of time (week 0, 2 and 4) 
 
 
The fine particle dose (FPD) of budesonide and formoterol following aersolisation of the 
micronised Bud/FFD and SAX Bud/FFD formulations are shown in Figure 6.12 before 
and after storage at 25˚C and 75% RH for two and four weeks. At the initial time-point, 
aerosolisation of the SAX Bud/FFD formulation resulted in significantly (p<0.05) greater 
FPD of budesonide (57.08 ± 0.91 µg) and formoterol (0.97 ± 0.06 µg) than the 
micronised Bud/FFD formulation [Bud (47.62 ± 2.75 µg) and FFD (0.48 ± 0.14 µg)]. 
Following aerosolisation of the SAX Bud/FFD formulation after storage at 25˚C and   
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75% RH for two weeks, the FPD of Bud (47.32 ± 2.24 µg) and FFD (0.74 ± 0.05 µg) 
were significantly higher (p<0.05) than FPD of Bud (32.58 ± 0.69 µg) and FFD (0.43 ± 
0.04 µg) from the micronised Bud/FFD formulation. After storage at 25˚C and 75% RH 
for four weeks, there were no differences in the FPD of budesonide or formoterol 
following aerosolisation of either formulation as shown in Figure 6.12. However, it is 
evident from Figure 6.12 that whilst storage conditions did not affect the FPD of FFD 
from either formulation at 2 and 4 weeks, the FPD of budesonide from both formulations 
significantly (p<0.05) decreased.  
 
Storage of the micronised Bud/FFD formulation for two weeks at 25˚C and 75% RH 
resulted in a significant (p<0.05) decrease in the FPD of Bud in comparison to the initial 
time-point. The decrease in the FPD of Bud on storage of the micronised Bud/FFD 
formulation was also seen upon aerosolisation of the SAX Bud/FFD formulation after 
storage. It is evident from Figure 6.12 that the FPD of Bud decreases following storage 
of the SAX Bud/FFD formulation for two and four weeks at 25˚C and 75% RH. Figure 
6.12 also shows that storage of the micronised and SAX Bud/FFD formulations at 25˚C 
and 75% RH for two and four weeks resulted in no significant change in the FPD of 
FFD in comparison to the initial time-point. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.12: The fine particle dose per capsule of micronised and SAX combination 
formulations stored at 25˚C/75% RH in different periods of time (week 0, 2 and 4) 
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The percentage fine particle fraction of the emitted dose (FPFED) of budesonide and 
formoterol following aersolisation of the micronised Bud/FFD and SAX Bud/FFD 
formulations are shown in Figure 6.13 before and after storage at 25˚C and 75% RH for 
two and four weeks.  
 
Upon aerosolisation of the SAX Bud/FFD formulation, the FPFED of budesonide and 
formoterol were 21.78 ± 1.40 % and 14.19 ± 0.92 %, respectively, which were 
significantly (p<0.05) greater than the FPFED of Bud (14.75 ± 0.63 %) and FFD (6.19 ± 
1.87 %) following aerosolisation of the micronised Bud/FFD formulation.  
 
Upon storage of both formulations at 25˚C and 75% RH for two weeks, the FPFED of 
budesonide (15.69 ± 0.85 %) and FFD (9.87 ± 0.64 %) upon aerosolisation of the SAX 
Bud/FFD were significantly higher (p<0.05) than FPFED of Bud (10.21 ± 0.24 %) and 
FFD (5.56 ± 0.60 %) following aerosolisation of the micronised Bud/FFD formulation. 
After storage of the formulations at 25˚C and 75% RH for four weeks, there were no 
significant differences in the FPFED of budesonide and formoterol following 
aerosolisation of both formulations. However, in comparison to the initial time-point the 
FPFED of budesonide decreased significantly (p<0.05) following aerosolisation of the 
micronised Bud/FFD and SAX Bud/FFD formulations following storage at 25˚C and 
75% RH for two and four weeks. In contrast, the FPFED of formoterol was not affected 
following storage of the micronised Bud/FFD formulation, however, the FPFED of 
formoterol decreased significantly (p<0.05) following storage of the SAX Bud/FFD 
formulation at two and four weeks.  
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Figure 6.13: The fine particle fraction of emitted dose (FPFED) per capsule of 
micronised and SAX combination formulations stored at 25˚C/75% RH in different 
periods of time (week 0, 2 and 4) 
 
The mean normalised mass ratios of Bud:FFD as a function of recovered dose 
deposited on stages 2 to 5 of the NGI following aerosolisation of both formulations at 
the initial time-point and following storage at 25˚C/75% RH for two and four weeks are 
shown in Figure 6.14. It is evident from Figure 6.14 that the ratios of Bud:FFD on 
stages 2 to 5 following aerosolisation of both micronised and SAX Bud/FFD 
formulations before and after storage are greater than one. These data suggest that 
deposition of both drugs were inconsistent and were not deposited in a uniform manner. 
However, Figure 6.14 shows that aerosolisation of the SAX Bud/FFD resulted in 
greater consistency in the delivery of both drugs on stage 2–5 than micronised 
Bud/FFD. This is further supported by Figure 6.14, which shows that the mass ratio of 
Bud:FFD following aerosolisation of the SAX Bud/FFD formulations were closer to one. 
Storage of the micronised Bud/FFD formulations at 25˚C/75% RH for two and four 
weeks resulted in significant variations in the mass ratio of Bud/FFD on stages 2–5, 
which may indicate towards significant under-and over dosing of either active. In 
contrast, the mass ratio of Bud:FFD on stages 2–5 remained more consistent following 
storage of the SAX Bud/FFD formulations at two and four weeks.  
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Figure 6.14: Ratios of Bud:FFD from mean normalised data of stage 2-5 of micronised 
Bud:FFD (36:1) compared with SAX-produced Bud:FFD (36:1) stored at 25˚C/75% RH 
for 0, 2 and 4 weeks 
 
Chapter 6: Pharmaceutical Engineering of a Low-Dose drug in Combination 
with a High-Dose Corticosteroid  200 
 
 
6.5.1.4 Study II: In-Vitro Performance of Bud-FFD Formulations at 40˚C/75% RH 
 
The in-vitro inhalation performance of combination based DPI formulations comsisting 
of micronised Bud and FFD and combined SAX particles of Bud/FFD was investigated. 
In addition, the performance of both formulations was assessed following storage of the 
materials for 2 and 4 weeks at 40˚C/75% RH. The mean mass data of drug deposited 
per capsule on each stage of the NGI for both micronised Bud/FFD and SAX Bud/FFD 
formulations are shown in Table 6.3 along with the ED, FPD, FPFED and MMAD. 
Furthermore, the stage-by-stage deposition of both drugs before and after storage can 
be observed in Figure 6.15 and 6.16. These data suggest that upon aersolisation of the 
SAX Bud/FFD formulation, more budesonide and formoterol were delivered to the 
lower stages of the impactor than the formulation containing micronised budesonide 
and formoterol.  
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Table 6.3 (continued on next page): NGI deposition per capsule of drug aerosolised from the formulations of micronised Bud:FFD and 
SAX-produced Bud:FFD with ratio 36:1 stored at 40˚C/75% RH in different periods of time (week 0, 2 and 4). 
Bud = budesonide; FFD = formoterol fumarate dihydrate 
 
Formulations 
Mean Drug Deposition on Impactor Stages 
(µg ± SD) 
Mean ED 
(µg ± SD) 
Mean FPD 
(µg ± SD) 
Mean 
FPFED 
(% ± SD) 
MMAD 
(µm ± GSD) 
 D & C MP &T PS S1 S2 S3 S4 S5 S6 S7 MOC     
Micronised Bud at week 0 
49.39 
± 
10.84 
12.38 
± 
2.01 
245.91 
± 
6.31 
4.79 
± 
0.59 
11.98 
± 
0.55 
16.09 
± 
0.62 
16.10 
± 
2.71 
8.34 
± 
0.41 
3.40 
± 
0.28 
2.31 
± 
0.42 
1.37 
± 
0.23 
322.69 
± 
9.34 
47.62 
± 
2.75 
14.75 
± 
0.63 
2.60 
 ±  
2.50 
Micronised FFD at week 0 
0.65 
± 
0.28 
0.16 
± 
0.02 
6.93 
± 
0.40 
0.07 
± 
0.02 
0.13 
± 
0.03 
0.19 
± 
0.06 
0.18 
± 
0.06 
0.07 
± 
0.02 
0.02 
± 
0.01 
0.01 
± 
0.01 
0.00 
± 
0.00 
7.77 
± 
0.25 
0.48 
± 
0.14 
6.19 
± 
1.87 
3.20  
± 
 2.00 
SAX-produced Bud at week 0 
66.92 
± 
13.04 
23.29 
± 
0.68 
154.86 
± 
14.75 
8.94 
± 
0.74 
18.73 
± 
4.67 
21.59 
± 
0.87 
19.88 
± 
0.70 
8.84 
± 
0.48 
2.86 
± 
0.91 
2.49 
± 
0.14 
1.44 
± 
0.17 
262.89 
± 
20.23 
57.08 
± 
0.91 
21.78 
± 
1.40 
3.00  
±  
2.60 
SAX-produced FFD at week 0 
1.11 
± 
0.39 
0.37 
± 
0.04 
5.15 
± 
0.59 
0.12 
± 
0.03 
0.26 
± 
0.10 
0.34 
± 
0.03 
0.36 
± 
0.03 
0.17 
± 
0.01 
0.06 
± 
0.01 
0.03 
± 
0.01 
0.01 
± 
0.01 
6.88 
± 
0.81 
0.97 
± 
0.06 
14.19 
± 
0.92 
2.90 
 ±  
2.40 
Micronised Bud  at week 2 
45.23 
± 
9.32 
15.73 
± 
2.92 
253.55 
± 
18.83 
5.12 
± 
0.76 
9.98 
± 
1.38 
11.15 
± 
1.49 
10.02 
± 
1.24 
4.16 
± 
0.70 
1.77 
± 
0.67 
0.94 
± 
0.50 
0.53 
± 
0.18 
312.94 
± 
25.83 
28.56 
± 
4.30 
9.09 
± 
0.66 
3.20  
±  
2.50 
Micronised FFD at week 2 
1.09 
± 
0.40 
0.19 
± 
0.03 
6.15 
± 
0.48 
0.06 
± 
0.02 
0.11 
± 
0.02 
0.18 
± 
0.03 
0.19 
± 
0.02 
0.07 
± 
0.01 
0.00 
± 
0.00 
0.00 
± 
0.00 
0.00 
± 
0.00 
6.95 
± 
0.60 
0.44 
± 
0.06 
6.25 
± 
0.42 
3.60  
±  
1.80 
SAX-produced Bud at week 2 
51.66 
± 
6.15 
30.49 
± 
5.96 
172.03 
± 
32.88 
9.58 
± 
1.28 
18.62 
± 
1.83 
15.36 
± 
0.88 
11.78 
± 
1.69 
5.27 
± 
0.56 
2.32 
± 
0.46 
0.97 
± 
0.43 
0.51 
± 
0.20 
266.94 
± 
43.10 
36.22 
± 
3.09 
13.70 
± 
1.42 
3.80  
±  
2.50 
SAX-produced FFD at week 2 
0.61 
± 
0.04 
0.41 
± 
0.08 
4.76 
± 
0.65 
0.13 
± 
0.01 
0.25 
± 
0.03 
0.20 
± 
0.01 
0.15 
± 
0.01 
0.06 
± 
0.02 
0.02 
± 
0.02 
0.00 
± 
0.00 
0.00 
± 
0.00 
5.97 
± 
0.74 
0.42 
± 
0.03 
7.17 
± 
1.08 
4.10  
±  
1.90 
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Table 6.3 (continued from previous page): NGI deposition per capsule of drug aerosolised from the formulations of micronised Bud:FFD and 
SAX-produced Bud:FFD with ratio 36:1 stored at 40˚C/75% RH in different periods of time (week 0, 2 and 4). 
Bud = budesonide; FFD = formoterol fumarate dihydrate 
 
Formulations 
Mean Drug Deposition on Impactor Stages 
(µg ± SD) 
Mean ED 
(µg ± SD) 
Mean FPD 
(µg ± SD) 
Mean 
FPFED 
(% ± SD) 
MMAD 
(µm ± GSD) 
 D & C MP &T PS S1 S2 S3 S4 S5 S6 S7 MOC     
Micronised Bud at week 4 
40.29 
± 
4.39 
16.68 
± 
0.48 
267.17 
± 
0.76 
5.49 
± 
0.44 
9.79 
± 
0.29 
10.29 
± 
0.51 
8.36 
± 
0.73 
3.98 
± 
0.47 
1.45 
± 
0.15 
0.61 
± 
0.09 
0.27 
± 
0.02 
324.08 
± 
1.35 
24.96 
± 
0.78 
7.70 
± 
0.21 
3.50  
± 
 2.40 
Micronised FFD at week 4 
0.45 
± 
0.23 
0.17 
± 
0.02 
5.90 
± 
0.23 
0.05 
± 
0.01 
0.10 
± 
0.02 
0.14 
± 
0.01 
0.14 
± 
0.04 
0.06 
± 
0.01 
0.00 
± 
0.00 
0.00 
± 
0.00 
0.00 
± 
0.00 
6.56 
± 
0.24 
0.34 
± 
0.06 
5.17 
± 
1.00 
3.70  
± 
 1.80 
SAX-produced Bud at week 4 
47.62 
± 
6.01 
27.23 
± 
1.16 
201.55 
± 
17.23 
9.60 
± 
1.76 
14.99 
± 
2.78 
11.21 
± 
1.78 
8.75 
± 
1.35 
3.40 
± 
1.14 
1.54 
± 
0.24 
0.66 
± 
0.28 
0.31 
± 
0.08 
279.24 
± 
23.08 
25.87 
± 
4.46 
9.24 
± 
1.15 
4.30 
 ± 
 2.60 
SAX-produced FFD at week 4 
0.34 
± 
0.19 
0.29 
± 
0.06 
4.65 
± 
0.49 
0.09 
± 
0.02 
0.15 
± 
0.02 
0.10 
± 
0.03 
0.07 
± 
0.01 
0.04 
± 
0.01 
0.00 
± 
0.00 
0.00 
± 
0.00 
0.00 
± 
0.00 
5.39 
± 
0.53 
0.21 
± 
0.03 
3.96 
± 
0.69 
4.90 
 ± 
 1.90 
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Figure 6.15: NGI deposition per capsule of Bud aerosolised from the combination 
formulations of micronised Bud:FFD (36:1) compared with SAX-produced Bud:FFD 
(36:1) at 40˚C/75% RH in different periods of time (week 0, 2 and 4) 
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Figure 6.16: NGI deposition per capsule of FFD aerosolised from the combination 
formulations of micronised Bud:FFD (36:1) compared with SAX-produced Bud:FFD 
(36:1) upon processing and storage at 40˚C/75% RH for 2 and 4 weeks 
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Upon storage of the micronised and SAX Bud/FFD formulations at 40˚C and 75% RH 
for two and four weeks, the ED of Bud were not affected as shown by Figure 6.17. 
Following storage of the formulations for four weeks under the same conditions, the ED 
of FFD decreased significantly (p<0.05) in comparison to the initial time-point. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.17: The emitted dose per capsule of micronised and SAX combination 
formulations stored at 40˚C/75% RH in different periods of time (week 0, 2 and 4) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 6: Pharmaceutical Engineering of a Low-Dose drug in Combination 
with a High-Dose Corticosteroid  206 
 
 
The fine particle dose (FPD) of budesonide and formoterol following aersolisation of the 
micronised Bud/FFD and SAX Bud/FFD formulations are shown in Figure 6.18 before 
and after storage at 40˚C and 75% RH for two and four weeks.  
 
After storage at 40˚C and 75% RH for two and four weeks, there were significant (p<0.05) 
differences in the FPD of budesonide following aerosolisation of both the micronised and 
SAX Bud/FFD formulation as shown in Figure 6.18. However, it is evident from Figure 
6.18 that whilst storage conditions did not significantly affect the FPD of FFD following 
storage of the micronised Bud/FFD formulation at either formulation at 2 and 4 weeks, 
the FPD of SAX produced FFD decreased significantly (p<0.05) upon storage. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.18: The fine particle dose per capsule of micronised and SAX combination 
formulations stored at 40˚C/75% RH in different periods of time (week 0, 2 and 4) 
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The percentage fine particle fraction of the emitted dose (FPFED) of budesonide and 
formoterol following aerosolisation of the micronised Bud/FFD and SAX Bud/FFD 
formulations are shown in Figure 6.19 following storage at 40˚C and 75% RH for two 
and four weeks.  
 
Upon storage of the micronised and SAX Bud/FFD formulations at 40˚C and 75% RH 
for two and four weeks, the FPFED of budesonide decreased significantly (p<0.05) in 
comparison to the respective initial time-points. In contrast, the FPFED of formoterol 
was not affected following storage of the micronised Bud/FFD formulation, however, 
the FPFED of formoterol decreased significantly (p<0.05) following storage of the SAX 
Bud/FFD formulation at two and four weeks.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.19: The fine particle fraction of emitted dose (FPFED) per capsule of 
micronised and SAX combination formulations stored at 40˚C/75% RH in different 
periods of time (week 0, 2 and 4) 
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The mean normalised mass ratios of Bud:FFD as a function of recovered dose 
deposited on stages 2 to 5 of the NGI following aerosolisation of both formulations at 
the initial time-point and following storage at 40˚C/75% RH for two and four weeks are 
shown in Figure 6.20. It is evident from Figure 6.20 that the ratios of Bud:FFD on 
stages 2 to 5 following aerosolisation of both micronised and SAX Bud/FFD 
formulations before and after storage at 40˚C and 75% RH were similar to those 
observed in Figure 6.14 following storage at 25˚C and 75% RH. Storage of the 
micronised Bud/FFD formulation at 40˚C/75% RH for two and four weeks resulted in 
significant variations in the mass ratio of Bud/FFD on stages 2–5, which may indicate 
towards significant under-and over dosing of either active. In contrast, the mass ratio of 
Bud:FFD on stages 2–5 remained more consistent following storage of the SAX 
Bud/FFD formulations.  
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Figure 6.20: Ratios of Bud:FFD from mean normalised data on stage 2-5 delivery of 
micronised Bud:FFD (36:1) compared with SAX-produced Bud:FFD (36:1) before and 
upon storage at 40˚C/75% RH for 2 and 4 weeks 
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6.5.2 Discussion  
 
In this study, the SAX approach was successfully implemented in the fabrication of low-
dose FFD in combination with Bud, which was suitable for pulmonary drug delivery. 
 
In order to assess the in-vitro performance of the SAX engineered combination 
particles of Bud/FFD, two formulations of the SAX-produced Bud/FFD and physical 
mixture of Bud/FFD were formulated. At the initial time point, the FPFED of Bud and 
FFD from a formulation containing SAX-produced Bud/FFD were significantly (p<0.05) 
greater than micronised Bud/FFD. These results suggest that the morphology of the 
SAX Bud/FFD particles may have aided greater delivery of the actives owing to lower 
surface contact area and therefore lower adhesion to components of the formulation. 
 
The mass ratio data of Bud:FFD as normalised as a function of recovered dose on 
stages 2 to 5 following aerosolisation of the micronised and SAX formulations were 
greater than one. These data suggest that though both actives were being delivered to 
the lower stages of the impactor, they were delivered independently of each other. 
However, in comparison to the micronised Bud/FFD formulation, the mass ratio of 
Bud:FFD on stages 2–5 following aerosolisation of the SAX Bud/FFD formulation was 
more consistent. The performance of the SAX Bud/FFD formulation suggests that both 
actives were within one geometric particle. This feature of the formulation containing 
SAX Bud/FFD particles is critical to the clinical efficacy observed with the SMART 
approach to asthma therapy, because significant variations in the delivery of both 
actives as observed with the formulation containing micronised Bud/FDD may lead to 
significant under or overdosing situations.   
 
Upon storage of the SAX Bud/FFD formulation under the different environmental 
conditions, data resulted in a significant decrease in the FPD and FPFED of both actives 
(P<0.05). This was also observed for the micronised Bud/FFD formulation, but only in 
relation to the FPD and FPFED of budesonide and not formoterol. Such data suggest 
that one or more components of the SAX Bud/FFD particles may have remained in the 
metastable state and may not have crystallised during processing by SAX, which would 
render the material susceptible to dynamic transformations that would affect product 
performance on storage. However, dynamic vapour sorption studies suggested that the 
SAX Bud/FFD particles were stable on exposure to elevated humidity and did not 
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indicate any signs of physical transformations. These data are also supported by DSC 
and XRPD studies. 
 
It is interesting to note that whilst the performance of micronised Bud was affected 
upon storage the performance of micronised FFD was not. In contrast, both the 
performance of Bud and FFD decreased significantly following storage of formulations 
containing SAX Bud/FFD particles. One possible explanation for this trend may be that 
as the SAX particles contain both drugs in one individual particle, failure in the delivery 
of one of the actives will also affect the performance of the other. In the case of the 
SAX Bud/FFD formulation, the particles contain more budesonide than FFD, therefore, 
a drop in the performance of budesonide will also result in a significant decrease in the 
delivery of FFD. In contrast, the micronised formulation contains both drugs in a 
physical mixture. Therefore, the drop in performance of micronised budesonide will be 
independent of micronised FFD.  
 
6.6 Conclusions 
 
The SAX process may be utilised to produce individual particulates of two active 
ingredients, which will effectively allow the delivery of combination medicaments 
containing low doses of one or more actives. Combination particles of Bud/FFD were 
successfully fabricated with desired surface properties, which enabled greater delivery 
of both actives to the lower stages of the impactor, in comparison to formulations 
containing physical mixtures of micronised forms of the actives. Furthermore, the 
delivery of both actives as combined SAX particles resulted in consistent delivery of 
both actives across the lower stages of the impactor. However, as both actives are 
present in one particle, the delivery of both actives is sensitive to change on storage.  
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Chapter 7: General Conclusions and Further work 
 
7.1 Introduction 
 
The objective of pharmaceutical engineering of inhalation dosage forms is the 
generation of a drug product that enable the delivery of medicines efficiently and 
effectively to the human airways. Currently, the processing of these dosage forms 
remains highly empirical, which corresponds with high failure rates of these drug 
products during development and manufacturing. The primary source of dry powder 
inhaler (DPI) formulation failure is the lack of control on key physicochemical properties 
of the active(s), which can be related to the process of micronisation that is used to 
generate respirable particles. We propose that to control the specific performance and 
stability properties of DPI dosage forms, the central design principle in DPI 
manufacturing must focus on tailoring the mesoscopic design of particle interfaces to 
enable careful control of particle-particle interactions and therefore, drug product 
performance. 
 
This principle must be taken one-step further with respect to combined inhalation 
products, which are significantly more complicated than binary formulations. As asthma 
and COPD are two-component conditions of the airways, the most effective treatment 
for reducing smooth muscle dysfunction and inflammation is to use combined therapy 
of long acting β2-agonist (LABA) and corticosteroid (ICS) together in order to illicit 
significant clinical advantages. It has been demonstrated that addition of a long-acting 
β2-agonist (LABA) to an inhaled corticosteroid (ICS) is superior to ICS alone in 
achieving asthma control (Matz, Emmett et al., 2001). Furthermore, there is evidence 
to suggest that patients with COPD may also benefit from combined inhalation therapy 
with ICS and LABA (Calverley, Pauwels et al., 2003).  
 
The improved clinical outcome on therapy on combined inhalation therapy with ICS and 
LABA is reported to be as a result of synergistic actions of LABA and ICS at the cellular, 
receptor and molecular level (Theophilus, Moore et al., 2006). The opportunity for 
synergistic action is enhanced by co-deposition of both particles on the same cells of 
the airways. Administration of the two drugs by a single inhaler would lead to an 
increased chance for co-deposition compared with administration via two separate 
inhalers. However, current combined inhalation products are subject to a greater 
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variability in dose delivery of each active, which may be perpetuated as a function of 
product storage conditions (Taki, Zeng et al., 2006). Hence, there is a requirement of 
processes that may enable production of combination inhaled products that will allow 
both drugs to be delivered more effectively and independently of dose variations.  
 
7.2 Summary 
 
Following physical characterisation of the materials utilised in the study, the 
development of the SAX process in the lab-scale size was successfully achieved by 
controlling many factors involved in the SAX system. Many factors, including pressure, 
solvents, non-solvents and temperatures, had a significant effect on properties of 
resultant materials. As a result, a laboratory SAX system was produced that enabled 
the formation of small scale batches of SAX material with a significant level of control 
and manipulation. 
 
The SAX process was applied as a single step droplet-to-particle operation to process 
drug particles for delivery to the respiratory tract. The SAX process was used to 
engineer crystalline drug particles and the result found that it was possible to modify 
crystalline particles of budesonide with suitable properties for the inhaled drug. 
Moreover, budesonide SAX particles were found to outperform micronised budesonide 
particles as determined by in-vitro performance testing. Furthermore, porous/hollow 
crystalline particles of budesonide with geometric diameter of 8–10 µm were produced, 
which were found to possess an aerodynamic diameter between 2–4 µm. These 
particles possessed the same delivery efficiency as micronised drug products.  
 
The SAX process was also used to produce individual particulates of two active 
ingredients, to allow effective delivery of combination medicaments independently of 
dose variations of the actives. All physicochemical characterisation demonstrated that 
the SAX-produced combined particles of FP and SX were successfully co-processed 
into individual particles with crystalline properties. Additionally, in-vitro performance 
studies strongly confirmed that all SAX FP/SX formulations delivered both drugs 
consistently and independently of dose variations to the lower stages of the impactor 
even after storage of the formulations at accelerated stability conditions.   
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In addition, low-dose combined drug particles of Bud and FFD were produced via the 
SAX system. For the combination of low-dose drugs, it has been demonstrated that the 
FPFED of Bud and FFD from SAX-produced Bud/FFD formulation was significantly 
(p<0.05) greater than a micronised Bud/FFD formulation. However, the mass ratio of 
Bud:FFD across stages 2 – 5 was not close to 1 when either formulation was 
aerosolised. However, the SAX combination Bud/FFD particles were more consistent in 
the delivery of both actives than micronised. Under stability conditions, the 
performance of the SAX Bud/FFD particles did decrease, which may be related to the 
fact that performance of both actives are affected by one another, therefore, changes in 
one active may affect the delivery of the other after storage.  
 
This approach, however, presents itself as novel means to produce inhaled 
combination dosage forms which may lead to enhanced clinical efficacy. 
 
7.3 General Conclusions 
 
In conclusion, it is evident from the work presented that the SAX process has been 
succesfully utilised in modifying the surface morphology of crystalline particles suitable 
for pulmonary drug delivery. The SAX process has been successfully developed by 
controlling all crucial factors which were involved in the system. Furthermore, the 
process has been successfully employed to engineer drug particles, with optimum 
properties for delivery to the lungs. Moreover, in-vitro performance SAX-produced 
formulation was significantly greater than the micronised formulation. Consequently, 
the SAX process was progressively utilised to produce individual particles of two active 
ingredients which would allow the delivery of combination medicaments effectively and 
independently of dose variation. All physical characterisation revealed that the SAX-
combined particles were co-processed into individual particles with the crystalline 
properties. Additionally, the in-vitro performance study strongly confirmed that all SAX 
combined formulations with high-dose ratio, stored in different conditions and periods 
of time had the higher FPFED than micronised formulations. However, for low dose ratio 
of the combination drugs, there was an inconsistent ratio between two combined drugs. 
This approach presents itself as a novel means to produce inhaled combination dosage 
forms for respiratory products. 
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7.4 Further Work 
 
According to these data presented in the thesis, the SAX process shows significant 
promise for generating single and, also, combination particles for delivery to the lungs. 
In Chapter 4, budesonide was used as a model drug for particle engineering via the 
SAX system, these particles were found to confer some functionality that affected drug 
product performance. A future development of this approach would be to engineer SAX 
particles in-situ with excipient particles to enable the one-step production of DPI 
formulations. This approach may involve either atomisation of a solution that contained 
both drug and excipient, however, such approach may be hampered by 
incompatibilities of a universal solvent to solubilise both drug and excipient. However, 
further work in this area may result in the development of a continuous processing 
route, which may improve the quality and efficiency of DPI drug product manufacturing.   
 
From Chapter 5 and 6, it can be seen that the particle engineering via the SAX process 
leads to an important opportunity to generate individual particulates of two active 
ingredients, which will allow the delivery of combination medicaments effectively and 
independently of dose variation. The high-dose combination particles produced from 
the SAX process were successfully co-processed into individual particles with the 
crystalline properties. As conditions such as COPD are multi-factorial, a further 
development of this approach may investigate the potential of the SAX process to 
generate particles with multiple actives in one particulate. It would be beneficial to 
design the work by adding another essential drug to generate triple drug particles in 
order to formulate the pulmonary dosage form to help prevent COPD and asthma 
patients for the long-term treatment.  
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